<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">68832</article-id><article-id pub-id-type="doi">10.7554/eLife.68832</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Short Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>A human-based multi-gene signature enables quantitative drug repurposing for metabolic disease</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-232135"><name><surname>Timmons</surname><given-names>James A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2255-1220</contrib-id><email>jamie.timmons@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-239983"><name><surname>Anighoro</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-239985"><name><surname>Brogan</surname><given-names>Robert J</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-239987"><name><surname>Stahl</surname><given-names>Jack</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-239982"><name><surname>Wahlestedt</surname><given-names>Claes</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-239986"><name><surname>Farquhar</surname><given-names>David Gordon</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-239984"><name><surname>Taylor-King</surname><given-names>Jake</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-239988"><name><surname>Volmar</surname><given-names>Claude-Henry</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9437-051X</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-19498"><name><surname>Kraus</surname><given-names>William E</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1930-9684</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-179256"><name><surname>Phillips</surname><given-names>Stuart M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1956-4098</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf7"/></contrib><aff id="aff1"><label>1</label><institution>William Harvey Research Institute, Queen Mary University of London</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff2"><label>2</label><institution>Augur Precision Medicine LTD</institution><addr-line><named-content content-type="city">Stirling</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff3"><label>3</label><institution>Relation Therapeutics LTD</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff4"><label>4</label><institution>Fiona Stanley Hospital</institution><addr-line><named-content content-type="city">Perth</named-content></addr-line><country>Australia</country></aff><aff id="aff5"><label>5</label><institution>Center for Therapeutic Innovation, Miller School of Medicine, University of Miami</institution><addr-line><named-content content-type="city">Miami</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>School of Medicine, Duke University</institution><addr-line><named-content content-type="city">Durham</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution>Faculty of Science, Kinesiology, McMaster University</institution><addr-line><named-content content-type="city">Hamilton</named-content></addr-line><country>Canada</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Reviewing Editor</role><aff><institution>Icahn School of Medicine at Mount Sinai</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Isales</surname><given-names>Carlos</given-names></name><role>Senior Editor</role><aff><institution>Medical College of Georgia at Augusta University</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>17</day><month>01</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e68832</elocation-id><history><date date-type="received" iso-8601-date="2021-03-26"><day>26</day><month>03</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-11-26"><day>26</day><month>11</month><year>2021</year></date></history><permissions><copyright-statement>© 2022, Timmons et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Timmons et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-68832-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-68832-figures.pdf"/><abstract><p>Insulin resistance (IR) contributes to the pathophysiology of diabetes, dementia, viral infection, and cardiovascular disease. Drug repurposing (DR) may identify treatments for IR; however, barriers include uncertainty whether in vitro transcriptomic assays yield quantitative pharmacological data, or how to optimise assay design to best reflect in vivo human disease. We developed a clinical-based human tissue IR signature by combining lifestyle-mediated treatment responses (&gt;500 human adipose and muscle biopsies) with biomarkers of disease status (fasting IR from &gt;1200 biopsies). The assay identified a chemically diverse set of &gt;130 positively acting compounds, highly enriched in true positives, that targeted 73 proteins regulating IR pathways. Our multi-gene RNA assay score reflected the quantitative pharmacological properties of a set of epidermal growth factor receptor-related tyrosine kinase inhibitors, providing insight into drug target specificity; an observation supported by deep learning-based genome-wide predicted pharmacology. Several drugs identified are suitable for evaluation in patients, particularly those with either acute or severe chronic IR.</p></abstract><abstract abstract-type="executive-summary"><title>eLife digest</title><p>Developing a new drug that is both safe and effective is a complex and expensive endeavor. An alternative approach is to ‘repurpose’ existing, safe compounds – that is, to establish if they could treat conditions others than the ones they were initially designed for. To achieve this, methods that can predict the activity of thousands of established drugs are necessary.</p><p>These approaches are particularly important for conditions for which it is hard to find promising treatment. This includes, for instance, heart failure, dementia and other diseases that are linked to the activity of the hormone insulin becoming modified throughout the body, a defect called insulin resistance. Unfortunately, it is difficult to model the complex actions of insulin using cells in the lab, because they involve intricate networks of proteins, tissues and metabolites.</p><p>Timmons et al. set out to develop a way to better assess whether a drug could be repurposed to treat insulin resistance. The aim was to build a biological signature of the disease in multiple human tissues, as this would help to make the findings more relevant to the clinic. This involved examining which genes were switched on or off in thousands of tissue samples from patients with different degrees of insulin resistance. Importantly, some of the patients had their condition reversed through lifestyle changes, while others did not respond well to treatment. These ‘non-responders’ provided crucial new clues to screen for active drugs.</p><p>Carefully piecing the data together revealed the molecules and pathways most related to the severity of insulin resistance. Cross-referencing these results with the way existing drugs act on gene activity<bold>,</bold> highlighted 138 compounds that directly bind 73 proteins responsible for regulating insulin resistance pathways. Some of the drugs identified are suitable for short-term clinical studies, and it may even be possible to rank similar compounds based on their chemical activity.</p><p>Beyond giving a glimpse into the complex molecular mechanisms of insulin resistance in humans, Timmons et al. provide a fresh approach to how drugs could be repurposed, which could be adapted to other conditions.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>drug repurposing</kwd><kwd>insulin biology</kwd><kwd>deep learning</kwd><kwd>Diabetes</kwd><kwd>Transcriptomics</kwd><kwd>Exercise</kwd><kwd>COVID-19</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000038</institution-id><institution>Natural Sciences and Engineering Research Council of Canada</institution></institution-wrap></funding-source><award-id>RGPIN-2020</award-id><principal-award-recipient><name><surname>Phillips</surname><given-names>Stuart M</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000049</institution-id><institution>National Institute on Aging</institution></institution-wrap></funding-source><award-id>R56AG061911</award-id><principal-award-recipient><name><surname>Volmar</surname><given-names>Claude-Henry</given-names></name><name><surname>Timmons</surname><given-names>James</given-names></name><name><surname>Wahlestedt</surname><given-names>Claes</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>Queen Mary University London</institution></institution-wrap></funding-source><award-id>BHF Senior Fellowship</award-id><principal-award-recipient><name><surname>Timmons</surname><given-names>James A</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Optimising the use of transcriptomics enables screening of thousands of compounds and illustrates an approach that yields quantitative pharmacology at the single-gene and pathway level.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Systemic insulin resistance (IR) is a multi-organ pathophysiological state and an early characteristic of type 2 diabetes mellitus (T2DM). IR contributes to the pathobiology of neurodegeneration (<xref ref-type="bibr" rid="bib84">Norambuena et al., 2017</xref>), heart failure (<xref ref-type="bibr" rid="bib132">Wamil et al., 2021</xref>) and viral infections, such as COVID-19 (<xref ref-type="bibr" rid="bib12">Ceriello et al., 2020</xref>; <xref ref-type="bibr" rid="bib25">Donath, 2021</xref>). Several T2DM drug treatments <italic>indirectly</italic> reduce IR following improved metabolic homeostasis, making them candidate treatments for various diseases (<xref ref-type="bibr" rid="bib25">Donath, 2021</xref>; <xref ref-type="bibr" rid="bib27">Everett et al., 2018</xref>; <xref ref-type="bibr" rid="bib84">Norambuena et al., 2017</xref>). Drug repurposing (DR) aims to accelerate the discovery and reduce the costs of new treatments. Multiple evolving strategies are being trialled, including mining of medical records, development of large databases of drug-gene interactions (<xref ref-type="bibr" rid="bib113">Subramanian et al., 2017</xref>) and virtual compound screening (<xref ref-type="bibr" rid="bib43">Himmelstein et al., 2017</xref>). Drug transcriptome responses in cells represent one of the most extensive resources (<xref ref-type="bibr" rid="bib113">Subramanian et al., 2017</xref>), while transcriptomics is also an ideal technology to capture complex biological processes in human tissues (<xref ref-type="bibr" rid="bib54">Jenkinson et al., 2016</xref>; <xref ref-type="bibr" rid="bib122">Timmons et al., 2018</xref>; <xref ref-type="bibr" rid="bib120">Timmons et al., 2005</xref>). Effectiveness at reversing of the molecular responses to disease (<xref ref-type="bibr" rid="bib130">Wagner et al., 2015</xref>) helps to predict drug efficacy in cancer (<xref ref-type="bibr" rid="bib8">Brown and Patel, 2018</xref>; <xref ref-type="bibr" rid="bib50">Iorio et al., 2018</xref>; <xref ref-type="bibr" rid="bib56">Karatzas et al., 2017</xref>; <xref ref-type="bibr" rid="bib134">Wang et al., 2016</xref>). Successful application of DR specifically to oncology may reflect that drug profiles are typically generated in tumour cell lines (<xref ref-type="bibr" rid="bib113">Subramanian et al., 2017</xref>) and that barriers to clinical validation can be lower compared with many other diseases.</p><p>Identifying informative disease signatures for DR in cells is challenging (<xref ref-type="bibr" rid="bib16">Chen et al., 2020</xref>; <xref ref-type="bibr" rid="bib56">Karatzas et al., 2017</xref>; <xref ref-type="bibr" rid="bib96">Regan-Fendt et al., 2019</xref>), particularly when no positive controls exist (<xref ref-type="bibr" rid="bib138">Williams et al., 2019</xref>). Currently, there are no reliable human cellular models for systemic IR, while it remains unclear if multi-gene assays can capture quantitative pharmacological relationships suitable for optimising drug design. However, clinically effective drugs typically target several proteins, many of which are unknown (<xref ref-type="bibr" rid="bib57">Keenan et al., 2018</xref>), highlighting the limitations of single-target drug development programmes. Network modelling and deep learning (DL) have been utilised to connect the pharmacological properties of active drugs to their protein targets (<xref ref-type="bibr" rid="bib140">Woo et al., 2015</xref>; <xref ref-type="bibr" rid="bib147">Zeng et al., 2020</xref>). For IR we also have effective non-drug treatments (<xref ref-type="bibr" rid="bib80">Nakhuda et al., 2016</xref>; <xref ref-type="bibr" rid="bib106">Slentz et al., 2016</xref>; <xref ref-type="bibr" rid="bib122">Timmons et al., 2018</xref>; <xref ref-type="bibr" rid="bib93">Phillips et al., 2017</xref>), and this enabled production of a novel human-based IR-DR assay – using more than 2000 tissue profiles generated in our laboratories (<xref ref-type="bibr" rid="bib80">Nakhuda et al., 2016</xref>; <xref ref-type="bibr" rid="bib106">Slentz et al., 2016</xref>; <xref ref-type="bibr" rid="bib122">Timmons et al., 2018</xref>) and one other (<xref ref-type="bibr" rid="bib22">Civelek et al., 2017</xref>). Performance of the present RNA-based multi-gene assays was judged against positive control in vivo drug signatures (<xref ref-type="bibr" rid="bib109">Stathias et al., 2020</xref>), genome-wide association (<xref ref-type="bibr" rid="bib71">Lotta et al., 2017</xref>; <xref ref-type="bibr" rid="bib129">Vujkovic et al., 2020</xref>) and blood proteome-based assays (<xref ref-type="bibr" rid="bib38">Gudmundsdottir et al., 2020</xref>). Validation of the in vitro results for &gt;2500 drugs (<xref ref-type="bibr" rid="bib113">Subramanian et al., 2017</xref>) relied on a variety of protein, drug- and disease-centric (<xref ref-type="bibr" rid="bib90">Parisi et al., 2020</xref>) criteria: DL-based modelling of drug-to-protein interactions; targeted gene knock down; and published evidence that the drug reduced IR in vivo (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>The project analysis process.</title><p>The three major phases of the project are defined by the grey boxes. A limited number of gene signatures were considered (four) to limit false-positive associations. The compound (CMPD) selection phase first confirmed that the drug repurposing signature provided valid matches with in vivo positive control drugs, and then a full list of in vitro active drug matches was generated. The third phase was an iterative process in that validation was considered on several levels. We utilised four main independent validation strategies, incorporating multiple data sources, to demonstrate that the insulin resistance drug repurposing (IR-DR) signature produced a high rate of likely true-positive drugs that would reverse IR.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68832-fig1-v1.tif"/></fig></sec><sec id="s2" sec-type="results|discussion"><title>Results and discussion</title><sec id="s2-1"><title>Feature selection and in vivo validation of novel IR-DR assays</title><p>Homeostasis model assessment version 2 (HOMA2-IR) was used to quantify IR (<xref ref-type="bibr" rid="bib131">Wallace et al., 2004</xref>). RNA biomarkers consistently related to fasting IR (‘disease’) across tissues were combined with those regulated in common across tissues following lifestyle-based reversal of IR (‘treatment’). Biomarkers were ranked based on consistent direction and strength of association across two major human organs targeted by insulin (human adipose and muscle) because most orally dosed drugs will act systemically. Quantitative network modelling (<xref ref-type="bibr" rid="bib107">Song and Zhang, 2015</xref>) was used to rank genes for their tissue-based hub connectedness (<xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1</xref>). In the present study, we considered the performance of only four RNA-based IR-DR assays (<xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1</xref>; <xref ref-type="bibr" rid="bib35">Ganter et al., 2006</xref>); testing their ability to match the in vivo directionality of positive controls, thiazolidinedione (TZD) and oestrogen, expression signatures correctly (<xref ref-type="bibr" rid="bib42">Hevener et al., 2018</xref>; <xref ref-type="bibr" rid="bib99">Sears et al., 2009</xref>). The top-scoring RNA signature (Signature 3A from <xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1</xref>) was a statistically ranked combination of disease- and treatment-associated genes (n = 120 genes) outranked selection by hub connectedness, recapitulated cellular gene expression patterns indicative of TZD treatment responses in vivo in muscle (moderated Z-score, p&lt;0.0000008, <xref ref-type="fig" rid="app1fig2">Appendix 1—figure 2</xref>) and is referred to as the IR-DR signature/assay hereafter (<xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1</xref>). Lack of superiority for the assay designed using hub connectedness may be considered at odds with other studies (<xref ref-type="bibr" rid="bib17">Cheng et al., 2012</xref>) but could reflect that inclusion of multi-tissue treatment response biomarkers supersedes any benefit of using network weighting. Several Genome-wide Association Study (GWAS) IR and T2DM (<xref ref-type="bibr" rid="bib71">Lotta et al., 2017</xref>; <xref ref-type="bibr" rid="bib129">Vujkovic et al., 2020</xref>)-derived signatures (e.g. Signature 4, <xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1</xref>) were considered but were unable to match positive control drugs in vivo. The T2DM blood proteome signature (<xref ref-type="bibr" rid="bib38">Gudmundsdottir et al., 2020</xref>) had a weak association with one positive control drug. Protein-level network interactions formed by each list (<xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1</xref>) were distinct (<xref ref-type="fig" rid="app1fig2">Appendix 1—figure 2</xref>) and were only possible to partially recreate from existing databases (<xref ref-type="bibr" rid="bib66">Li et al., 2018a</xref>).</p></sec><sec id="s2-2"><title>IR-DR assay identifies drugs and pathways with established links with insulin signalling</title><p>The largest available database of in vitro drug signatures (<xref ref-type="bibr" rid="bib113">Subramanian et al., 2017</xref>) was used to identify cell-type agnostic drug responses. To achieve this, we utilised aggregated scores (the maximum quantile statistic from the within-cell line-normalised scores) from across nine human cell lines. This approach also increases the sample size per drug by at least ninefold, making any inferences more reliable (<xref ref-type="bibr" rid="bib113">Subramanian et al., 2017</xref>). At the request of a reviewer, we provide results from individual cells (Table S3 <xref ref-type="fig" rid="app1fig3">Appendix 1—figure 3</xref>); however, we caution that these within-cell rank-order values are known to be less robust (<xref ref-type="bibr" rid="bib113">Subramanian et al., 2017</xref>; <xref ref-type="bibr" rid="bib142">Xu et al., 2018</xref>). Critically, we noted that members of each drug ‘class’ (drugs sharing a nominal primary protein target in common) were segregated with either active or neutral IR-DR scores, with extremely few drug classes having both positive- and negative-scoring compounds. Only 10% of the database matched the IR-DR signature (n = 254, <xref ref-type="fig" rid="app1fig3">Appendix 1—figure 3</xref> and Table S3), and 138 compounds (after excluding assay codes with ambiguous compound labels) positively regulated the IR-DR signature (potential treatments), 45% of which were kinase inhibitors (<xref ref-type="fig" rid="app1fig4">Appendix 1—figure 4</xref>). Most negative acting drugs targeted tubulin and cell cycle proteins or were pro-inflammatory agents (<xref ref-type="fig" rid="app1fig5">Appendix 1—figure 5</xref>). Positive and negative acting compounds did not differ in average physiochemical properties (<xref ref-type="fig" rid="app1fig6">Appendix 1—figure 6</xref>), while assays based on GWAS-selected genes for IR (<xref ref-type="bibr" rid="bib71">Lotta et al., 2017</xref>; <xref ref-type="bibr" rid="bib129">Vujkovic et al., 2020</xref>) and T2DM produced no discernible pattern of in vitro hits.</p><p>The pharmacology of the 138 positive compounds indicated that a substantial number of targeted aspects of insulin signalling were known, empirically, to reverse IR in vivo (<xref ref-type="table" rid="table1">Table 1</xref>). Compounds identified varied in nature from inhibitors of glucosylceramide synthase, which reverses IR and fatty liver disease (<xref ref-type="bibr" rid="bib2">Aerts et al., 2007</xref>; <xref ref-type="bibr" rid="bib41">Herrera Moro Chao et al., 2019</xref>), to 10 mTOR inhibitors. The mTOR complex, mTORC1, coordinates a negative feedback loop on insulin signalling, for example, through activation of GRB10 or via S6K1 (<xref ref-type="bibr" rid="bib126">Um et al., 2004</xref>). mTORC1 signalling is also regulated by protein kinase C (PKC) (<xref ref-type="bibr" rid="bib148">Zhan et al., 2019</xref>), and specific PKC isoforms are dysregulated in ageing, metabolic, neurodegenerative and inflammatory diseases (<xref ref-type="bibr" rid="bib64">Li et al., 2015</xref>; <xref ref-type="bibr" rid="bib97">Sajan et al., 2018</xref>; <xref ref-type="bibr" rid="bib101">Sharma et al., 2019</xref>). We observed that the broad-spectrum PKC inhibitor, bisindolylmaleimide I, induced a strong positive IR signature score (+87) and the related compound, ruboxistaurin, reverses IR in vivo (<xref ref-type="bibr" rid="bib39">Guo et al., 2020</xref>; <xref ref-type="bibr" rid="bib81">Naruse et al., 2006</xref>). In contrast, bisindolylmaleimide IX, a 20-fold more potent broad-spectrum PKC inhibitor, was inactive in the IR-DR assay, probably reflecting its greater non-specific pharmacology (against other kinase families). Three so-called PKC activators (<xref ref-type="bibr" rid="bib32">French et al., 2020</xref>; <xref ref-type="bibr" rid="bib63">Lee et al., 2020</xref>) induced <italic>negative</italic> IR-DR scores (phorbol-12-myristate-13-acetate = –87, ingenol = –96 and prostratin = –97). RNAi targeting of individual PKC isoforms (<ext-link ext-link-type="uri" xlink:href="https://clue.io/">clue.io</ext-link>) demonstrated that the IR-DR assay was sensitive to specific PKC isoformactivity. While &gt;95% of all RNAi assays produced no significant scores, knock-down (KD) of PKC-beta (+74) and PKC-theta (+97) yielded positive IR-DR scores, while loss of PKC-alpha (–75) and -eta (–75) produced negative IR-DR scores and overexpression (OE) of PKC-alpha was positive scoring (+85). The multi-gene IR-DR assay therefore identifies numerous true-positive drugs (<xref ref-type="table" rid="table1">Table 1</xref>) and reflects isoform-specific activity, strongly validating the cell-agnostic aggregation methodology.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Examples of the major drug classes producing a positive insulin resistance-drug repurposing (IR-DR) score and associated literature evidencing efficacy.</title><p>In vivo refers to evidence for in vivo validation of the drug and/or its target proteins.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Pathway</th><th align="left" valign="top">Example drug</th><th align="left" valign="top">Biology narrative</th><th align="left" valign="top">In vivo</th><th align="left" valign="top">Example literature</th></tr></thead><tbody><tr><td align="left" valign="top">ATPase/cardiac glycoside</td><td align="left" valign="top">Proscillaridin, digoxin</td><td align="left" valign="top">Heart failure drug; possibly mimicking the action of metformin on mitochondria in vitro; senolytic.</td><td align="left" valign="top">No</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib34">Fürstenwerth, 2012</xref>; <xref ref-type="bibr" rid="bib125">Triana-Martínez et al., 2019</xref></td></tr><tr><td align="left" valign="top">Calcium channel</td><td align="left" valign="top">Nifedipine</td><td align="left" valign="top">Restores autophagy, improves glucose tolerance and insulin action.</td><td align="left" valign="top">Yes</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib51">Iwai et al., 2011</xref>; <xref ref-type="bibr" rid="bib60">Koyama et al., 2002</xref>; <xref ref-type="bibr" rid="bib62">Lee et al., 2019</xref>; <xref ref-type="bibr" rid="bib103">Sheu et al., 1991</xref></td></tr><tr><td align="left" valign="top">Calcium/calmodulin signalling</td><td align="left" valign="top">NM-PP1</td><td align="left" valign="top">Insulin signalling upstream of p38; restores ATF6-related autophagy; insulin resistance, diabetes and Alzheimer’s pathophysiology.</td><td align="left" valign="top">Yes</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib3">Alfazema et al., 2019</xref>; <xref ref-type="bibr" rid="bib88">Ozcan et al., 2015</xref>; <xref ref-type="bibr" rid="bib87">Ozcan et al., 2013</xref>; <xref ref-type="bibr" rid="bib145">Yin et al., 2017</xref></td></tr><tr><td align="left" valign="top">Dopamine</td><td align="left" valign="top">L-741626</td><td align="left" valign="top">Central and peripheral role in regulation of glucose tolerance – contradictory/paradoxical behavioural/hepatic agonist/antagonist activity.</td><td align="left" valign="top">Yes</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib4">Amamoto et al., 2006</xref>; <xref ref-type="bibr" rid="bib30">Fontaine et al., 2020</xref>; <xref ref-type="bibr" rid="bib58">Kellar and Craft, 2020</xref>; <xref ref-type="bibr" rid="bib91">Park et al., 2007</xref>; <xref ref-type="bibr" rid="bib110">Stoelzel et al., 2020</xref></td></tr><tr><td align="left" valign="top">Tyrosine kinase/ERBB receptor inhibitors</td><td align="left" valign="top">Canertinib, gefitinib, afatinib</td><td align="left" valign="top">Inhibition of EGFR, DDR1, ABL1 and related kinases produces a positive IR-DR score. Extensive data link EGFR and inhibitors of EGFR to insulin resistance and neurodegeneration. Pro-inflammatory signalling via iRHOM2 and MAP3K7; circulating biomarker of insulin resistance and hepatic metabolic disease.</td><td align="left" valign="top">Yes</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib15">Chen et al., 2019</xref>; <xref ref-type="bibr" rid="bib19">Chiu et al., 2020</xref>; <xref ref-type="bibr" rid="bib31">Fowler et al., 2020</xref>; <xref ref-type="bibr" rid="bib61">Kyohara et al., 2020</xref>; <xref ref-type="bibr" rid="bib67">Li et al., 2018b</xref>; <xref ref-type="bibr" rid="bib104">Skurski et al., 2020</xref>; <xref ref-type="bibr" rid="bib127">Vella et al., 2019</xref>; <xref ref-type="bibr" rid="bib133">Wang et al., 2012</xref>; <xref ref-type="bibr" rid="bib141">Wu et al., 2017</xref></td></tr><tr><td align="left" valign="top">Glucocorticoid/anti-inflammatory</td><td align="left" valign="top">Valdecoxib, Spectrum_001832</td><td align="left" valign="top">Anti-inflammatory; various steroidal and non-steroidal anti-inflammatory drugs reduce IR in a variety of models of diabetes/obesity. Excess corticosteroids induce IR.</td><td align="left" valign="top">Yes</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib13">Chakraborti et al., 2010</xref>; <xref ref-type="bibr" rid="bib14">Chan et al., 2018</xref>; <xref ref-type="bibr" rid="bib94">Reading et al., 2013</xref></td></tr><tr><td align="left" valign="top">Glucosylceramide synthase</td><td align="left" valign="top">BRD-K88761633, AMP-DNM</td><td align="left" valign="top">Glycosphingolipid biosynthesis – inhibition treats insulin resistance and fatty liver disease.</td><td align="left" valign="top">Yes</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib2">Aerts et al., 2007</xref>; <xref ref-type="bibr" rid="bib41">Herrera Moro Chao et al., 2019</xref></td></tr><tr><td align="left" valign="top">Heat-shock protein 90</td><td align="left" valign="top">Luminespib</td><td align="left" valign="top">ATPase cycle and chaperone function – inhibition improves insulin sensitivity; Hsp90 activated in dementia. Role in INSR turnover and protein phosphatase 5 activation.</td><td align="left" valign="top">Yes</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib49">Imamura et al., 1998</xref>; <xref ref-type="bibr" rid="bib55">Jing et al., 2018</xref>; <xref ref-type="bibr" rid="bib102">Shelton et al., 2017</xref>; <xref ref-type="bibr" rid="bib143">Yang et al., 2005</xref></td></tr><tr><td align="left" valign="top">MAPK/MEK/ERK inhibitors</td><td align="left" valign="top">PD-184352, PD-0325901, XMD-892</td><td align="left" valign="top">Multiple roles in insulin signalling and metabolism; inhibitors target multiple kinases.</td><td align="left" valign="top">Yes</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib86">Ozaki et al., 2016</xref>; <xref ref-type="bibr" rid="bib100">Sharma et al., 2014</xref>; <xref ref-type="bibr" rid="bib119">Tarragó et al., 2018</xref>; <xref ref-type="bibr" rid="bib136">Wauson et al., 2013</xref></td></tr><tr><td align="left" valign="top">mTOR related</td><td align="left" valign="top">AZD-8055, WYE-354, torin-2</td><td align="left" valign="top">Inhibition of mTORC1 activity – including knock-down of RAPTOR – produces a strong positive IR-DR score. In multiple studies, mTOR inhibition reduces age-related metabolic dysfunction.</td><td align="left" valign="top">Yes</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib46">Howell et al., 2017</xref>; <xref ref-type="bibr" rid="bib52">Jahng et al., 2019</xref>; <xref ref-type="bibr" rid="bib78">Morita et al., 2013</xref>; <xref ref-type="bibr" rid="bib82">Nie et al., 2018a</xref>; <xref ref-type="bibr" rid="bib84">Norambuena et al., 2017</xref>; <xref ref-type="bibr" rid="bib148">Zhan et al., 2019</xref></td></tr><tr><td align="left" valign="top">Nicotinamide phosphoribosyltransferase</td><td align="left" valign="top">CAY-10618 (GPP78)</td><td align="left" valign="top">NAMPT (or visfatin) inhibitor which attenuates atherosclerosis in the high-fat-induced insulin resistance model and is anti-inflammatory.</td><td align="left" valign="top">Yes</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib65">Li et al., 2016</xref>; <xref ref-type="bibr" rid="bib70">Lockman et al., 2010</xref>; <xref ref-type="bibr" rid="bib124">Travelli et al., 2017</xref></td></tr><tr><td align="left" valign="top">Phosphodiesterase 5A</td><td align="left" valign="top">MBCQ, sidenafil</td><td align="left" valign="top">PDE5A is negative regulator of insulin, aspects of ageing – potentially via miR-22-3p.</td><td align="left" valign="top">Yes</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib6">Blagosklonny, 2017</xref>; <xref ref-type="bibr" rid="bib29">Fiore et al., 2018</xref>; <xref ref-type="bibr" rid="bib28">Fiore et al., 2016</xref>; <xref ref-type="bibr" rid="bib69">Liu et al., 2019</xref></td></tr><tr><td align="left" valign="top">Phosphoinositide 3-kinase</td><td align="left" valign="top">AZD-6482, PI-103, GDC-0941</td><td align="left" valign="top">Multiple PI3K inhibitors produce strong positive IR-DR scores. In multiple studies PI3K varies with metabolic dysfunction; however, all kinase inhibitors target multiple related kinases, so specific target unclear.</td><td align="left" valign="top">No</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib19">Chiu et al., 2020</xref>; <xref ref-type="bibr" rid="bib23">Copps et al., 2016</xref>; <xref ref-type="bibr" rid="bib135">Wang et al., 2020</xref>; <xref ref-type="bibr" rid="bib150">Zou et al., 2004</xref></td></tr><tr><td align="left" valign="top">RAF kinase</td><td align="left" valign="top">AZ-628, vemurafenib</td><td align="left" valign="top">RAF1 is increased in obesity-induced IR, inhibitors can block insulin/AKT1/MAPK signalling in a context-specific manner. AZ-628 also RIP3 inhibitor – anti-arthritis strategy.</td><td align="left" valign="top">No</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib73">MacLaren et al., 2008</xref>; <xref ref-type="bibr" rid="bib85">Osrodek et al., 2020</xref>; <xref ref-type="bibr" rid="bib115">Sun et al., 2016</xref></td></tr></tbody></table><table-wrap-foot><fn><p>EGFR, epidermal growth factor receptor.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-3"><title>Identification of the active drug-protein targets through single-gene targeting and network biology</title><p>The 138 positive scoring IR-DR drugs target 1007 proteins (<xref ref-type="bibr" rid="bib76">Mendez et al., 2019</xref>; <xref ref-type="bibr" rid="bib77">Moret et al., 2019</xref>). Of these, 465 genes had single-gene KD or OE scores, aggregated across 6–9 cell lines (<xref ref-type="fig" rid="app1fig7">Appendix 1—figure 7</xref>). Seventy-three targets (15.7%) yielded a significant IR-DR score; double the assay hit rate (p&lt;0.0001, see Methods and <xref ref-type="fig" rid="fig2">Figure 2</xref>). Predictably, due to input bias (<xref ref-type="bibr" rid="bib121">Timmons et al., 2015</xref>), these targets regulated ‘peptidyl-serine phosphorylation-related processes’ (q-value &lt;1 × 10<sup>–23</sup>). None belonged to the IR-DR gene signature (<xref ref-type="fig" rid="app1fig8">Appendix 1—figure 8</xref>), but they did belong to numerous common pathways (<xref ref-type="fig" rid="app1fig8">Appendix 1—figure 8</xref>). These observations are consistent with the idea that an effective DR signature captures the pathway biology of the disease and/or treatment (<xref ref-type="bibr" rid="bib8">Brown and Patel, 2018</xref>; <xref ref-type="bibr" rid="bib16">Chen et al., 2020</xref>; <xref ref-type="bibr" rid="bib56">Karatzas et al., 2017</xref>; <xref ref-type="bibr" rid="bib57">Keenan et al., 2018</xref>; <xref ref-type="bibr" rid="bib96">Regan-Fendt et al., 2019</xref>; <xref ref-type="bibr" rid="bib130">Wagner et al., 2015</xref>; <xref ref-type="bibr" rid="bib140">Woo et al., 2015</xref>) but does not necessarily include the nominal drug targets (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>The overlap between protein targets of positively acting drugs and the insulin resistance-drug repurposing (IR-DR) input signature.</title><p>(<bold>A</bold>) A network of significant pathways coloured by p-values, derived from the IR-DR input genes and the 73 validated protein targets of the 150 positively acting drugs. (<bold>B</bold>) Edges represent connected Gene Ontology (GO) biological processes (&gt;0.3), and nodes within each cluster are coloured/named by their most statistically enriched GO term. (<bold>C</bold>) Each node is presented as a pie chart, scaled in size by the total number of terms represented by that (top-scoring) ontology, and with the ‘slices’ coloured to indicate which gene list the terms originate from. The same network structure is separately colour-coded by list membership to identify when pathways include members of Signature 3A (red), or protein targets which are negative acting genes (blue, where inhibition yields a positive and overexpression yields a negative IR-DR score) or genes appear to be positively acting (green).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68832-fig2-v1.tif"/></fig><p>Network representation of how these 73 <italic>independently</italic> validated target proteins of active drugs (<xref ref-type="fig" rid="app1fig4">Appendix 1—figure 4</xref>) interact with IR-DR signature at a pathway level is presented in <xref ref-type="fig" rid="fig2">Figure 2</xref>A (Benjamini-Hochberg corrected p-values). The GO terms are scaled by the total number of significant terms and labelled by the top-level category (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Coloured orange (<xref ref-type="fig" rid="fig2">Figure 2</xref>B), a module of the ‘carboxylic acid biosynthetic process’ pathway contains genes that, when more ‘active,’ positively modulate the IR-DR signature (Z = 8.3, p=1 × 10<sup>–9</sup>). Each pathway is also coloured (<xref ref-type="fig" rid="fig2">Figure 2</xref>C) to indicate whether it contains a known drug target or was part of the IR-DR signature. The IR-DR assay genes formed eight pathway clusters, of which the majority directly contain some RNAi validated protein targets, for example, ‘negative regulation of phosphate metabolic process’ (coloured brown, q-value 1 × 10<sup>–7</sup>). As with the analysis of the individual PKC isoforms, there are compelling examples of proteins contributing to metabolic disease, for example, SMAD3 (+87 IR-DR score from OE and –95 IR-DR score from RNAi) is an in vivo-validated IR pathway (<xref ref-type="bibr" rid="bib9">Budi et al., 2019</xref>; <xref ref-type="bibr" rid="bib114">Sun et al., 2015</xref>; <xref ref-type="bibr" rid="bib116">Tan et al., 2011</xref>). However, if multi-gene DR assays are to be used for optimising drug properties, it is critical to establish that they can produce quantitative pharmacological feedback when comparing related drugs (<xref ref-type="bibr" rid="bib45">Hopkins, 2008</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>An analysis of the relationship between the insulin resistance-drug repurposing (IR-DR) score and laboratory-based pharmacological potency and selectivity or deep learning-based predictions of compound potency and selectivity.</title><p>(<bold>A</bold>) Inhibitory constants (nM) derived from laboratory assays against top-ranked targets for a series of epidermal growth factor receptor (EGFR) inhibitors. (<bold>B</bold>) Relationship between IR-DR score (100 = best score) and log potency against EGFR. (<bold>C</bold>) Expanded range of known targets, for at least one of the inhibitors, helps identify potentially positive (red box) and negative (blue box) off-target inhibitory actions. (<bold>D</bold>) Rank order score (RS, 1–19211) of predicted compound binding for all protein-coding genes using the DeepPurpose ML model; lab-validated targets feature in top 0.15% of target predictions. Log rank order (‘predicted potency’) for EGFR, over the protein-coding genome, partly predicts efficacy in IR-DR assay, confirming that the ML model matches the relationship observed using the laboratory pharmacology. (<bold>E</bold>) Using the predicted protein targets and the DeepPurpose rank order scores, it is possible to cluster positively acting ‘EGFR’ compounds from less active or negatively acting compounds.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68832-fig3-v1.tif"/></fig></sec><sec id="s2-4"><title>Aggregated IR-DR assay score directly relates to pharmacologically derived in vitro potency</title><p>The relationship between in vitro drug potency and IR-DR assay score for 37 compounds (<xref ref-type="fig" rid="app1fig5">Appendix 1—figure 5</xref>), nominally targeting epidermal growth factor receptor (EGFR or HER1) tyrosine kinase, was investigated. This stress-induced inflammatory protein has recently emerged as a target for treating metabolic disease and neurodegeneration (<xref ref-type="bibr" rid="bib25">Donath, 2021</xref>; <xref ref-type="bibr" rid="bib75">Menden et al., 2019</xref>; <xref ref-type="bibr" rid="bib84">Norambuena et al., 2017</xref>). One endogenous EGFR ligand, amphiregulin, is induced by high-fat feeding to drive TNF-mediated IR (<xref ref-type="bibr" rid="bib104">Skurski et al., 2020</xref>), while EGFR is overexpressed in astrocytes of Alzheimer’s disease (AD). The EGFR inhibitor afatinib (IR-DR score = 77) attenuates astrocyte activation (<xref ref-type="bibr" rid="bib15">Chen et al., 2019</xref>) while inhibition of EGFR can reduce FOXK1 and FOXK2 phosphorylation (<xref ref-type="bibr" rid="bib59">Klaeger et al., 2017</xref>) to normalise mTORC1-regulated autophagy and reduce IR (<xref ref-type="bibr" rid="bib7">Bowman et al., 2014</xref>; <xref ref-type="bibr" rid="bib52">Jahng et al., 2019</xref>). Nine EGFR inhibitors have been screened against &gt;300 kinases (<xref ref-type="bibr" rid="bib24">Davis et al., 2011</xref>; <xref ref-type="bibr" rid="bib59">Klaeger et al., 2017</xref>), which enabled us to directly contrast laboratory-derived kinase selectivity with the IR-DR score. Potency versus EGFR directly related to IR-DR assay score (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), yet this could not fully explain why certain compounds were inactive. Cluster analysis of the most targeted proteins (&lt;300 nM potency for at least one compound) illustrated that alisertib, the only potent EGFR inhibitor with a negative IR-DR score (–90), inhibited PLK4, AURKB and AURKA (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Orantinib, a 24 nM inhibitor of AURKB, also had a negative IR-DR score (–77), as did MK-5108, an inhibitor of AURKB and AURKA (–90), indicating that alisertib’s profile reflects pharmacology beyond EGFR (probably AURKB as AURKB KD had an IR-DR score of –83, Table S3).</p></sec><sec id="s2-5"><title>Multiple protein targets help explain the positive activity of EGFR targeting drugs</title><p>A broader exploration of ‘EGFR’ inhibitor targets provides a better understanding of the activity of this group of compounds in the IR-DR assay. For example, neutral scoring bosutinib and neratinib target several mitogen-activated protein kinase (MAPK) family members, and some of these oppose positive IR-DR scoring, for example, MAP2K2 (–78, Table S4). Neutral scoring, yet potent EGFR inhibitors (e.g. neratinib, bosutinib and lapatinib) also inhibit the related proteins, ERBB2, ERBB3 and ERBB4 (&lt;5 nM, HER2-4). Some of these family members may represent beneficial ‘off targets’ while others may be detrimental (<xref ref-type="bibr" rid="bib77">Moret et al., 2019</xref>). For example, hyperglycaemia induces erbb4 in mice and erbb4 expression is increased in AD (<xref ref-type="bibr" rid="bib48">Huh et al., 2016</xref>; <xref ref-type="bibr" rid="bib139">Woo et al., 2011</xref>), where OE increases tau phosphorylation via mTOR activation (<xref ref-type="bibr" rid="bib83">Nie et al., 2018b</xref>). Gefitinib (an EGFR inhibitor) reduces IR-mediated glucose excursions in vivo in a RIPK2-dependent manner (<xref ref-type="bibr" rid="bib26">Duggan et al., 2020</xref>) and rescues memory deficits in mice at a very low chronic dose of 0.01 mg/kg (<xref ref-type="bibr" rid="bib133">Wang et al., 2012</xref>). Loss of RIPK2 (or a dominant-negative mutant of RIPK2) prevents excessive NFκB activation (<xref ref-type="bibr" rid="bib18">Chin et al., 2002</xref>), and RIPK2 is a downstream effector of innate immunity (TLR signalling).</p><p>Some EGFR targeting drugs also potently inhibit the tyrosine kinase ABL1, and loss of adipose ABL1 reduces obesity-induced IR in the mouse (<xref ref-type="bibr" rid="bib141">Wu et al., 2017</xref>). Erlotinib (IR-DR score = +72), which also inhibits ABL1, reduces kidney inflammation and preserves pancreas function and insulin sensitivity in a mouse model of diabetes (<xref ref-type="bibr" rid="bib67">Li et al., 2018b</xref>). Furthermore, Aβ activates neuronal ABL1 in vitro, intra-hippocampal injection of Aβ fibrils increases expression of ABL1 in vivo and imatinib (STI571), a 90 nM inhibitor of ABL1, inhibits ABL1-mediated Aβ neurodegenerative pathways (<xref ref-type="bibr" rid="bib11">Cancino et al., 2011</xref>; <xref ref-type="bibr" rid="bib10">Cancino et al., 2008</xref>; <xref ref-type="bibr" rid="bib40">Gutierrez et al., 2019</xref>). However, imatinib does not yield a significant IR-DR score (nor inhibit EGFR), indicating that targeting ABL1 alone might be insufficient to treat human IR. Importantly, potency of the EGFR inhibitors against ABL1 also correlates with their potency against several ephrin receptors (EPHA5 <italic>R</italic> = 0.74, EPHA6 <italic>R</italic> = 0.95 and EPHA8 <italic>R</italic> = 0.76), as well as with RIPK2 (<italic>R</italic> = 0.77). Oral dosing of the ephrin A receptor inhibitor, UniPR500, reverses high-fat feeding-induced glucose intolerance without changes in plasma insulin (<xref ref-type="bibr" rid="bib37">Giorgio et al., 2019</xref>), and these benefits likely reflect UniPR500 targeting proteins in common with our top-ranked ‘EGFR’ kinase inhibitors. Thus, while drug potency against EGFR quantitatively tracks with the IR-DR score (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), this may reflect binding affinity at other related protein kinases, and identification of these additional targets is important (<xref ref-type="bibr" rid="bib95">Redhead et al., 2021</xref>).</p></sec><sec id="s2-6"><title>A DL model of genome-wide binding affinity ranks compound affinity in the IR-DR assay</title><p>Thus we find that (<xref ref-type="fig" rid="fig3">Figure 3A–C</xref>) the best scoring potent ‘EGFR’ kinase inhibitors reflect a balance of activities against positively and negatively acting <italic>kinases</italic> and that this is partly interpretable versus the extensive in vitro screening data for those drugs (<xref ref-type="bibr" rid="bib24">Davis et al., 2011</xref>; <xref ref-type="bibr" rid="bib59">Klaeger et al., 2017</xref>). Genome-wide pharmacological profiles are however prohibitively costly and thus often unavailable. Predicted drug-protein interactions, using emerging techniques from graph machine learning (<xref ref-type="bibr" rid="bib112">Sturm et al., 2020</xref>), aim to overcome this lack of laboratory data. Using the DeepPurpose DL suite of algorithms (<xref ref-type="bibr" rid="bib47">Huang et al., 2021</xref>), we modelled EGFR family kinase inhibitors as simplified molecular-input line-entry system (SMILES) string and all proteins by their amino acid sequence (a strategy that obfuscates the need for 3D structures obtained by costly experimental models). This expanded the scope of drug target information of the EGFR inhibitors discussed above to a genome-wide level (Tables S6-S8). Each of the EGFR inhibitors was scored against 19,211 proteins using 14 pre-trained models (Table S9), and we relied on a fusion of ranking scores across models to identify the top protein targets of each compound.</p><p>The nine EGFR inhibitors described above inhibit 25 proteins with nanomolar potency (&lt;300 nM), and the DL model accurately ranked these proteins in the top 0.1–1.7% of all 2,420,586 predictions (median = 0.15%, Table S6). The DL-predicted rank score (‘potency’) against EGFR strongly related to the measured IR-DR score (<xref ref-type="fig" rid="fig3">Figure 3D</xref>), replicating the potency-activity relationship noted using laboratory data (<xref ref-type="fig" rid="fig3">Figure 3A</xref>) correctly clustering the nine compounds (<xref ref-type="fig" rid="fig3">Figure 3C</xref>, <xref ref-type="fig" rid="app1fig9">Appendix 1—figure 9A</xref>). DL also ranked several proteins that we already identified may compromise a positive IR-DR score (<xref ref-type="fig" rid="fig3">Figure 3E</xref>, <xref ref-type="fig" rid="app1fig9">Appendix 1—figure 9</xref>). For example, AURKB was a top-ranked predicted target for alisertib (26/19211), aligning with the data that inhibition of AURKB drives a negative IR-DR score. Additional predicted protein targets (Table S8) will also influence the IR-DR score, independently of EGFR, for example, MERTK, KCNH6 and PTK2B (<xref ref-type="fig" rid="app1fig9">Appendix 1—figure 9</xref>). Loss of PTK2B (focal adhesion kinase 2 [FAK2]), a risk gene for the development of tauopathy in AD (<xref ref-type="bibr" rid="bib117">Tan et al., 2021</xref>), can promote the development of IR in vivo and in adipocytes (<xref ref-type="bibr" rid="bib72">Luk et al., 2017</xref>; <xref ref-type="bibr" rid="bib146">Yu et al., 2005</xref>) while inhibition of KCNH6 should probably be avoided,as it regulates insulin secretion (<xref ref-type="bibr" rid="bib144">Yang et al., 2018</xref>). In contrast, a genetic loss-of-function variation in MERTK appears protective against IR, fatty liver disease and pro-inflammatory mediators in humans (<xref ref-type="bibr" rid="bib79">Musso et al., 2017</xref>), and thus it represents a potential protein target against which current ‘EGFR’ inhibitors should be screened against. Therefore, we applied the same modelling strategy to 16 of the 28 less well-characterised EGFR inhibitors with proven sub-micromolar activity. Each was ranked highly by the model against EGFR (Table S7)<bold>,</bold> with MAP3K19 being one of the highest ranked additional targets (<xref ref-type="fig" rid="app1fig10">Appendix 1—figure 10</xref>)<bold>,</bold> and there was a negative correlation between predicted MAP3K19 binding and IR-DR score (<xref ref-type="fig" rid="app1fig10">Appendix 1—figure 10</xref>). Little is known about MAP3K19 (a ‘dark’ kinase) other than that it may contribute to ERK pathway activation (<xref ref-type="bibr" rid="bib44">Hoang et al., 2020</xref>) – and some ERK inhibitors proved positive scoring in the IR-DR assay (<xref ref-type="fig" rid="app1fig3">Appendix 1—figure 3</xref>) – and thus MAP3K19 may be a novel positive effector of insulin signalling. MAP3K19 is not abundantly expressed in adipose or muscle tissue (lowest 10th percentile of gene expression in our studies) such that net compound efficacy in vivo may also reflect tissue-specific patterns of protein activity.</p></sec><sec id="s2-7"><title>General conclusions and limitations</title><p>We illustrate that a cell-line transcriptome-based high-throughput DR assay yields interpretable and quantitative pharmacological data when designed around robust clinical RNA signatures, and that DL-based drug target predictions can be used to interpret assay scores. Some of the drugs we identified may be suitable for treating acute IR, such as occurring during infection (<xref ref-type="bibr" rid="bib12">Ceriello et al., 2020</xref>; <xref ref-type="bibr" rid="bib25">Donath, 2021</xref>), and encouragingly several positive scoring drugs appear tolerable in longer-term preclinical models of metabolic or neurogenerative disease (<xref ref-type="bibr" rid="bib67">Li et al., 2018b</xref>; <xref ref-type="bibr" rid="bib133">Wang et al., 2012</xref>). The present approach could be extended to include a stratified medicine component, where evaluation of positively acting compounds is first trialled in T2DM patients with extreme IR (<xref ref-type="bibr" rid="bib20">Choi et al., 2019</xref>). A number of positively acting IR-DR compounds, including selected mTOR inhibitors (<xref ref-type="fig" rid="app1fig3">Appendix 1—figure 3</xref>), are able to mimic a longevity-related RNA signature (<xref ref-type="bibr" rid="bib123">Timmons et al., 2019</xref>) and thus may be potential geroprotectors (<xref ref-type="bibr" rid="bib33">Fuentealba et al., 2019</xref>). A more extensive multi-disease signature approach could ultimately help tailor the DR process to the individual patient. We do acknowledge that some IR-DR assay negative scores may be false negatives, for example, selective HDAC inhibition (HDACi) can, through lower and shorter daily exposure (<xref ref-type="bibr" rid="bib98">Sartor et al., 2019</xref>; <xref ref-type="bibr" rid="bib128">Volmar et al., 2017</xref>), be beneficial (although positive attributes of HDACi on IR appear to reflect non-specific actions; <xref ref-type="bibr" rid="bib74">Martins et al., 2019</xref>). Furthermore, despite correctly matching with nuclear receptor-induced muscle transcriptome signatures in vivo, there was a dearth of matches in vitro indicating that further optimisation of the IR-DR assay format is merited. It can be the case that certain classes of ligand require more sophisticated assay condition or require the use of primary cells. In conclusion; human transcriptome signatures, classic pharmacological assays, drug action in vivo and DL-based target prediction consistently link with drug transcriptional profiles in cell lines, establishing that expansion of such resources represents an important strategy for future DR efforts.</p></sec></sec><sec id="s3" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">R</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.r-project.org/">https://www.r-project.org/</ext-link></td><td align="char" char="." valign="bottom">3.6.3 and 4.04</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Python</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.python.org/">https://www.python.org/</ext-link></td><td align="left" valign="bottom">D1306</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">DeepPurpose</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://github.com/kexinhuang12345/DeepPurpose.git">https://github.com/kexinhuang12345/DeepPurpose.git</ext-link>; <break/><xref ref-type="bibr" rid="bib47">Huang et al., 2021</xref></td><td align="char" char="." valign="bottom">2020</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Venny</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://bioinfogp.cnb.csic.es/tools/venny/">https://bioinfogp.cnb.csic.es/tools/venny/</ext-link></td><td align="char" char="." valign="bottom">2.10</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Metascape</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://metascape.org/gp/index.html#/main/step1">http://metascape.org/gp/index.html#/main/step1</ext-link></td><td align="char" char="." valign="bottom">2020</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">CLUE</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://clue.io/">https://clue.io/</ext-link></td><td align="left" valign="bottom">March 2020</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">PubChem</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/">https://pubchem.ncbi.nlm.nih.gov/</ext-link></td><td align="left" valign="bottom">December 2020</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">PubMed</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/">https://pubmed.ncbi.nlm.nih.gov/</ext-link></td><td align="left" valign="bottom">December 2020</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">SMS</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://labsyspharm.shinyapps.io/smallmoleculesuite/">https://labsyspharm.shinyapps.io/smallmoleculesuite/</ext-link></td><td align="left" valign="bottom">December 2020</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">iLINCS</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://www.ilincs.org/ilincs/signatures/search/">http://www.ilincs.org/ilincs/signatures/search/</ext-link></td><td align="left" valign="bottom">March 2020</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Morpheus</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://clue.io/morpheus">https://clue.io/morpheus</ext-link></td><td align="char" char="." valign="bottom">2021</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Code</td><td align="left" valign="bottom">Source_code_file.docx</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">R/Python code used in project</td></tr></tbody></table></table-wrap><p>We utilised human muscle and adipose tissue transcriptome profiles from multiple large studies (<xref ref-type="bibr" rid="bib22">Civelek et al., 2017</xref>; <xref ref-type="bibr" rid="bib80">Nakhuda et al., 2016</xref>; <xref ref-type="bibr" rid="bib106">Slentz et al., 2016</xref>; <xref ref-type="bibr" rid="bib122">Timmons et al., 2018</xref>). The individual sample identifiers utilised in this study are reported (<xref ref-type="fig" rid="app1fig10">Appendix 1—figure 10</xref>) and deposited online at GEO. Gene expression (IRON-normalised data; <xref ref-type="bibr" rid="bib137">Welsh et al., 2013</xref>) was contrasted against log-transformed HOMA2-IR values (measured in fasting blood [<xref ref-type="bibr" rid="bib131">Wallace et al., 2004</xref>] using the Excel-based version of <ext-link ext-link-type="uri" xlink:href="http://www.dtu.ox.ac.uk/homacalculator">http://www.dtu.ox.ac.uk/homacalculator</ext-link>, adjusting for patient age) using ANOVA and linear regression (<xref ref-type="bibr" rid="bib122">Timmons et al., 2018</xref>). A robust transcriptional signature of IR shared across two human insulin-targeted tissues was identified (from a total of 337 genes significantly regulated in muscle, FDR &lt; 5%, absolute correlation-coefficient (CC) &gt;0.15); this represented our ‘disease signature’ (<xref ref-type="fig" rid="app1fig11">Appendix 1—figure 11</xref>). Gene expression responses that are proportional to treatment efficacy (reduced IR) and consistent across two human tissue types have not been previously investigated. Change in gene expression was derived from biopsy samples obtained before and following supervised lifestyle intervention. Lifestyle intervention ranged from aerobic to resistance training with modest calorie restriction, and varied in duration from 15 min (e.g. high-intensity cycle-based exercise) to &gt;1 hr 3 days a week, as previously detailed (<xref ref-type="bibr" rid="bib1">AbouAssi et al., 2015</xref>; <xref ref-type="bibr" rid="bib80">Nakhuda et al., 2016</xref>; <xref ref-type="bibr" rid="bib93">Phillips et al., 2017</xref>; <xref ref-type="bibr" rid="bib105">Slentz et al., 2011</xref>). In short, we located genes tracking with efficacy, regardless of clinical protocol or ‘dosage’. Change in gene expression was related to change in HOMA2-IR identifying a consistent ‘treatment signature’ for muscle (mean q-value &lt; 0.08, CC values consistent in 3/4 of muscle studies), and then those similarly regulated in adipose tissue were retained.</p><sec id="s3-1"><title>Feature selection and in vivo DR validation step</title><p>The disease and the treatment genes lists represent the pool of features from which we selected IR-DR signatures. Quantitative network modelling (<xref ref-type="bibr" rid="bib107">Song and Zhang, 2015</xref>) was applied to tissue expression values of these genes, as previously described (<xref ref-type="bibr" rid="bib123">Timmons et al., 2019</xref>), to identify hub genes; genes with greater connectivity (<xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1</xref>). Four alternative similarly sized sets of genes were selected for validation, comprising 60 positively associated and 60 negatively associated RNAs. The final models shared only two genes named as candidates from genome-wide IR association studies (<xref ref-type="bibr" rid="bib71">Lotta et al., 2017</xref>), and those genes (INSR and GRB14) were not essential for our analysis. To rank the performance of each of our four RNA assays (Table S1), we utilised DrugMatrix, a database of in vivo rodent tissue drug-response signatures (<ext-link ext-link-type="uri" xlink:href="http://www.ilincs.org/ilincs/">http://www.ilincs.org/ilincs/</ext-link>) that includes TZD and oestrogen-related molecules known to reverse IR in vivo (<xref ref-type="bibr" rid="bib42">Hevener et al., 2018</xref>; <xref ref-type="bibr" rid="bib99">Sears et al., 2009</xref>) and target IR pathways in cell models (<xref ref-type="bibr" rid="bib108">Sood et al., 2016</xref>). Signatures validated at this stage were considered suitable for further use. Lists that failed this step (lists 4 and 5) included genes inferred from genome-wide IR association studies, and T2DM proteome biomarkers (<xref ref-type="bibr" rid="bib38">Gudmundsdottir et al., 2020</xref>; <xref ref-type="bibr" rid="bib71">Lotta et al., 2017</xref>; <xref ref-type="bibr" rid="bib129">Vujkovic et al., 2020</xref>) were modelled in vitro only to produce summary statistics for Table S1.</p></sec><sec id="s3-2"><title>In vitro DR analysis</title><p>The in vivo-validated IR signatures were screened using the largest public database of in vitro drug signatures (<xref ref-type="bibr" rid="bib113">Subramanian et al., 2017</xref>) via the <ext-link ext-link-type="uri" xlink:href="https://clue.io/">clue.io</ext-link> resource (version 1, 2020). These drug transcriptional signatures were generated in nine cell lines, and while each cell line captures some unique signals from each compound (<xref ref-type="bibr" rid="bib5">Baillif et al., 2020</xref>), part of this will be noise, reflecting the small sample size (typically n = 3). Therefore, we used aggregated signature matching across the nine human cell lines (PC3, VCAP, A375, A549, HA1E, HCC515, HT29, MCF7 and HEPG2) to both deliberately reduce the influence of cell line-specific effects (<xref ref-type="bibr" rid="bib142">Xu et al., 2018</xref>) and to increase the sample size ninefold (<xref ref-type="bibr" rid="bib113">Subramanian et al., 2017</xref>). Active compounds were those with scores exceeding ~10th percentile of positive and negative scores (<xref ref-type="fig" rid="app1fig3">Appendix 1—figure 3</xref>), a value that represents the mean threshold (±1 standard deviation) of scores exceeding the assay scoring threshold (<xref ref-type="bibr" rid="bib113">Subramanian et al., 2017</xref>). The use of aggregated scores across cell types was validated using an extensive validation process (<xref ref-type="fig" rid="fig1">Figure 1</xref>). In addition to our IR-DR assay, we considered two additional in vivo RNA models. One is a novel 141-gene human-derived muscle growth signature (<xref ref-type="bibr" rid="bib111">Stokes et al., 2020</xref>), which demonstrated – as expected – that the <ext-link ext-link-type="uri" xlink:href="https://clue.io/">clue.io</ext-link> database contains a sizeable number of compounds known to inhibit cell growth (negative-scoring compounds, <xref ref-type="fig" rid="app1fig2">Appendix 1—figure 2</xref> and <xref ref-type="fig" rid="app1fig3">Appendix 1—figure 3</xref>). The second was an IR-adjusted longevity-associated signature (<xref ref-type="bibr" rid="bib123">Timmons et al., 2019</xref>), which identified relevant drug matches from the cell-line perturbagen database (<xref ref-type="fig" rid="app1fig2">Appendix 1—figure 2</xref> and ‘Discussion’). The output from each assay was a list of &gt;2500 DR scores, each assigned to a particular assay ID and drug name. There then followed a laborious manual annotation process, reflecting that study of drugs is challenging (<xref ref-type="bibr" rid="bib21">Christmann-Franck et al., 2016</xref>), and annotation errors populate all databases, including iLINCS. For all of the active compounds, we carried out a manual check to ensure that compound labels in CLUE were verifiable in Chembl (<xref ref-type="bibr" rid="bib76">Mendez et al., 2019</xref>), and that both were consistent with the data deposited in the small molecule suit (<xref ref-type="bibr" rid="bib77">Moret et al., 2019</xref>). The manually confirmed data progressed to the next phase of the analysis.</p></sec><sec id="s3-3"><title>Characterisation of active compounds</title><p>Active compounds belonged to a wide range of distinct pharmacological classes (<xref ref-type="fig" rid="app1fig4">Appendix 1—figures 4</xref> and <xref ref-type="fig" rid="app1fig5">5</xref>). To identify if positive and negatively acting compounds (from IR-DR score) could be easily distinguished from each other, we calculated simple molecular descriptors. A set of 2837 compounds for which in vitro results were available was considered, and chemical structures were extracted from the CLUE database (<ext-link ext-link-type="uri" xlink:href="https://clue.io/">https://clue.io/</ext-link>) as SMILES strings. These were parsed with RDKit (version 2020.03.6), with 14 compounds failing to parse correctly. For each compound, a set of 13 physicochemical descriptors was calculated with RDKit including molecular weight, heavy atom count, number of heteroatoms, LogP, number of rotatable bonds, topological polar surface area (TPSA), number of rings, number of aromatic rings, number of saturated rings, number of aliphatic rings, Balaban’s J index, number of hydrogen bond donors and number of hydrogen bond acceptors. Positive acting compounds were coloured in orange, and negative acting in blue (<xref ref-type="fig" rid="app1fig6">Appendix 1—figure 6</xref>). For each compound active against list 3A IR-DR signature (<xref ref-type="fig" rid="app1fig3">Appendix 1—figure 3</xref>), we identified their protein targets using a variety of resources (<xref ref-type="bibr" rid="bib21">Christmann-Franck et al., 2016</xref>, <ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/chembl/">https://www.ebi.ac.uk/chembl/</ext-link>, <ext-link ext-link-type="uri" xlink:href="https://clue.io/">https://clue.io/</ext-link>, and <ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/">https://pubchem.ncbi.nlm.nih.gov/</ext-link>). The small-molecule suite was used to extract laboratory-derived potency values against each protein (<ext-link ext-link-type="uri" xlink:href="https://labsyspharm.shinyapps.io/smallmoleculesuite/">https://labsyspharm.shinyapps.io/smallmoleculesuite/</ext-link>). Very few compounds are profiled against the majority (&gt;300) kinases. For those that had values, in vitro potency values (log10) were plotted against the IR-DR scores and Pearson’s correlation coefficients calculated in Excel, allowing us to establish the relationship between potency against a protein and the IR-DR score. Very extensive manual PubMed searches were then undertaken to characterise the positive and negative acting drugs using the terms ‘drug name’ ‘alternative drug name’ with the following terms used in sequence until either relevant publications were identified or no hits were obtained; insulin, diabetes, obesity, dementia, Alzheimer’s disease, COVID-19 and inflammation (during 2020).</p></sec><sec id="s3-4"><title>Single-gene manipulation and network biology</title><p>The in vitro drug signatures in <ext-link ext-link-type="uri" xlink:href="https://clue.io/">clue.io</ext-link> are the most robust data from that project (<xref ref-type="bibr" rid="bib113">Subramanian et al., 2017</xref>). However, the database also contains gene KD (n = 3799 genes) and OE (n = 2161 genes) data, making it possible to link the IR-DR signature with specific protein targets. The KD or OE activity score was again averaged across 6–9 cell lines, and we considered protein targets derived from the known targets of the active compound list (to limit the known higher false-positive rate with the KD/OE data; <xref ref-type="bibr" rid="bib113">Subramanian et al., 2017</xref>). As stated in the results, &gt;15% of IR-active drug targets yielded a significant IR-DR score. In comparison, a total of 459 genes were associated with an IR-DR score at a threshold of &gt;70 or &lt;-70, representing 265 positive associations (mean = 85) and 194 negative IR-DR scores (mean = –83), equalling only ~7% of all 5954 genomic assays. The pathway biology of the 73 independently validated protein targets was analysed using Metascape (<xref ref-type="bibr" rid="bib149">Zhou et al., 2019</xref>), along with the IR-DR signature (<xref ref-type="table" rid="table1">Table 1</xref>, <xref ref-type="fig" rid="app1fig2">Appendix 1—figure 2</xref>), where ‘Combo_sig’ represents the IR-DR pathways, and the 73 genes split into two lists depending on how KD or OE impacted on the IR-DR signature match (Table S4). For the data plot, edges represent connected GO biological processes (&gt;0.3), and nodes within each cluster are coloured/named by their most statistically enriched GO term (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Each node is presented as a pie chart, scaled in size by the total number of terms represented by that (top-scoring) ontology, and with the ‘slices’ coloured to indicate from which gene list the terms originate. The network structure is separately colour-coded (<xref ref-type="fig" rid="fig3">Figure 3C</xref>) by list membership to identify when drugs directly target IR-DR assay pathways (red); when KD or OE genes negatively correlated (blue) with the IR-DR score (inhibition yields a positive or OE yields a negative IR-DR score) or positively correlated (green) with the IR-DR score.</p></sec><sec id="s3-5"><title>Drug-target interaction prediction with DeepPurpose</title><p>To investigate the mechanisms of action of positively acting IR-DR compounds, we extended the existing pharmacological data with computationally derived drug-target interaction (DTI) predictions. Publicly available chemogenomic databases are very far from complete, and therefore, ML modelling approaches can be used to provide estimates for missing data. DL-based models have shown promise in this context (<xref ref-type="bibr" rid="bib36">Gaudelet et al., 2021</xref>; <xref ref-type="bibr" rid="bib53">James et al., 2020</xref>). We used DeepPurpose, a DL library for DTI prediction (<xref ref-type="bibr" rid="bib47">Huang et al., 2021</xref>) that takes as an input SMILES of the small molecules of interest and the amino acid sequences of the protein-coding genome. Different encoders were implemented to provide a compound and a protein embedding. The small molecule and protein embeddings are concatenated and fed to a multi-layer perceptron that predicts the binding affinity as a dissociation constant (K<sub>d</sub>). DeepPurpose provides a set of pre-trained models that can be used ‘off-the-shelf’. We used 14 pre-trained models that were available as of 01/12/2020. Those models differ from one another depending on the encoders and on the DTI training set. Drug encoders included convolutional neural network (CNN), daylight fingerprints, Morgan fingerprints and message-passing neural network (MPNN), while protein encoders amino acid composition (AAC) and CNN were used. The training sets were BindingDB (<xref ref-type="bibr" rid="bib68">Liu et al., 2007</xref>), DAVIS (<xref ref-type="bibr" rid="bib24">Davis et al., 2011</xref>) and KIBA (<xref ref-type="bibr" rid="bib118">Tang et al., 2014</xref>). A list of the models used is shown in Table S9. All DTI models described above were applied to obtain 14 rankings of 19,211 human proteins as potential targets for each compound. A final score was obtained by an average ranking of each protein across 14 models, with the final top-ranking targets predicted to be the most likely protein targets of the input drug list. Comparable consensus-oriented strategies are often applied in virtual screening to exploit the strengths of multiple models (<xref ref-type="bibr" rid="bib36">Gaudelet et al., 2021</xref>; <xref ref-type="bibr" rid="bib53">James et al., 2020</xref>) and achieve improved performance (<xref ref-type="bibr" rid="bib89">Palacio-Rodríguez et al., 2019</xref>; <xref ref-type="bibr" rid="bib92">Perez-Castillo et al., 2017</xref>). DeepPurpose models showed promising performance in various testing scenarios, and we refer to the original publication for further details. The code used for the entire analysis can be located in the supplemental document.</p></sec></sec></body><back><sec id="s4" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>received consultancy fees from McMaster University, and has a majority share of the stock in Augur Precision Medicine LTD. A patent may be processed for the drug screen</p></fn><fn fn-type="COI-statement" id="conf2"><p>is an employee of Relation Therapeutics LTD and owns stocks in the company. The author has no other competing interests to declare</p></fn><fn fn-type="COI-statement" id="conf3"><p>is affiliated with Augur Precision Medicine LTD. An application for the drug signature may be processed by the lead parties in the project</p></fn><fn fn-type="COI-statement" id="conf4"><p>An application for the drug signature may be processed by the lead parties in the project</p></fn><fn fn-type="COI-statement" id="conf5"><p>is affiliated with Augur Precision Medicine LTD and owns stocks in the company. An application for the drug signature may be processed by the lead parties in the project</p></fn><fn fn-type="COI-statement" id="conf6"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf7"><p>received travel fees and honoraria from the US National Dairy Council and the US Dairy Export Council. SP also received fees from Enhanced Recovery which were donated to charity. SP has a Canadian patent issued (Canadian patent 3052324 issued to Exerkine) and a US patent pending US patent 16/182891 pending to Exerkine, with no financial gains associated with these patents. The author has no other competing interests to declare</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Funding acquisition, Investigation, Project administration, Resources, Supervision, Visualization, Writing – original draft, Writing – review and editing, Data curation, Methodology</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Writing – review and editing, Formal analysis, Validation</p></fn><fn fn-type="con" id="con4"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Funding acquisition, Project administration, Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Funding acquisition, Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Data curation, Funding acquisition, Investigation, Resources, Writing – original draft</p></fn></fn-group></sec><sec id="s5" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-68832-transrepform1-v1.docx"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Supplementary Tables 1–10.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-68832-supp1-v1.xlsx"/></supplementary-material><supplementary-material id="scode1"><label>Source code 1.</label><caption><title>Computational code used in the present study.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-68832-supp2-v1.zip"/></supplementary-material></sec><sec id="s6" sec-type="data-availability"><title>Data availability</title><p>The gene expression data sets are available at GSE154846, GSE58559 and GSE70353.</p><p>The following previously published datasets were used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Timmons</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2018">2018</year><data-title>META-PREDICT: Dynamic responses of the global human skeletal muscle coding and noncoding transcriptome to exercise</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE154846">GSE154846</pub-id></element-citation></p><p><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Civelek</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><data-title>Subcutaneous adipose tissue gene expression from men that are part of the METSIM study</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE70353">GSE70353</pub-id></element-citation></p><p><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Josse</surname><given-names>AR</given-names></name><name><surname>Timmons</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2016">2016</year><data-title>Human adipose tissue profiled before and after 16 weeks of intense exercise training with a modest energy deficit</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE58559">GSE58559</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We acknowledge the contributions of current and former members of our research groups to the clinical studies and the funding associated with those published projects. Aspects of the present work were supported by a grant from the National Science and Engineering Research Council (NSERC) of Canada (RGPIN-2020) and R56AG061911 (NIA). JAT was supported by the British Heart Foundation. SMP was supported by the Canada Research Chairs funding scheme. The funders were not involved in the decision to submit the work for publication. Additional informatics analysis costs were supported by APM and RT LTD. A patent application for the use of RNA signatures to discover treatments for metabolic disease may be filed. JAT and DGF are shareholders in APM LTD, while AA and JPTK are shareholders in RT LTD. RJB is affiliated with APM LTD on a non-commercial basis. There are no other competing interests to declare.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>AbouAssi</surname><given-names>H</given-names></name><name><surname>Slentz</surname><given-names>CA</given-names></name><name><surname>Mikus</surname><given-names>CR</given-names></name><name><surname>Tanner</surname><given-names>CJ</given-names></name><name><surname>Bateman</surname><given-names>LA</given-names></name><name><surname>Willis</surname><given-names>LH</given-names></name><name><surname>Shields</surname><given-names>AT</given-names></name><name><surname>Piner</surname><given-names>LW</given-names></name><name><surname>Penry</surname><given-names>LE</given-names></name><name><surname>Kraus</surname><given-names>EA</given-names></name><name><surname>Huffman</surname><given-names>KM</given-names></name><name><surname>Bales</surname><given-names>CW</given-names></name><name><surname>Houmard</surname><given-names>JA</given-names></name><name><surname>Kraus</surname><given-names>WE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The effects of aerobic, resistance, and combination training on insulin sensitivity and secretion in overweight adults from STRRIDE AT/RT: a randomized trial</article-title><source>Journal of Applied Physiology</source><volume>118</volume><fpage>1474</fpage><lpage>1482</lpage><pub-id pub-id-type="doi">10.1152/japplphysiol.00509.2014</pub-id><pub-id pub-id-type="pmid">25882384</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aerts</surname><given-names>JM</given-names></name><name><surname>Ottenhoff</surname><given-names>R</given-names></name><name><surname>Powlson</surname><given-names>AS</given-names></name><name><surname>Grefhorst</surname><given-names>A</given-names></name><name><surname>van Eijk</surname><given-names>M</given-names></name><name><surname>Dubbelhuis</surname><given-names>PF</given-names></name><name><surname>Aten</surname><given-names>J</given-names></name><name><surname>Kuipers</surname><given-names>F</given-names></name><name><surname>Serlie</surname><given-names>MJ</given-names></name><name><surname>Wennekes</surname><given-names>T</given-names></name><name><surname>Sethi</surname><given-names>JK</given-names></name><name><surname>O’Rahilly</surname><given-names>S</given-names></name><name><surname>Overkleeft</surname><given-names>HS</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity</article-title><source>Diabetes</source><volume>56</volume><fpage>1341</fpage><lpage>1349</lpage><pub-id pub-id-type="doi">10.2337/db06-1619</pub-id><pub-id pub-id-type="pmid">17287460</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alfazema</surname><given-names>N</given-names></name><name><surname>Barrier</surname><given-names>M</given-names></name><name><surname>de Procé</surname><given-names>SM</given-names></name><name><surname>Menzies</surname><given-names>RI</given-names></name><name><surname>Carter</surname><given-names>R</given-names></name><name><surname>Stewart</surname><given-names>K</given-names></name><name><surname>Diaz</surname><given-names>AG</given-names></name><name><surname>Moyon</surname><given-names>B</given-names></name><name><surname>Webster</surname><given-names>Z</given-names></name><name><surname>Bellamy</surname><given-names>COC</given-names></name><name><surname>Arends</surname><given-names>MJ</given-names></name><name><surname>Stimson</surname><given-names>RH</given-names></name><name><surname>Morton</surname><given-names>NM</given-names></name><name><surname>Aitman</surname><given-names>TJ</given-names></name><name><surname>Coan</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Camk2n1 Is a Negative Regulator of Blood Pressure, Left Ventricular Mass, Insulin Sensitivity, and Promotes Adiposity</article-title><source>Hypertension</source><volume>74</volume><fpage>687</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.118.12409</pub-id><pub-id pub-id-type="pmid">31327268</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amamoto</surname><given-names>T</given-names></name><name><surname>Kumai</surname><given-names>T</given-names></name><name><surname>Nakaya</surname><given-names>S</given-names></name><name><surname>Matsumoto</surname><given-names>N</given-names></name><name><surname>Tsuzuki</surname><given-names>Y</given-names></name><name><surname>Kobayashi</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The elucidation of the mechanism of weight gain and glucose tolerance abnormalities induced by chlorpromazine</article-title><source>Journal of Pharmacological Sciences</source><volume>102</volume><fpage>213</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1254/jphs.fp0060673</pub-id><pub-id pub-id-type="pmid">17031068</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baillif</surname><given-names>B</given-names></name><name><surname>Wichard</surname><given-names>J</given-names></name><name><surname>Méndez-Lucio</surname><given-names>O</given-names></name><name><surname>Rouquié</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Exploring the Use of Compound-Induced Transcriptomic Data Generated From Cell Lines to Predict Compound Activity Toward Molecular Targets</article-title><source>Frontiers in Chemistry</source><volume>8</volume><elocation-id>296</elocation-id><pub-id pub-id-type="doi">10.3389/fchem.2020.00296</pub-id><pub-id pub-id-type="pmid">32391323</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blagosklonny</surname><given-names>MV</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>From rapalogs to anti-aging formula</article-title><source>Oncotarget</source><volume>8</volume><fpage>35492</fpage><lpage>35507</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.18033</pub-id><pub-id pub-id-type="pmid">28548953</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowman</surname><given-names>CJ</given-names></name><name><surname>Ayer</surname><given-names>DE</given-names></name><name><surname>Dynlacht</surname><given-names>BD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Foxk proteins repress the initiation of starvation-induced atrophy and autophagy programs</article-title><source>Nature Cell Biology</source><volume>16</volume><fpage>1202</fpage><lpage>1214</lpage><pub-id pub-id-type="doi">10.1038/ncb3062</pub-id><pub-id pub-id-type="pmid">25402684</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>AS</given-names></name><name><surname>Patel</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A review of validation strategies for computational drug repositioning</article-title><source>Briefings in Bioinformatics</source><volume>19</volume><fpage>174</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1093/bib/bbw110</pub-id><pub-id pub-id-type="pmid">27881429</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Budi</surname><given-names>EH</given-names></name><name><surname>Hoffman</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>YE</given-names></name><name><surname>Derynck</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Integration of TGF-β-induced Smad signaling in the insulin-induced transcriptional response in endothelial cells</article-title><source>Scientific Reports</source><volume>9</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1038/s41598-019-53490-x</pub-id><pub-id pub-id-type="pmid">31740700</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cancino</surname><given-names>GI</given-names></name><name><surname>Toledo</surname><given-names>EM</given-names></name><name><surname>Leal</surname><given-names>NR</given-names></name><name><surname>Hernandez</surname><given-names>DE</given-names></name><name><surname>Yévenes</surname><given-names>LF</given-names></name><name><surname>Inestrosa</surname><given-names>NC</given-names></name><name><surname>Alvarez</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>STI571 prevents apoptosis, tau phosphorylation and behavioural impairments induced by Alzheimer’s beta-amyloid deposits</article-title><source>Brain : A Journal of Neurology</source><volume>131</volume><fpage>2425</fpage><lpage>2442</lpage><pub-id pub-id-type="doi">10.1093/brain/awn125</pub-id><pub-id pub-id-type="pmid">18559370</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cancino</surname><given-names>GI</given-names></name><name><surname>Perez de Arce</surname><given-names>K</given-names></name><name><surname>Castro</surname><given-names>PU</given-names></name><name><surname>Toledo</surname><given-names>EM</given-names></name><name><surname>von Bernhardi</surname><given-names>R</given-names></name><name><surname>Alvarez</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>c-Abl tyrosine kinase modulates tau pathology and Cdk5 phosphorylation in AD transgenic mice</article-title><source>Neurobiology of Aging</source><volume>32</volume><fpage>1249</fpage><lpage>1261</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2009.07.007</pub-id><pub-id pub-id-type="pmid">19700222</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceriello</surname><given-names>A</given-names></name><name><surname>Standl</surname><given-names>E</given-names></name><name><surname>Catrinoiu</surname><given-names>D</given-names></name><name><surname>Itzhak</surname><given-names>B</given-names></name><name><surname>Lalic</surname><given-names>NM</given-names></name><name><surname>Rahelic</surname><given-names>D</given-names></name><name><surname>Schnell</surname><given-names>O</given-names></name><name><surname>Škrha</surname><given-names>J</given-names></name><name><surname>Valensi</surname><given-names>P</given-names></name><collab>Diabetes and Cardiovascular Disease (D&amp;CVD) EASD Study Group</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era</article-title><source>Diabetes Care</source><volume>43</volume><fpage>1427</fpage><lpage>1432</lpage><pub-id pub-id-type="doi">10.2337/dc20-0941</pub-id><pub-id pub-id-type="pmid">32409501</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakraborti</surname><given-names>AK</given-names></name><name><surname>Garg</surname><given-names>SK</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Motiwala</surname><given-names>HF</given-names></name><name><surname>Jadhavar</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Progress in COX-2 inhibitors: a journey so far</article-title><source>Current Medicinal Chemistry</source><volume>17</volume><fpage>1563</fpage><lpage>1593</lpage><pub-id pub-id-type="doi">10.2174/092986710790979980</pub-id><pub-id pub-id-type="pmid">20166930</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>PC</given-names></name><name><surname>Wu</surname><given-names>TN</given-names></name><name><surname>Chen</surname><given-names>YC</given-names></name><name><surname>Lu</surname><given-names>CH</given-names></name><name><surname>Wabitsch</surname><given-names>M</given-names></name><name><surname>Tian</surname><given-names>YF</given-names></name><name><surname>Hsieh</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Targetted inhibition of CD74 attenuates adipose COX-2-MIF-mediated M1 macrophage polarization and retards obesity-related adipose tissue inflammation and insulin resistance</article-title><source>Clinical Science</source><volume>132</volume><fpage>1581</fpage><lpage>1596</lpage><pub-id pub-id-type="doi">10.1042/CS20180041</pub-id><pub-id pub-id-type="pmid">29773671</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YJ</given-names></name><name><surname>Hsu</surname><given-names>CC</given-names></name><name><surname>Shiao</surname><given-names>YJ</given-names></name><name><surname>Wang</surname><given-names>HT</given-names></name><name><surname>Lo</surname><given-names>YL</given-names></name><name><surname>Lin</surname><given-names>AMY</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation</article-title><source>Scientific Reports</source><volume>9</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1038/s41598-019-38676-7</pub-id><pub-id pub-id-type="pmid">30792526</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Cheng</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>iDrug: Integration of drug repositioning and drug-target prediction via cross-network embedding</article-title><source>PLOS Computational Biology</source><volume>16</volume><elocation-id>e1008040</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1008040</pub-id><pub-id pub-id-type="pmid">32667925</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Prediction of drug-target interactions and drug repositioning via network-based inference</article-title><source>PLOS Computational Biology</source><volume>8</volume><elocation-id>e1002503</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1002503</pub-id><pub-id pub-id-type="pmid">22589709</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chin</surname><given-names>AI</given-names></name><name><surname>Dempsey</surname><given-names>PW</given-names></name><name><surname>Bruhn</surname><given-names>K</given-names></name><name><surname>Miller</surname><given-names>JF</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Involvement of receptor-interacting protein 2 in innate and adaptive immune responses</article-title><source>Nature</source><volume>416</volume><fpage>190</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1038/416190a</pub-id><pub-id pub-id-type="pmid">11894097</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiu</surname><given-names>HY</given-names></name><name><surname>Chiang</surname><given-names>CM</given-names></name><name><surname>Yeh</surname><given-names>SP</given-names></name><name><surname>Jong</surname><given-names>DS</given-names></name><name><surname>Wu</surname><given-names>LS</given-names></name><name><surname>Liu</surname><given-names>HC</given-names></name><name><surname>Chiu</surname><given-names>CH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Effects of hyperinsulinemia on acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor via the PI3K/AKT pathway in non-small cell lung cancer cells in vitro</article-title><source>Oncology Letters</source><volume>20</volume><elocation-id>206</elocation-id><pub-id pub-id-type="doi">10.3892/ol.2020.12069</pub-id><pub-id pub-id-type="pmid">32963612</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>SE</given-names></name><name><surname>Berkowitz</surname><given-names>SA</given-names></name><name><surname>Yudkin</surname><given-names>JS</given-names></name><name><surname>Naci</surname><given-names>H</given-names></name><name><surname>Basu</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Personalizing Second-Line Type 2 Diabetes Treatment Selection: Combining Network Meta-analysis, Individualized Risk, and Patient Preferences for Unified Decision Support</article-title><source>Medical Decision Making</source><volume>39</volume><fpage>239</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1177/0272989X19829735</pub-id><pub-id pub-id-type="pmid">30767632</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christmann-Franck</surname><given-names>S</given-names></name><name><surname>van Westen</surname><given-names>GJP</given-names></name><name><surname>Papadatos</surname><given-names>G</given-names></name><name><surname>Beltran Escudie</surname><given-names>F</given-names></name><name><surname>Roberts</surname><given-names>A</given-names></name><name><surname>Overington</surname><given-names>JP</given-names></name><name><surname>Domine</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Unprecedently Large-Scale Kinase Inhibitor Set Enabling the Accurate Prediction of Compound-Kinase Activities: A Way toward Selective Promiscuity by Design?</article-title><source>Journal of Chemical Information and Modeling</source><volume>56</volume><fpage>1654</fpage><lpage>1675</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.6b00122</pub-id><pub-id pub-id-type="pmid">27482722</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Civelek</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>C</given-names></name><name><surname>Raulerson</surname><given-names>CK</given-names></name><name><surname>Ko</surname><given-names>A</given-names></name><name><surname>He</surname><given-names>A</given-names></name><name><surname>Tilford</surname><given-names>C</given-names></name><name><surname>Saleem</surname><given-names>NK</given-names></name><name><surname>Stančáková</surname><given-names>A</given-names></name><name><surname>Scott</surname><given-names>LJ</given-names></name><name><surname>Fuchsberger</surname><given-names>C</given-names></name><name><surname>Stringham</surname><given-names>HM</given-names></name><name><surname>Jackson</surname><given-names>AU</given-names></name><name><surname>Narisu</surname><given-names>N</given-names></name><name><surname>Chines</surname><given-names>PS</given-names></name><name><surname>Small</surname><given-names>KS</given-names></name><name><surname>Kuusisto</surname><given-names>J</given-names></name><name><surname>Parks</surname><given-names>BW</given-names></name><name><surname>Pajukanta</surname><given-names>P</given-names></name><name><surname>Kirchgessner</surname><given-names>T</given-names></name><name><surname>Collins</surname><given-names>FS</given-names></name><name><surname>Gargalovic</surname><given-names>PS</given-names></name><name><surname>Boehnke</surname><given-names>M</given-names></name><name><surname>Laakso</surname><given-names>M</given-names></name><name><surname>Mohlke</surname><given-names>KL</given-names></name><name><surname>Lusis</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genetic Regulation of Adipose Gene Expression and Cardio-Metabolic Traits</article-title><source>American Journal of Human Genetics</source><volume>100</volume><fpage>428</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2017.01.027</pub-id><pub-id pub-id-type="pmid">28257690</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Copps</surname><given-names>KD</given-names></name><name><surname>Hançer</surname><given-names>NJ</given-names></name><name><surname>Qiu</surname><given-names>W</given-names></name><name><surname>White</surname><given-names>MF</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Serine 302 Phosphorylation of Mouse Insulin Receptor Substrate 1 (IRS1) Is Dispensable for Normal Insulin Signaling and Feedback Regulation by Hepatic S6 Kinase</article-title><source>The Journal of Biological Chemistry</source><volume>291</volume><fpage>8602</fpage><lpage>8617</lpage><pub-id pub-id-type="doi">10.1074/jbc.M116.714915</pub-id><pub-id pub-id-type="pmid">26846849</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>MI</given-names></name><name><surname>Hunt</surname><given-names>JP</given-names></name><name><surname>Herrgard</surname><given-names>S</given-names></name><name><surname>Ciceri</surname><given-names>P</given-names></name><name><surname>Wodicka</surname><given-names>LM</given-names></name><name><surname>Pallares</surname><given-names>G</given-names></name><name><surname>Hocker</surname><given-names>M</given-names></name><name><surname>Treiber</surname><given-names>DK</given-names></name><name><surname>Zarrinkar</surname><given-names>PP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Comprehensive analysis of kinase inhibitor selectivity</article-title><source>Nature Biotechnology</source><volume>29</volume><fpage>1046</fpage><lpage>1051</lpage><pub-id pub-id-type="doi">10.1038/nbt.1990</pub-id><pub-id pub-id-type="pmid">22037378</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donath</surname><given-names>MY</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Glucose or Insulin, Which Is the Culprit in Patients with COVID-19 and Diabetes?</article-title><source>Cell Metabolism</source><volume>33</volume><fpage>2</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2020.11.015</pub-id><pub-id pub-id-type="pmid">33248018</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duggan</surname><given-names>BM</given-names></name><name><surname>Cavallari</surname><given-names>JF</given-names></name><name><surname>Foley</surname><given-names>KP</given-names></name><name><surname>Barra</surname><given-names>NG</given-names></name><name><surname>Schertzer</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>RIPK2 Dictates Insulin Responses to Tyrosine Kinase Inhibitors in Obese Male Mice</article-title><source>Endocrinology</source><volume>161</volume><elocation-id>bqaa086</elocation-id><pub-id pub-id-type="doi">10.1210/endocr/bqaa086</pub-id><pub-id pub-id-type="pmid">32473019</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Everett</surname><given-names>BM</given-names></name><name><surname>Donath</surname><given-names>MY</given-names></name><name><surname>Pradhan</surname><given-names>AD</given-names></name><name><surname>Thuren</surname><given-names>T</given-names></name><name><surname>Pais</surname><given-names>P</given-names></name><name><surname>Nicolau</surname><given-names>JC</given-names></name><name><surname>Glynn</surname><given-names>RJ</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Ridker</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes</article-title><source>Journal of the American College of Cardiology</source><volume>71</volume><fpage>2392</fpage><lpage>2401</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2018.03.002</pub-id><pub-id pub-id-type="pmid">29544870</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiore</surname><given-names>D</given-names></name><name><surname>Gianfrilli</surname><given-names>D</given-names></name><name><surname>Giannetta</surname><given-names>E</given-names></name><name><surname>Galea</surname><given-names>N</given-names></name><name><surname>Panio</surname><given-names>G</given-names></name><name><surname>di Dato</surname><given-names>C</given-names></name><name><surname>Pofi</surname><given-names>R</given-names></name><name><surname>Pozza</surname><given-names>C</given-names></name><name><surname>Sbardella</surname><given-names>E</given-names></name><name><surname>Carbone</surname><given-names>I</given-names></name><name><surname>Naro</surname><given-names>F</given-names></name><name><surname>Lenzi</surname><given-names>A</given-names></name><name><surname>Venneri</surname><given-names>MA</given-names></name><name><surname>Isidori</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>PDE5 Inhibition Ameliorates Visceral Adiposity Targeting the miR-22/SIRT1 Pathway: Evidence From the CECSID Trial</article-title><source>The Journal of Clinical Endocrinology and Metabolism</source><volume>101</volume><fpage>1525</fpage><lpage>1534</lpage><pub-id pub-id-type="doi">10.1210/jc.2015-4252</pub-id><pub-id pub-id-type="pmid">26964730</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiore</surname><given-names>D</given-names></name><name><surname>Gianfrilli</surname><given-names>D</given-names></name><name><surname>Cardarelli</surname><given-names>S</given-names></name><name><surname>Naro</surname><given-names>F</given-names></name><name><surname>Lenzi</surname><given-names>A</given-names></name><name><surname>Isidori</surname><given-names>AM</given-names></name><name><surname>Venneri</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Chronic phosphodiesterase type 5 inhibition has beneficial effects on subcutaneous adipose tissue plasticity in type 2 diabetic mice</article-title><source>Journal of Cellular Physiology</source><volume>233</volume><fpage>8411</fpage><lpage>8417</lpage><pub-id pub-id-type="doi">10.1002/jcp.26796</pub-id><pub-id pub-id-type="pmid">29797572</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fontaine</surname><given-names>J</given-names></name><name><surname>Tavernier</surname><given-names>G</given-names></name><name><surname>Morin</surname><given-names>N</given-names></name><name><surname>Carpéné</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Vanadium-dependent activation of glucose transport in adipocytes by catecholamines is not mediated via adrenoceptor stimulation or monoamine oxidase activity</article-title><source>World Journal of Diabetes</source><volume>11</volume><fpage>622</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.4239/wjd.v11.i12.622</pub-id><pub-id pub-id-type="pmid">33384769</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fowler</surname><given-names>AJ</given-names></name><name><surname>Hebron</surname><given-names>M</given-names></name><name><surname>Balaraman</surname><given-names>K</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Missner</surname><given-names>AA</given-names></name><name><surname>Greenzaid</surname><given-names>JD</given-names></name><name><surname>Chiu</surname><given-names>TL</given-names></name><name><surname>Ullman</surname><given-names>C</given-names></name><name><surname>Weatherdon</surname><given-names>E</given-names></name><name><surname>Duka</surname><given-names>V</given-names></name><name><surname>Torres-Yaghi</surname><given-names>Y</given-names></name><name><surname>Pagan</surname><given-names>FL</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Ressom</surname><given-names>H</given-names></name><name><surname>Ahn</surname><given-names>J</given-names></name><name><surname>Wolf</surname><given-names>C</given-names></name><name><surname>Moussa</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseases</article-title><source>Human Molecular Genetics</source><volume>29</volume><fpage>2882</fpage><lpage>2898</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddaa177</pub-id><pub-id pub-id-type="pmid">32776088</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>French</surname><given-names>AJ</given-names></name><name><surname>Natesampillai</surname><given-names>S</given-names></name><name><surname>Krogman</surname><given-names>A</given-names></name><name><surname>Correia</surname><given-names>C</given-names></name><name><surname>Peterson</surname><given-names>KL</given-names></name><name><surname>Alto</surname><given-names>A</given-names></name><name><surname>Chandrasekar</surname><given-names>AP</given-names></name><name><surname>Misra</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Kaufmann</surname><given-names>SH</given-names></name><name><surname>Badley</surname><given-names>AD</given-names></name><name><surname>Cummins</surname><given-names>NW</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Reactivating latent HIV with PKC agonists induces resistance to apoptosis and is associated with phosphorylation and activation of BCL2</article-title><source>PLOS Pathogens</source><volume>16</volume><elocation-id>e1008906</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1008906</pub-id><pub-id pub-id-type="pmid">33075109</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuentealba</surname><given-names>M</given-names></name><name><surname>Dönertaş</surname><given-names>HM</given-names></name><name><surname>Williams</surname><given-names>R</given-names></name><name><surname>Labbadia</surname><given-names>J</given-names></name><name><surname>Thornton</surname><given-names>JM</given-names></name><name><surname>Partridge</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Using the drug-protein interactome to identify anti-ageing compounds for humans</article-title><source>PLOS Computational Biology</source><volume>15</volume><elocation-id>e1006639</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1006639</pub-id><pub-id pub-id-type="pmid">30625143</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fürstenwerth</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Rethinking Heart Failure</article-title><source>Cardiology Research</source><volume>3</volume><fpage>243</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.4021/cr228w</pub-id><pub-id pub-id-type="pmid">28352413</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganter</surname><given-names>B</given-names></name><name><surname>Snyder</surname><given-names>RD</given-names></name><name><surname>Halbert</surname><given-names>DN</given-names></name><name><surname>Lee</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Toxicogenomics in drug discovery and development: mechanistic analysis of compound/class-dependent effects using the DrugMatrix database</article-title><source>Pharmacogenomics</source><volume>7</volume><fpage>1025</fpage><lpage>1044</lpage><pub-id pub-id-type="doi">10.2217/14622416.7.7.1025</pub-id><pub-id pub-id-type="pmid">17054413</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaudelet</surname><given-names>T</given-names></name><name><surname>Day</surname><given-names>B</given-names></name><name><surname>Jamasb</surname><given-names>AR</given-names></name><name><surname>Soman</surname><given-names>J</given-names></name><name><surname>Regep</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Hayter</surname><given-names>JBR</given-names></name><name><surname>Vickers</surname><given-names>R</given-names></name><name><surname>Roberts</surname><given-names>C</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Roblin</surname><given-names>D</given-names></name><name><surname>Blundell</surname><given-names>TL</given-names></name><name><surname>Bronstein</surname><given-names>MM</given-names></name><name><surname>Taylor-King</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Utilizing graph machine learning within drug discovery and development</article-title><source>Briefings in Bioinformatics</source><volume>22</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1093/bib/bbab159</pub-id><pub-id pub-id-type="pmid">34013350</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giorgio</surname><given-names>C</given-names></name><name><surname>Incerti</surname><given-names>M</given-names></name><name><surname>Pala</surname><given-names>D</given-names></name><name><surname>Russo</surname><given-names>S</given-names></name><name><surname>Chiodelli</surname><given-names>P</given-names></name><name><surname>Rusnati</surname><given-names>M</given-names></name><name><surname>Cantoni</surname><given-names>AM</given-names></name><name><surname>Di Lecce</surname><given-names>R</given-names></name><name><surname>Barocelli</surname><given-names>E</given-names></name><name><surname>Bertoni</surname><given-names>S</given-names></name><name><surname>Ravassard</surname><given-names>P</given-names></name><name><surname>Manenti</surname><given-names>F</given-names></name><name><surname>Piemonti</surname><given-names>L</given-names></name><name><surname>Ferlenghi</surname><given-names>F</given-names></name><name><surname>Lodola</surname><given-names>A</given-names></name><name><surname>Tognolini</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice</article-title><source>Pharmacological Research</source><volume>141</volume><fpage>319</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2019.01.011</pub-id><pub-id pub-id-type="pmid">30625359</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gudmundsdottir</surname><given-names>V</given-names></name><name><surname>Zaghlool</surname><given-names>SB</given-names></name><name><surname>Emilsson</surname><given-names>V</given-names></name><name><surname>Aspelund</surname><given-names>T</given-names></name><name><surname>Ilkov</surname><given-names>M</given-names></name><name><surname>Gudmundsson</surname><given-names>EF</given-names></name><name><surname>Jonsson</surname><given-names>SM</given-names></name><name><surname>Zilhão</surname><given-names>NR</given-names></name><name><surname>Lamb</surname><given-names>JR</given-names></name><name><surname>Suhre</surname><given-names>K</given-names></name><name><surname>Jennings</surname><given-names>LL</given-names></name><name><surname>Gudnason</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Circulating Protein Signatures and Causal Candidates for Type 2 Diabetes</article-title><source>Diabetes</source><volume>69</volume><fpage>1843</fpage><lpage>1853</lpage><pub-id pub-id-type="doi">10.2337/db19-1070</pub-id><pub-id pub-id-type="pmid">32385057</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Lv</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Du</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>eEF1A2 exacerbated insulin resistance in male skeletal muscle via PKCβ and ER stress</article-title><source>The Journal of Endocrinology</source><volume>244</volume><fpage>25</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1530/JOE-19-0051</pub-id><pub-id pub-id-type="pmid">31539873</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutierrez</surname><given-names>DA</given-names></name><name><surname>Vargas</surname><given-names>LM</given-names></name><name><surname>Chandia-Cristi</surname><given-names>A</given-names></name><name><surname>de la Fuente</surname><given-names>C</given-names></name><name><surname>Leal</surname><given-names>N</given-names></name><name><surname>Alvarez</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>c-Abl Deficiency Provides Synaptic Resiliency Against Aβ-Oligomers</article-title><source>Frontiers in Cellular Neuroscience</source><volume>13</volume><elocation-id>526</elocation-id><pub-id pub-id-type="doi">10.3389/fncel.2019.00526</pub-id><pub-id pub-id-type="pmid">31849613</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrera Moro Chao</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Foppen</surname><given-names>E</given-names></name><name><surname>Ottenhoff</surname><given-names>R</given-names></name><name><surname>van Roomen</surname><given-names>C</given-names></name><name><surname>Parlevliet</surname><given-names>ET</given-names></name><name><surname>van Eijk</surname><given-names>M</given-names></name><name><surname>Verhoek</surname><given-names>M</given-names></name><name><surname>Boot</surname><given-names>R</given-names></name><name><surname>Marques</surname><given-names>AR</given-names></name><name><surname>Scheij</surname><given-names>S</given-names></name><name><surname>Mirzaian</surname><given-names>M</given-names></name><name><surname>Kooijman</surname><given-names>S</given-names></name><name><surname>Jansen</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Mergen</surname><given-names>C</given-names></name><name><surname>Seeley</surname><given-names>RJ</given-names></name><name><surname>Tschöp</surname><given-names>MH</given-names></name><name><surname>Overkleeft</surname><given-names>H</given-names></name><name><surname>Rensen</surname><given-names>PCN</given-names></name><name><surname>Kalsbeek</surname><given-names>A</given-names></name><name><surname>Aerts</surname><given-names>J</given-names></name><name><surname>Yi</surname><given-names>CX</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The Iminosugar AMP-DNM Improves Satiety and Activates Brown Adipose Tissue Through GLP1</article-title><source>Diabetes</source><volume>68</volume><fpage>2223</fpage><lpage>2234</lpage><pub-id pub-id-type="doi">10.2337/db19-0049</pub-id><pub-id pub-id-type="pmid">31578192</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hevener</surname><given-names>AL</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Moore</surname><given-names>TM</given-names></name><name><surname>Drew</surname><given-names>BG</given-names></name><name><surname>Ribas</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The impact of ERα action on muscle metabolism and insulin sensitivity - Strong enough for a man, made for a woman</article-title><source>Molecular Metabolism</source><volume>15</volume><fpage>20</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.molmet.2018.06.013</pub-id><pub-id pub-id-type="pmid">30005878</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Himmelstein</surname><given-names>DS</given-names></name><name><surname>Lizee</surname><given-names>A</given-names></name><name><surname>Hessler</surname><given-names>C</given-names></name><name><surname>Brueggeman</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>SL</given-names></name><name><surname>Hadley</surname><given-names>D</given-names></name><name><surname>Green</surname><given-names>A</given-names></name><name><surname>Khankhanian</surname><given-names>P</given-names></name><name><surname>Baranzini</surname><given-names>SE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Systematic integration of biomedical knowledge prioritizes drugs for repurposing</article-title><source>eLife</source><volume>6</volume><elocation-id>e26726</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.26726</pub-id><pub-id pub-id-type="pmid">28936969</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoang</surname><given-names>VT</given-names></name><name><surname>Nyswaner</surname><given-names>K</given-names></name><name><surname>Torres-Ayuso</surname><given-names>P</given-names></name><name><surname>Brognard</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The protein kinase MAP3K19 phosphorylates MAP2Ks and thereby activates ERK and JNK kinases and increases viability of KRAS-mutant lung cancer cells</article-title><source>The Journal of Biological Chemistry</source><volume>295</volume><fpage>8470</fpage><lpage>8479</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA119.012365</pub-id><pub-id pub-id-type="pmid">32358059</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hopkins</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Network pharmacology: the next paradigm in drug discovery</article-title><source>Nature Chemical Biology</source><volume>4</volume><fpage>682</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1038/nchembio.118</pub-id><pub-id pub-id-type="pmid">18936753</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howell</surname><given-names>JJ</given-names></name><name><surname>Hellberg</surname><given-names>K</given-names></name><name><surname>Turner</surname><given-names>M</given-names></name><name><surname>Talbott</surname><given-names>G</given-names></name><name><surname>Kolar</surname><given-names>MJ</given-names></name><name><surname>Ross</surname><given-names>DS</given-names></name><name><surname>Hoxhaj</surname><given-names>G</given-names></name><name><surname>Saghatelian</surname><given-names>A</given-names></name><name><surname>Shaw</surname><given-names>RJ</given-names></name><name><surname>Manning</surname><given-names>BD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex</article-title><source>Cell Metabolism</source><volume>25</volume><fpage>463</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2016.12.009</pub-id><pub-id pub-id-type="pmid">28089566</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>K</given-names></name><name><surname>Fu</surname><given-names>T</given-names></name><name><surname>Glass</surname><given-names>LM</given-names></name><name><surname>Zitnik</surname><given-names>M</given-names></name><name><surname>Xiao</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>DeepPurpose: a deep learning library for drug-target interaction prediction</article-title><source>Bioinformatics</source><volume>36</volume><fpage>5545</fpage><lpage>5547</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btaa1005</pub-id><pub-id pub-id-type="pmid">33275143</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huh</surname><given-names>S</given-names></name><name><surname>Baek</surname><given-names>SJ</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Whitcomb</surname><given-names>DJ</given-names></name><name><surname>Jo</surname><given-names>J</given-names></name><name><surname>Choi</surname><given-names>SM</given-names></name><name><surname>Kim</surname><given-names>DH</given-names></name><name><surname>Park</surname><given-names>MS</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Kim</surname><given-names>BC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The reemergence of long-term potentiation in aged Alzheimer’s disease mouse model</article-title><source>Scientific Reports</source><volume>6</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1038/srep29152</pub-id><pub-id pub-id-type="pmid">27377368</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imamura</surname><given-names>T</given-names></name><name><surname>Haruta</surname><given-names>T</given-names></name><name><surname>Takata</surname><given-names>Y</given-names></name><name><surname>Usui</surname><given-names>I</given-names></name><name><surname>Iwata</surname><given-names>M</given-names></name><name><surname>Ishihara</surname><given-names>H</given-names></name><name><surname>Ishiki</surname><given-names>M</given-names></name><name><surname>Ishibashi</surname><given-names>O</given-names></name><name><surname>Ueno</surname><given-names>E</given-names></name><name><surname>Sasaoka</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Involvement of heat shock protein 90 in the degradation of mutant insulin receptors by the proteasome</article-title><source>The Journal of Biological Chemistry</source><volume>273</volume><fpage>11183</fpage><lpage>11188</lpage><pub-id pub-id-type="doi">10.1074/jbc.273.18.11183</pub-id><pub-id pub-id-type="pmid">9556607</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iorio</surname><given-names>F</given-names></name><name><surname>Garcia-Alonso</surname><given-names>L</given-names></name><name><surname>Brammeld</surname><given-names>JS</given-names></name><name><surname>Martincorena</surname><given-names>I</given-names></name><name><surname>Wille</surname><given-names>DR</given-names></name><name><surname>McDermott</surname><given-names>U</given-names></name><name><surname>Saez-Rodriguez</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Pathway-based dissection of the genomic heterogeneity of cancer hallmarks’ acquisition with SLAPenrich</article-title><source>Scientific Reports</source><volume>8</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1038/s41598-018-25076-6</pub-id><pub-id pub-id-type="pmid">29713020</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwai</surname><given-names>M</given-names></name><name><surname>Kanno</surname><given-names>H</given-names></name><name><surname>Inaba</surname><given-names>S</given-names></name><name><surname>Senba</surname><given-names>I</given-names></name><name><surname>Sone</surname><given-names>H</given-names></name><name><surname>Nakaoka</surname><given-names>H</given-names></name><name><surname>Horiuchi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Nifedipine, a calcium-channel blocker, attenuated glucose intolerance and white adipose tissue dysfunction in type 2 diabetic KK-A(y) mice</article-title><source>American Journal of Hypertension</source><volume>24</volume><fpage>169</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1038/ajh.2010.198</pub-id><pub-id pub-id-type="pmid">20847723</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jahng</surname><given-names>JWS</given-names></name><name><surname>Alsaadi</surname><given-names>RM</given-names></name><name><surname>Palanivel</surname><given-names>R</given-names></name><name><surname>Song</surname><given-names>E</given-names></name><name><surname>Hipolito</surname><given-names>VEB</given-names></name><name><surname>Sung</surname><given-names>HK</given-names></name><name><surname>Botelho</surname><given-names>RJ</given-names></name><name><surname>Russell</surname><given-names>RC</given-names></name><name><surname>Sweeney</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Iron overload inhibits late stage autophagic flux leading to insulin resistance</article-title><source>EMBO Reports</source><volume>20</volume><elocation-id>e47911</elocation-id><pub-id pub-id-type="doi">10.15252/embr.201947911</pub-id><pub-id pub-id-type="pmid">31441223</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>T</given-names></name><name><surname>Sardar</surname><given-names>A</given-names></name><name><surname>Anighoro</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Enhancing Chemogenomics with Predictive Pharmacology</article-title><source>Journal of Medicinal Chemistry</source><volume>63</volume><fpage>12243</fpage><lpage>12255</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c00445</pub-id><pub-id pub-id-type="pmid">32573226</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkinson</surname><given-names>CP</given-names></name><name><surname>Göring</surname><given-names>HHH</given-names></name><name><surname>Arya</surname><given-names>R</given-names></name><name><surname>Blangero</surname><given-names>J</given-names></name><name><surname>Duggirala</surname><given-names>R</given-names></name><name><surname>DeFronzo</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Transcriptomics in type 2 diabetes: Bridging the gap between genotype and phenotype</article-title><source>Genomics Data</source><volume>8</volume><fpage>25</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.gdata.2015.12.001</pub-id><pub-id pub-id-type="pmid">27114903</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jing</surname><given-names>E</given-names></name><name><surname>Sundararajan</surname><given-names>P</given-names></name><name><surname>Majumdar</surname><given-names>ID</given-names></name><name><surname>Hazarika</surname><given-names>S</given-names></name><name><surname>Fowler</surname><given-names>S</given-names></name><name><surname>Szeto</surname><given-names>A</given-names></name><name><surname>Gesta</surname><given-names>S</given-names></name><name><surname>Mendez</surname><given-names>AJ</given-names></name><name><surname>Vishnudas</surname><given-names>VK</given-names></name><name><surname>Sarangarajan</surname><given-names>R</given-names></name><name><surname>Narain</surname><given-names>NR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Hsp90β knockdown in DIO mice reverses insulin resistance and improves glucose tolerance</article-title><source>Nutrition &amp; Metabolism</source><volume>15</volume><elocation-id>11</elocation-id><pub-id pub-id-type="doi">10.1186/s12986-018-0242-6</pub-id><pub-id pub-id-type="pmid">29434648</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karatzas</surname><given-names>E</given-names></name><name><surname>Bourdakou</surname><given-names>MM</given-names></name><name><surname>Kolios</surname><given-names>G</given-names></name><name><surname>Spyrou</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Drug repurposing in idiopathic pulmonary fibrosis filtered by a bioinformatics-derived composite score</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>12569</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-12849-8</pub-id><pub-id pub-id-type="pmid">28974751</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keenan</surname><given-names>AB</given-names></name><name><surname>Jenkins</surname><given-names>SL</given-names></name><name><surname>Jagodnik</surname><given-names>KM</given-names></name><name><surname>Koplev</surname><given-names>S</given-names></name><name><surname>He</surname><given-names>E</given-names></name><name><surname>Torre</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Dohlman</surname><given-names>AB</given-names></name><name><surname>Silverstein</surname><given-names>MC</given-names></name><name><surname>Lachmann</surname><given-names>A</given-names></name><name><surname>Kuleshov</surname><given-names>MV</given-names></name><name><surname>Ma’ayan</surname><given-names>A</given-names></name><name><surname>Stathias</surname><given-names>V</given-names></name><name><surname>Terryn</surname><given-names>R</given-names></name><name><surname>Cooper</surname><given-names>D</given-names></name><name><surname>Forlin</surname><given-names>M</given-names></name><name><surname>Koleti</surname><given-names>A</given-names></name><name><surname>Vidovic</surname><given-names>D</given-names></name><name><surname>Chung</surname><given-names>C</given-names></name><name><surname>Schürer</surname><given-names>SC</given-names></name><name><surname>Vasiliauskas</surname><given-names>J</given-names></name><name><surname>Pilarczyk</surname><given-names>M</given-names></name><name><surname>Shamsaei</surname><given-names>B</given-names></name><name><surname>Fazel</surname><given-names>M</given-names></name><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Niu</surname><given-names>W</given-names></name><name><surname>Clark</surname><given-names>NA</given-names></name><name><surname>White</surname><given-names>S</given-names></name><name><surname>Mahi</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Kouril</surname><given-names>M</given-names></name><name><surname>Reichard</surname><given-names>JF</given-names></name><name><surname>Sivaganesan</surname><given-names>S</given-names></name><name><surname>Medvedovic</surname><given-names>M</given-names></name><name><surname>Meller</surname><given-names>J</given-names></name><name><surname>Koch</surname><given-names>RJ</given-names></name><name><surname>Birtwistle</surname><given-names>MR</given-names></name><name><surname>Iyengar</surname><given-names>R</given-names></name><name><surname>Sobie</surname><given-names>EA</given-names></name><name><surname>Azeloglu</surname><given-names>EU</given-names></name><name><surname>Kaye</surname><given-names>J</given-names></name><name><surname>Osterloh</surname><given-names>J</given-names></name><name><surname>Haston</surname><given-names>K</given-names></name><name><surname>Kalra</surname><given-names>J</given-names></name><name><surname>Finkbiener</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Milani</surname><given-names>P</given-names></name><name><surname>Adam</surname><given-names>M</given-names></name><name><surname>Escalante-Chong</surname><given-names>R</given-names></name><name><surname>Sachs</surname><given-names>K</given-names></name><name><surname>Lenail</surname><given-names>A</given-names></name><name><surname>Ramamoorthy</surname><given-names>D</given-names></name><name><surname>Fraenkel</surname><given-names>E</given-names></name><name><surname>Daigle</surname><given-names>G</given-names></name><name><surname>Hussain</surname><given-names>U</given-names></name><name><surname>Coye</surname><given-names>A</given-names></name><name><surname>Rothstein</surname><given-names>J</given-names></name><name><surname>Sareen</surname><given-names>D</given-names></name><name><surname>Ornelas</surname><given-names>L</given-names></name><name><surname>Banuelos</surname><given-names>M</given-names></name><name><surname>Mandefro</surname><given-names>B</given-names></name><name><surname>Ho</surname><given-names>R</given-names></name><name><surname>Svendsen</surname><given-names>CN</given-names></name><name><surname>Lim</surname><given-names>RG</given-names></name><name><surname>Stocksdale</surname><given-names>J</given-names></name><name><surname>Casale</surname><given-names>MS</given-names></name><name><surname>Thompson</surname><given-names>TG</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Thompson</surname><given-names>LM</given-names></name><name><surname>Dardov</surname><given-names>V</given-names></name><name><surname>Venkatraman</surname><given-names>V</given-names></name><name><surname>Matlock</surname><given-names>A</given-names></name><name><surname>Van Eyk</surname><given-names>JE</given-names></name><name><surname>Jaffe</surname><given-names>JD</given-names></name><name><surname>Papanastasiou</surname><given-names>M</given-names></name><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Erickson</surname><given-names>SD</given-names></name><name><surname>Fallahi-Sichani</surname><given-names>M</given-names></name><name><surname>Hafner</surname><given-names>M</given-names></name><name><surname>Gray</surname><given-names>NS</given-names></name><name><surname>Lin</surname><given-names>JR</given-names></name><name><surname>Mills</surname><given-names>CE</given-names></name><name><surname>Muhlich</surname><given-names>JL</given-names></name><name><surname>Niepel</surname><given-names>M</given-names></name><name><surname>Shamu</surname><given-names>CE</given-names></name><name><surname>Williams</surname><given-names>EH</given-names></name><name><surname>Wrobel</surname><given-names>D</given-names></name><name><surname>Sorger</surname><given-names>PK</given-names></name><name><surname>Heiser</surname><given-names>LM</given-names></name><name><surname>Gray</surname><given-names>JW</given-names></name><name><surname>Korkola</surname><given-names>JE</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>LaBarge</surname><given-names>M</given-names></name><name><surname>Feiler</surname><given-names>HS</given-names></name><name><surname>Dane</surname><given-names>MA</given-names></name><name><surname>Bucher</surname><given-names>E</given-names></name><name><surname>Nederlof</surname><given-names>M</given-names></name><name><surname>Sudar</surname><given-names>D</given-names></name><name><surname>Gross</surname><given-names>S</given-names></name><name><surname>Kilburn</surname><given-names>DF</given-names></name><name><surname>Smith</surname><given-names>R</given-names></name><name><surname>Devlin</surname><given-names>K</given-names></name><name><surname>Margolis</surname><given-names>R</given-names></name><name><surname>Derr</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Pillai</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations</article-title><source>Cell Systems</source><volume>6</volume><fpage>13</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2017.11.001</pub-id><pub-id pub-id-type="pmid">29199020</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kellar</surname><given-names>D</given-names></name><name><surname>Craft</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Brain insulin resistance in Alzheimer’s disease and related disorders: mechanisms and therapeutic approaches</article-title><source>The Lancet. Neurology</source><volume>19</volume><fpage>758</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(20)30231-3</pub-id><pub-id pub-id-type="pmid">32730766</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klaeger</surname><given-names>S</given-names></name><name><surname>Heinzlmeir</surname><given-names>S</given-names></name><name><surname>Wilhelm</surname><given-names>M</given-names></name><name><surname>Polzer</surname><given-names>H</given-names></name><name><surname>Vick</surname><given-names>B</given-names></name><name><surname>Koenig</surname><given-names>PA</given-names></name><name><surname>Reinecke</surname><given-names>M</given-names></name><name><surname>Ruprecht</surname><given-names>B</given-names></name><name><surname>Petzoldt</surname><given-names>S</given-names></name><name><surname>Meng</surname><given-names>C</given-names></name><name><surname>Zecha</surname><given-names>J</given-names></name><name><surname>Reiter</surname><given-names>K</given-names></name><name><surname>Qiao</surname><given-names>H</given-names></name><name><surname>Helm</surname><given-names>D</given-names></name><name><surname>Koch</surname><given-names>H</given-names></name><name><surname>Schoof</surname><given-names>M</given-names></name><name><surname>Canevari</surname><given-names>G</given-names></name><name><surname>Casale</surname><given-names>E</given-names></name><name><surname>Depaolini</surname><given-names>SR</given-names></name><name><surname>Feuchtinger</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Schmidt</surname><given-names>T</given-names></name><name><surname>Rueckert</surname><given-names>L</given-names></name><name><surname>Becker</surname><given-names>W</given-names></name><name><surname>Huenges</surname><given-names>J</given-names></name><name><surname>Garz</surname><given-names>AK</given-names></name><name><surname>Gohlke</surname><given-names>BO</given-names></name><name><surname>Zolg</surname><given-names>DP</given-names></name><name><surname>Kayser</surname><given-names>G</given-names></name><name><surname>Vooder</surname><given-names>T</given-names></name><name><surname>Preissner</surname><given-names>R</given-names></name><name><surname>Hahne</surname><given-names>H</given-names></name><name><surname>Tõnisson</surname><given-names>N</given-names></name><name><surname>Kramer</surname><given-names>K</given-names></name><name><surname>Götze</surname><given-names>K</given-names></name><name><surname>Bassermann</surname><given-names>F</given-names></name><name><surname>Schlegl</surname><given-names>J</given-names></name><name><surname>Ehrlich</surname><given-names>HC</given-names></name><name><surname>Aiche</surname><given-names>S</given-names></name><name><surname>Walch</surname><given-names>A</given-names></name><name><surname>Greif</surname><given-names>PA</given-names></name><name><surname>Schneider</surname><given-names>S</given-names></name><name><surname>Felder</surname><given-names>ER</given-names></name><name><surname>Ruland</surname><given-names>J</given-names></name><name><surname>Médard</surname><given-names>G</given-names></name><name><surname>Jeremias</surname><given-names>I</given-names></name><name><surname>Spiekermann</surname><given-names>K</given-names></name><name><surname>Kuster</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The target landscape of clinical kinase drugs</article-title><source>Science</source><volume>358</volume><elocation-id>eaan4368</elocation-id><pub-id pub-id-type="doi">10.1126/science.aan4368</pub-id><pub-id pub-id-type="pmid">29191878</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koyama</surname><given-names>Y</given-names></name><name><surname>Kodama</surname><given-names>K</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Harano</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Improvement of insulin sensitivity by a long-acting nifedipine preparation (nifedipine-CR) in patients with essential hypertension</article-title><source>American Journal of Hypertension</source><volume>15</volume><fpage>927</fpage><lpage>931</lpage><pub-id pub-id-type="doi">10.1016/s0895-7061(02)03019-4</pub-id><pub-id pub-id-type="pmid">12441210</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kyohara</surname><given-names>M</given-names></name><name><surname>Shirakawa</surname><given-names>J</given-names></name><name><surname>Okuyama</surname><given-names>T</given-names></name><name><surname>Togashi</surname><given-names>Y</given-names></name><name><surname>Inoue</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Miyashita</surname><given-names>D</given-names></name><name><surname>Terauchi</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Soluble EGFR, a hepatokine, and adipsin, an adipokine, are biomarkers correlated with distinct aspects of insulin resistance in type 2 diabetes subjects</article-title><source>Diabetology &amp; Metabolic Syndrome</source><volume>12</volume><elocation-id>83</elocation-id><pub-id pub-id-type="doi">10.1186/s13098-020-00591-7</pub-id><pub-id pub-id-type="pmid">33005239</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>D</given-names></name><name><surname>Kang</surname><given-names>HG</given-names></name><name><surname>Jeong</surname><given-names>SJ</given-names></name><name><surname>Jo</surname><given-names>JE</given-names></name><name><surname>Shin</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>DK</given-names></name><name><surname>Park</surname><given-names>HW</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Intravenous sustained-release nifedipine ameliorates nonalcoholic fatty liver disease by restoring autophagic clearance</article-title><source>Biomaterials</source><volume>197</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2019.01.008</pub-id><pub-id pub-id-type="pmid">30623792</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>TH</given-names></name><name><surname>Chen</surname><given-names>JL</given-names></name><name><surname>Liu</surname><given-names>PS</given-names></name><name><surname>Tsai</surname><given-names>MM</given-names></name><name><surname>Wang</surname><given-names>SJ</given-names></name><name><surname>Hsieh</surname><given-names>HL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Rottlerin, a natural polyphenol compound, inhibits upregulation of matrix metalloproteinase-9 and brain astrocytic migration by reducing PKC-δ-dependent ROS signal</article-title><source>Journal of Neuroinflammation</source><volume>17</volume><elocation-id>177</elocation-id><pub-id pub-id-type="doi">10.1186/s12974-020-01859-5</pub-id><pub-id pub-id-type="pmid">32505192</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Vienberg</surname><given-names>SG</given-names></name><name><surname>Bezy</surname><given-names>O</given-names></name><name><surname>O’Neill</surname><given-names>BT</given-names></name><name><surname>Kahn</surname><given-names>CR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Role of PKCδ in Insulin Sensitivity and Skeletal Muscle Metabolism</article-title><source>Diabetes</source><volume>64</volume><fpage>4023</fpage><lpage>4032</lpage><pub-id pub-id-type="doi">10.2337/db14-1891</pub-id><pub-id pub-id-type="pmid">26307588</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Tian</surname><given-names>M</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Jia</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Boden</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>NAMPT knockdown attenuates atherosclerosis and promotes reverse cholesterol transport in ApoE KO mice with high-fat-induced insulin resistance</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>26746</elocation-id><pub-id pub-id-type="doi">10.1038/srep26746</pub-id><pub-id pub-id-type="pmid">27229177</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>A</given-names></name><name><surname>Rosenbluh</surname><given-names>J</given-names></name><name><surname>Horn</surname><given-names>H</given-names></name><name><surname>Greenfeld</surname><given-names>L</given-names></name><name><surname>An</surname><given-names>D</given-names></name><name><surname>Zimmer</surname><given-names>A</given-names></name><name><surname>Liberzon</surname><given-names>A</given-names></name><name><surname>Bistline</surname><given-names>J</given-names></name><name><surname>Natoli</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Tsherniak</surname><given-names>A</given-names></name><name><surname>Narayan</surname><given-names>R</given-names></name><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Liefeld</surname><given-names>T</given-names></name><name><surname>Wong</surname><given-names>B</given-names></name><name><surname>Thompson</surname><given-names>D</given-names></name><name><surname>Calvo</surname><given-names>S</given-names></name><name><surname>Carr</surname><given-names>S</given-names></name><name><surname>Boehm</surname><given-names>J</given-names></name><name><surname>Jaffe</surname><given-names>J</given-names></name><name><surname>Mesirov</surname><given-names>J</given-names></name><name><surname>Hacohen</surname><given-names>N</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Lage</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018a</year><article-title>GeNets: a unified web platform for network-based genomic analyses</article-title><source>Nature Methods</source><volume>15</volume><fpage>543</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1038/s41592-018-0039-6</pub-id><pub-id pub-id-type="pmid">29915188</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Overstreet</surname><given-names>JM</given-names></name><name><surname>Chung</surname><given-names>S</given-names></name><name><surname>Niu</surname><given-names>A</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>MZ</given-names></name><name><surname>Harris</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2018">2018b</year><article-title>Inhibition of Epidermal Growth Factor Receptor Activation Is Associated With Improved Diabetic Nephropathy and Insulin Resistance in Type 2 Diabetes</article-title><source>Diabetes</source><volume>67</volume><fpage>1847</fpage><lpage>1857</lpage><pub-id pub-id-type="doi">10.2337/db17-1513</pub-id><pub-id pub-id-type="pmid">29959129</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Wen</surname><given-names>X</given-names></name><name><surname>Jorissen</surname><given-names>RN</given-names></name><name><surname>Gilson</surname><given-names>MK</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities</article-title><source>Nucleic Acids Research</source><volume>35</volume><fpage>D198</fpage><lpage>D201</lpage><pub-id pub-id-type="doi">10.1093/nar/gkl999</pub-id><pub-id pub-id-type="pmid">17145705</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Tian</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>PDE5A Suppresses Proteasome Activity Leading to Insulin Resistance in C2C12 Myotubes</article-title><source>International Journal of Endocrinology</source><volume>2019</volume><elocation-id>3054820</elocation-id><pub-id pub-id-type="doi">10.1155/2019/3054820</pub-id><pub-id pub-id-type="pmid">30774657</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lockman</surname><given-names>JW</given-names></name><name><surname>Murphy</surname><given-names>BR</given-names></name><name><surname>Zigar</surname><given-names>DF</given-names></name><name><surname>Judd</surname><given-names>WR</given-names></name><name><surname>Slattum</surname><given-names>PM</given-names></name><name><surname>Gao</surname><given-names>ZH</given-names></name><name><surname>Ostanin</surname><given-names>K</given-names></name><name><surname>Green</surname><given-names>J</given-names></name><name><surname>McKinnon</surname><given-names>R</given-names></name><name><surname>Terry-Lorenzo</surname><given-names>RT</given-names></name><name><surname>Fleischer</surname><given-names>TC</given-names></name><name><surname>Boniface</surname><given-names>JJ</given-names></name><name><surname>Shenderovich</surname><given-names>M</given-names></name><name><surname>Willardsen</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Analogues of 4-[(7-Bromo-2-methyl-4-oxo-3H-quinazolin-6-yl)methylprop-2-ynylamino]-N-(3-pyridylmethyl)benzamide (CB-30865) as potent inhibitors of nicotinamide phosphoribosyltransferase (Nampt)</article-title><source>Journal of Medicinal Chemistry</source><volume>53</volume><fpage>8734</fpage><lpage>8746</lpage><pub-id pub-id-type="doi">10.1021/jm101145b</pub-id><pub-id pub-id-type="pmid">21080724</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lotta</surname><given-names>LA</given-names></name><name><surname>Gulati</surname><given-names>P</given-names></name><name><surname>Day</surname><given-names>FR</given-names></name><name><surname>Payne</surname><given-names>F</given-names></name><name><surname>Ongen</surname><given-names>H</given-names></name><name><surname>van de Bunt</surname><given-names>M</given-names></name><name><surname>Gaulton</surname><given-names>KJ</given-names></name><name><surname>Eicher</surname><given-names>JD</given-names></name><name><surname>Sharp</surname><given-names>SJ</given-names></name><name><surname>Luan</surname><given-names>J</given-names></name><name><surname>De Lucia Rolfe</surname><given-names>E</given-names></name><name><surname>Stewart</surname><given-names>ID</given-names></name><name><surname>Wheeler</surname><given-names>E</given-names></name><name><surname>Willems</surname><given-names>SM</given-names></name><name><surname>Adams</surname><given-names>C</given-names></name><name><surname>Yaghootkar</surname><given-names>H</given-names></name><collab>EPIC-InterAct Consortium</collab><collab>Cambridge FPLD1 Consortium</collab><name><surname>Forouhi</surname><given-names>NG</given-names></name><name><surname>Khaw</surname><given-names>KT</given-names></name><name><surname>Johnson</surname><given-names>AD</given-names></name><name><surname>Semple</surname><given-names>RK</given-names></name><name><surname>Frayling</surname><given-names>T</given-names></name><name><surname>Perry</surname><given-names>JRB</given-names></name><name><surname>Dermitzakis</surname><given-names>E</given-names></name><name><surname>McCarthy</surname><given-names>MI</given-names></name><name><surname>Barroso</surname><given-names>I</given-names></name><name><surname>Wareham</surname><given-names>NJ</given-names></name><name><surname>Savage</surname><given-names>DB</given-names></name><name><surname>Langenberg</surname><given-names>C</given-names></name><name><surname>O’Rahilly</surname><given-names>S</given-names></name><name><surname>Scott</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance</article-title><source>Nature Genetics</source><volume>49</volume><fpage>17</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1038/ng.3714</pub-id><pub-id pub-id-type="pmid">27841877</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luk</surname><given-names>CT</given-names></name><name><surname>Shi</surname><given-names>SY</given-names></name><name><surname>Cai</surname><given-names>EP</given-names></name><name><surname>Sivasubramaniyam</surname><given-names>T</given-names></name><name><surname>Krishnamurthy</surname><given-names>M</given-names></name><name><surname>Brunt</surname><given-names>JJ</given-names></name><name><surname>Schroer</surname><given-names>SA</given-names></name><name><surname>Winer</surname><given-names>DA</given-names></name><name><surname>Woo</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>FAK signalling controls insulin sensitivity through regulation of adipocyte survival</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>14360</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms14360</pub-id><pub-id pub-id-type="pmid">28165007</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacLaren</surname><given-names>R</given-names></name><name><surname>Cui</surname><given-names>W</given-names></name><name><surname>Simard</surname><given-names>S</given-names></name><name><surname>Cianflone</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Influence of obesity and insulin sensitivity on insulin signaling genes in human omental and subcutaneous adipose tissue</article-title><source>Journal of Lipid Research</source><volume>49</volume><fpage>308</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1194/jlr.M700199-JLR200</pub-id><pub-id pub-id-type="pmid">17986714</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martins</surname><given-names>VF</given-names></name><name><surname>Begur</surname><given-names>M</given-names></name><name><surname>Lakkaraju</surname><given-names>S</given-names></name><name><surname>Svensson</surname><given-names>K</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Hetrick</surname><given-names>B</given-names></name><name><surname>McCurdy</surname><given-names>CE</given-names></name><name><surname>Schenk</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Acute inhibition of protein deacetylases does not impact skeletal muscle insulin action</article-title><source>American Journal of Physiology. Cell Physiology</source><volume>317</volume><fpage>C964</fpage><lpage>C968</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00159.2019</pub-id><pub-id pub-id-type="pmid">31461343</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menden</surname><given-names>MP</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Mason</surname><given-names>MJ</given-names></name><name><surname>Szalai</surname><given-names>B</given-names></name><name><surname>Bulusu</surname><given-names>KC</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Kang</surname><given-names>J</given-names></name><name><surname>Jeon</surname><given-names>M</given-names></name><name><surname>Wolfinger</surname><given-names>R</given-names></name><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Zaslavskiy</surname><given-names>M</given-names></name><collab>AstraZeneca-Sanger Drug Combination DREAM Consortium</collab><name><surname>Jang</surname><given-names>IS</given-names></name><name><surname>Ghazoui</surname><given-names>Z</given-names></name><name><surname>Ahsen</surname><given-names>ME</given-names></name><name><surname>Vogel</surname><given-names>R</given-names></name><name><surname>Neto</surname><given-names>EC</given-names></name><name><surname>Norman</surname><given-names>T</given-names></name><name><surname>Tang</surname><given-names>EKY</given-names></name><name><surname>Garnett</surname><given-names>MJ</given-names></name><name><surname>Veroli</surname><given-names>GYD</given-names></name><name><surname>Fawell</surname><given-names>S</given-names></name><name><surname>Stolovitzky</surname><given-names>G</given-names></name><name><surname>Guinney</surname><given-names>J</given-names></name><name><surname>Dry</surname><given-names>JR</given-names></name><name><surname>Saez-Rodriguez</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen</article-title><source>Nature Communications</source><volume>10</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1038/s41467-019-09799-2</pub-id><pub-id pub-id-type="pmid">31209238</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendez</surname><given-names>D</given-names></name><name><surname>Gaulton</surname><given-names>A</given-names></name><name><surname>Bento</surname><given-names>AP</given-names></name><name><surname>Chambers</surname><given-names>J</given-names></name><name><surname>De Veij</surname><given-names>M</given-names></name><name><surname>Félix</surname><given-names>E</given-names></name><name><surname>Magariños</surname><given-names>MP</given-names></name><name><surname>Mosquera</surname><given-names>JF</given-names></name><name><surname>Mutowo</surname><given-names>P</given-names></name><name><surname>Nowotka</surname><given-names>M</given-names></name><name><surname>Gordillo-Marañón</surname><given-names>M</given-names></name><name><surname>Hunter</surname><given-names>F</given-names></name><name><surname>Junco</surname><given-names>L</given-names></name><name><surname>Mugumbate</surname><given-names>G</given-names></name><name><surname>Rodriguez-Lopez</surname><given-names>M</given-names></name><name><surname>Atkinson</surname><given-names>F</given-names></name><name><surname>Bosc</surname><given-names>N</given-names></name><name><surname>Radoux</surname><given-names>CJ</given-names></name><name><surname>Segura-Cabrera</surname><given-names>A</given-names></name><name><surname>Hersey</surname><given-names>A</given-names></name><name><surname>Leach</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>ChEMBL: towards direct deposition of bioassay data</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>D930</fpage><lpage>D940</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1075</pub-id><pub-id pub-id-type="pmid">30398643</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moret</surname><given-names>N</given-names></name><name><surname>Clark</surname><given-names>NA</given-names></name><name><surname>Hafner</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Lounkine</surname><given-names>E</given-names></name><name><surname>Medvedovic</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Gray</surname><given-names>N</given-names></name><name><surname>Jenkins</surname><given-names>J</given-names></name><name><surname>Sorger</surname><given-names>PK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cheminformatics Tools for Analyzing and Designing Optimized Small-Molecule Collections and Libraries</article-title><source>Cell Chemical Biology</source><volume>26</volume><fpage>765</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2019.02.018</pub-id><pub-id pub-id-type="pmid">30956147</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morita</surname><given-names>M</given-names></name><name><surname>Gravel</surname><given-names>SP</given-names></name><name><surname>Chénard</surname><given-names>V</given-names></name><name><surname>Sikström</surname><given-names>K</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Alain</surname><given-names>T</given-names></name><name><surname>Gandin</surname><given-names>V</given-names></name><name><surname>Avizonis</surname><given-names>D</given-names></name><name><surname>Arguello</surname><given-names>M</given-names></name><name><surname>Zakaria</surname><given-names>C</given-names></name><name><surname>McLaughlan</surname><given-names>S</given-names></name><name><surname>Nouet</surname><given-names>Y</given-names></name><name><surname>Pause</surname><given-names>A</given-names></name><name><surname>Pollak</surname><given-names>M</given-names></name><name><surname>Gottlieb</surname><given-names>E</given-names></name><name><surname>Larsson</surname><given-names>O</given-names></name><name><surname>St-Pierre</surname><given-names>J</given-names></name><name><surname>Topisirovic</surname><given-names>I</given-names></name><name><surname>Sonenberg</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation</article-title><source>Cell Metabolism</source><volume>18</volume><fpage>698</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2013.10.001</pub-id><pub-id pub-id-type="pmid">24206664</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musso</surname><given-names>G</given-names></name><name><surname>Cassader</surname><given-names>M</given-names></name><name><surname>De Michieli</surname><given-names>F</given-names></name><name><surname>Paschetta</surname><given-names>E</given-names></name><name><surname>Pinach</surname><given-names>S</given-names></name><name><surname>Saba</surname><given-names>F</given-names></name><name><surname>Bongiovanni</surname><given-names>D</given-names></name><name><surname>Framarin</surname><given-names>L</given-names></name><name><surname>Berrutti</surname><given-names>M</given-names></name><name><surname>Leone</surname><given-names>N</given-names></name><name><surname>Corvisieri</surname><given-names>S</given-names></name><name><surname>Parente</surname><given-names>R</given-names></name><name><surname>Molinaro</surname><given-names>F</given-names></name><name><surname>Sircana</surname><given-names>A</given-names></name><name><surname>Bo</surname><given-names>S</given-names></name><name><surname>Gambino</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>MERTK rs4374383 variant predicts incident nonalcoholic fatty liver disease and diabetes: role of mononuclear cell activation and adipokine response to dietary fat</article-title><source>Human Molecular Genetics</source><volume>26</volume><fpage>1747</fpage><lpage>1758</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddw400</pub-id><pub-id pub-id-type="pmid">28334911</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakhuda</surname><given-names>A</given-names></name><name><surname>Josse</surname><given-names>AR</given-names></name><name><surname>Gburcik</surname><given-names>V</given-names></name><name><surname>Crossland</surname><given-names>H</given-names></name><name><surname>Raymond</surname><given-names>F</given-names></name><name><surname>Metairon</surname><given-names>S</given-names></name><name><surname>Good</surname><given-names>L</given-names></name><name><surname>Atherton</surname><given-names>PJ</given-names></name><name><surname>Phillips</surname><given-names>SM</given-names></name><name><surname>Timmons</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Biomarkers of browning of white adipose tissue and their regulation</article-title><source>The American Journal of Clinical Nutrition</source><volume>1</volume><fpage>557</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.3945/ajcn.116.132563</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naruse</surname><given-names>K</given-names></name><name><surname>Rask-Madsen</surname><given-names>C</given-names></name><name><surname>Takahara</surname><given-names>N</given-names></name><name><surname>Ha</surname><given-names>S</given-names></name><name><surname>Suzuma</surname><given-names>K</given-names></name><name><surname>Way</surname><given-names>KJ</given-names></name><name><surname>Jacobs</surname><given-names>JRC</given-names></name><name><surname>Clermont</surname><given-names>AC</given-names></name><name><surname>Ueki</surname><given-names>K</given-names></name><name><surname>Ohshiro</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Goldfine</surname><given-names>AB</given-names></name><name><surname>King</surname><given-names>GL</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Activation of vascular protein kinase C-beta inhibits Akt-dependent endothelial nitric oxide synthase function in obesity-associated insulin resistance</article-title><source>Diabetes</source><volume>55</volume><fpage>691</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.2337/diabetes.55.03.06.db05-0771</pub-id><pub-id pub-id-type="pmid">16505232</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nie</surname><given-names>C</given-names></name><name><surname>He</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2018">2018a</year><article-title>Branched Chain Amino Acids: Beyond Nutrition Metabolism</article-title><source>International Journal of Molecular Sciences</source><volume>19</volume><elocation-id>E954</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19040954</pub-id><pub-id pub-id-type="pmid">29570613</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nie</surname><given-names>SD</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>CE</given-names></name><name><surname>Min</surname><given-names>FY</given-names></name><name><surname>Shi</surname><given-names>XJ</given-names></name><name><surname>Wu</surname><given-names>LY</given-names></name><name><surname>Zhou</surname><given-names>SL</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>T</given-names></name><name><surname>Dai</surname><given-names>ZJ</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>JJ</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018b</year><article-title>High glucose forces a positive feedback loop connecting ErbB4 expression and mTOR/S6K pathway to aggravate the formation of tau hyperphosphorylation in differentiated SH-SY5Y cells</article-title><source>Neurobiology of Aging</source><volume>67</volume><fpage>171</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2018.03.023</pub-id><pub-id pub-id-type="pmid">29674181</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norambuena</surname><given-names>A</given-names></name><name><surname>Wallrabe</surname><given-names>H</given-names></name><name><surname>McMahon</surname><given-names>L</given-names></name><name><surname>Silva</surname><given-names>A</given-names></name><name><surname>Swanson</surname><given-names>E</given-names></name><name><surname>Khan</surname><given-names>SS</given-names></name><name><surname>Baerthlein</surname><given-names>D</given-names></name><name><surname>Kodis</surname><given-names>E</given-names></name><name><surname>Oddo</surname><given-names>S</given-names></name><name><surname>Mandell</surname><given-names>JW</given-names></name><name><surname>Bloom</surname><given-names>GS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>mTOR and neuronal cell cycle reentry: How impaired brain insulin signaling promotes Alzheimer’s disease</article-title><source>Alzheimer’s &amp; Dementia</source><volume>13</volume><fpage>152</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2016.08.015</pub-id><pub-id pub-id-type="pmid">27693185</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osrodek</surname><given-names>M</given-names></name><name><surname>Rozanski</surname><given-names>M</given-names></name><name><surname>Czyz</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Insulin Reduces the Efficacy of Vemurafenib and Trametinib in Melanoma Cells</article-title><source>Cancer Management and Research</source><volume>12</volume><fpage>7231</fpage><lpage>7250</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S263767</pub-id><pub-id pub-id-type="pmid">32982400</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozaki</surname><given-names>KI</given-names></name><name><surname>Awazu</surname><given-names>M</given-names></name><name><surname>Tamiya</surname><given-names>M</given-names></name><name><surname>Iwasaki</surname><given-names>Y</given-names></name><name><surname>Harada</surname><given-names>A</given-names></name><name><surname>Kugisaki</surname><given-names>S</given-names></name><name><surname>Tanimura</surname><given-names>S</given-names></name><name><surname>Kohno</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Targeting the ERK signaling pathway as a potential treatment for insulin resistance and type 2 diabetes</article-title><source>American Journal of Physiology. Endocrinology and Metabolism</source><volume>310</volume><fpage>E643</fpage><lpage>E651</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00445.2015</pub-id><pub-id pub-id-type="pmid">26860984</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozcan</surname><given-names>Lale</given-names></name><name><surname>Cristina de Souza</surname><given-names>J</given-names></name><name><surname>Harari</surname><given-names>AA</given-names></name><name><surname>Backs</surname><given-names>J</given-names></name><name><surname>Olson</surname><given-names>EN</given-names></name><name><surname>Tabas</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Activation of calcium/calmodulin-dependent protein kinase II in obesity mediates suppression of hepatic insulin signaling</article-title><source>Cell Metabolism</source><volume>18</volume><fpage>803</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2013.10.011</pub-id><pub-id pub-id-type="pmid">24268736</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozcan</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Deng</surname><given-names>SX</given-names></name><name><surname>Ghorpade</surname><given-names>DS</given-names></name><name><surname>Thomas</surname><given-names>T</given-names></name><name><surname>Cremers</surname><given-names>S</given-names></name><name><surname>Hubbard</surname><given-names>B</given-names></name><name><surname>Serrano-Wu</surname><given-names>MH</given-names></name><name><surname>Gaestel</surname><given-names>M</given-names></name><name><surname>Landry</surname><given-names>DW</given-names></name><name><surname>Tabas</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Treatment of Obese Insulin-Resistant Mice With an Allosteric MAPKAPK2/3 Inhibitor Lowers Blood Glucose and Improves Insulin Sensitivity</article-title><source>Diabetes</source><volume>64</volume><fpage>3396</fpage><lpage>3405</lpage><pub-id pub-id-type="doi">10.2337/db14-1945</pub-id><pub-id pub-id-type="pmid">26068544</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palacio-Rodríguez</surname><given-names>K</given-names></name><name><surname>Lans</surname><given-names>I</given-names></name><name><surname>Cavasotto</surname><given-names>CN</given-names></name><name><surname>Cossio</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Exponential consensus ranking improves the outcome in docking and receptor ensemble docking</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>5142</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-41594-3</pub-id><pub-id pub-id-type="pmid">30914702</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parisi</surname><given-names>D</given-names></name><name><surname>Adasme</surname><given-names>MF</given-names></name><name><surname>Sveshnikova</surname><given-names>A</given-names></name><name><surname>Bolz</surname><given-names>SN</given-names></name><name><surname>Moreau</surname><given-names>Y</given-names></name><name><surname>Schroeder</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Drug repositioning or target repositioning: A structural perspective of drug-target-indication relationship for available repurposed drugs</article-title><source>Computational and Structural Biotechnology Journal</source><volume>18</volume><fpage>1043</fpage><lpage>1055</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2020.04.004</pub-id><pub-id pub-id-type="pmid">32419905</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Hong</surname><given-names>SM</given-names></name><name><surname>Lee</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Chlorpromazine exacerbates hepatic insulin sensitivity via attenuating insulin and leptin signaling pathway, while exercise partially reverses the adverse effects</article-title><source>Life Sciences</source><volume>80</volume><fpage>2428</fpage><lpage>2435</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2007.04.001</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Castillo</surname><given-names>Y</given-names></name><name><surname>Helguera</surname><given-names>AM</given-names></name><name><surname>Cordeiro</surname><given-names>M</given-names></name><name><surname>Tejera</surname><given-names>E</given-names></name><name><surname>Paz-Y-Mino</surname><given-names>C</given-names></name><name><surname>Sanchez-Rodriguez</surname><given-names>A</given-names></name><name><surname>Borges</surname><given-names>F</given-names></name><name><surname>Cruz-Monteagudo</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Fusing Docking Scoring Functions Improves the Virtual Screening Performance for Discovering Parkinson’s Disease Dual Target Ligands</article-title><source>Current Neuropharmacology</source><volume>15</volume><fpage>1107</fpage><lpage>1116</lpage><pub-id pub-id-type="doi">10.2174/1570159X15666170109143757</pub-id><pub-id pub-id-type="pmid">28067172</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>BE</given-names></name><name><surname>Kelly</surname><given-names>BM</given-names></name><name><surname>Lilja</surname><given-names>M</given-names></name><name><surname>Ponce-González</surname><given-names>JG</given-names></name><name><surname>Brogan</surname><given-names>RJ</given-names></name><name><surname>Morris</surname><given-names>DL</given-names></name><name><surname>Gustafsson</surname><given-names>T</given-names></name><name><surname>Kraus</surname><given-names>WE</given-names></name><name><surname>Atherton</surname><given-names>PJ</given-names></name><name><surname>Vollaard</surname><given-names>NBJ</given-names></name><name><surname>Rooyackers</surname><given-names>O</given-names></name><name><surname>Timmons</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A Practical and Time-Efficient High-Intensity Interval Training Program Modifies Cardio-Metabolic Risk Factors in Adults with Risk Factors for Type II Diabetes</article-title><source>Frontiers in Endocrinology</source><volume>8</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.3389/fendo.2017.00229</pub-id><pub-id pub-id-type="pmid">28943861</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reading</surname><given-names>CL</given-names></name><name><surname>Stickney</surname><given-names>DR</given-names></name><name><surname>Flores-Riveros</surname><given-names>J</given-names></name><name><surname>Destiche</surname><given-names>DA</given-names></name><name><surname>Ahlem</surname><given-names>CN</given-names></name><name><surname>Cefalu</surname><given-names>WT</given-names></name><name><surname>Frincke</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A synthetic anti-inflammatory sterol improves insulin sensitivity in insulin-resistant obese impaired glucose tolerance subjects</article-title><source>Obesity</source><volume>21</volume><fpage>E343</fpage><lpage>E349</lpage><pub-id pub-id-type="doi">10.1002/oby.20207</pub-id><pub-id pub-id-type="pmid">23670958</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redhead</surname><given-names>MA</given-names></name><name><surname>Owen</surname><given-names>CD</given-names></name><name><surname>Brewitz</surname><given-names>L</given-names></name><name><surname>Collette</surname><given-names>AH</given-names></name><name><surname>Lukacik</surname><given-names>P</given-names></name><name><surname>Strain-Damerell</surname><given-names>C</given-names></name><name><surname>Robinson</surname><given-names>SW</given-names></name><name><surname>Collins</surname><given-names>PM</given-names></name><name><surname>Schäfer</surname><given-names>P</given-names></name><name><surname>Swindells</surname><given-names>M</given-names></name><name><surname>Radoux</surname><given-names>CJ</given-names></name><name><surname>Hopkins</surname><given-names>IN</given-names></name><name><surname>Fearon</surname><given-names>D</given-names></name><name><surname>Douangamath</surname><given-names>A</given-names></name><name><surname>von Delft</surname><given-names>F</given-names></name><name><surname>Malla</surname><given-names>TR</given-names></name><name><surname>Vangeel</surname><given-names>L</given-names></name><name><surname>Vercruysse</surname><given-names>T</given-names></name><name><surname>Thibaut</surname><given-names>J</given-names></name><name><surname>Leyssen</surname><given-names>P</given-names></name><name><surname>Nguyen</surname><given-names>TT</given-names></name><name><surname>Hull</surname><given-names>M</given-names></name><name><surname>Tumber</surname><given-names>A</given-names></name><name><surname>Hallett</surname><given-names>DJ</given-names></name><name><surname>Schofield</surname><given-names>CJ</given-names></name><name><surname>Stuart</surname><given-names>DI</given-names></name><name><surname>Hopkins</surname><given-names>AL</given-names></name><name><surname>Walsh</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19</article-title><source>Scientific Reports</source><volume>11</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1038/s41598-021-92416-4</pub-id><pub-id pub-id-type="pmid">34168183</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regan-Fendt</surname><given-names>KE</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>DiVincenzo</surname><given-names>M</given-names></name><name><surname>Duggan</surname><given-names>MC</given-names></name><name><surname>Shakya</surname><given-names>R</given-names></name><name><surname>Na</surname><given-names>R</given-names></name><name><surname>Carson</surname><given-names>WE</given-names></name><name><surname>Payne</surname><given-names>PRO</given-names></name><name><surname>Li</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Synergy from gene expression and network mining (SynGeNet) method predicts synergistic drug combinations for diverse melanoma genomic subtypes</article-title><source>NPJ Systems Biology and Applications</source><volume>5</volume><elocation-id>6</elocation-id><pub-id pub-id-type="doi">10.1038/s41540-019-0085-4</pub-id><pub-id pub-id-type="pmid">30820351</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sajan</surname><given-names>MP</given-names></name><name><surname>Hansen</surname><given-names>BC</given-names></name><name><surname>Higgs</surname><given-names>MG</given-names></name><name><surname>Kahn</surname><given-names>CR</given-names></name><name><surname>Braun</surname><given-names>U</given-names></name><name><surname>Leitges</surname><given-names>M</given-names></name><name><surname>Park</surname><given-names>CR</given-names></name><name><surname>Diamond</surname><given-names>DM</given-names></name><name><surname>Farese</surname><given-names>RV</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Atypical PKC, PKCλ/ι, activates β-secretase and increases Aβ1-40/42 and phospho-tau in mouse brain and isolated neuronal cells, and may link hyperinsulinemia and other aPKC activators to development of pathological and memory abnormalities in Alzheimer’s disease</article-title><source>Neurobiology of Aging</source><volume>61</volume><fpage>225</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2017.09.001</pub-id><pub-id pub-id-type="pmid">29032894</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sartor</surname><given-names>GC</given-names></name><name><surname>Malvezzi</surname><given-names>AM</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Andrade</surname><given-names>NS</given-names></name><name><surname>Wiedner</surname><given-names>HJ</given-names></name><name><surname>Vilca</surname><given-names>SJ</given-names></name><name><surname>Janczura</surname><given-names>KJ</given-names></name><name><surname>Bagheri</surname><given-names>A</given-names></name><name><surname>Al-Ali</surname><given-names>H</given-names></name><name><surname>Powell</surname><given-names>SK</given-names></name><name><surname>Brown</surname><given-names>PT</given-names></name><name><surname>Volmar</surname><given-names>CH</given-names></name><name><surname>Foster</surname><given-names>TC</given-names></name><name><surname>Zeier</surname><given-names>Z</given-names></name><name><surname>Wahlestedt</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Enhancement of BDNF Expression and Memory by HDAC Inhibition Requires BET Bromodomain Reader Proteins</article-title><source>The Journal of Neuroscience</source><volume>39</volume><fpage>612</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1604-18.2018</pub-id><pub-id pub-id-type="pmid">30504275</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sears</surname><given-names>DD</given-names></name><name><surname>Hsiao</surname><given-names>G</given-names></name><name><surname>Hsiao</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>JG</given-names></name><name><surname>Courtney</surname><given-names>CH</given-names></name><name><surname>Ofrecio</surname><given-names>JM</given-names></name><name><surname>Chapman</surname><given-names>J</given-names></name><name><surname>Subramaniam</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Mechanisms of human insulin resistance and thiazolidinedione-mediated insulin sensitization</article-title><source>PNAS</source><volume>106</volume><fpage>18745</fpage><lpage>18750</lpage><pub-id pub-id-type="doi">10.1073/pnas.0903032106</pub-id><pub-id pub-id-type="pmid">19841271</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>MK</given-names></name><name><surname>Jalewa</surname><given-names>J</given-names></name><name><surname>Hölscher</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress</article-title><source>Journal of Neurochemistry</source><volume>128</volume><fpage>459</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1111/jnc.12469</pub-id><pub-id pub-id-type="pmid">24112036</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Maurya</surname><given-names>CK</given-names></name><name><surname>Arha</surname><given-names>D</given-names></name><name><surname>Rai</surname><given-names>AK</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Varshney</surname><given-names>S</given-names></name><name><surname>Schertzer</surname><given-names>JD</given-names></name><name><surname>Tamrakar</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Nod1-mediated lipolysis promotes diacylglycerol accumulation and successive inflammation via PKCδ-IRAK axis in adipocytes</article-title><source>Biochimica et Biophysica Acta. Molecular Basis of Disease</source><volume>1865</volume><fpage>136</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2018.10.036</pub-id><pub-id pub-id-type="pmid">30391544</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shelton</surname><given-names>LB</given-names></name><name><surname>Baker</surname><given-names>JD</given-names></name><name><surname>Zheng</surname><given-names>D</given-names></name><name><surname>Sullivan</surname><given-names>LE</given-names></name><name><surname>Solanki</surname><given-names>PK</given-names></name><name><surname>Webster</surname><given-names>JM</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Sabbagh</surname><given-names>JJ</given-names></name><name><surname>Nordhues</surname><given-names>BA</given-names></name><name><surname>Koren</surname><given-names>J</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Blagg</surname><given-names>BSJ</given-names></name><name><surname>Blair</surname><given-names>LJ</given-names></name><name><surname>Dickey</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Hsp90 activator Aha1 drives production of pathological tau aggregates</article-title><source>PNAS</source><volume>114</volume><fpage>9707</fpage><lpage>9712</lpage><pub-id pub-id-type="doi">10.1073/pnas.1707039114</pub-id><pub-id pub-id-type="pmid">28827321</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheu</surname><given-names>WH</given-names></name><name><surname>Swislocki</surname><given-names>ALM</given-names></name><name><surname>Hoffman</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>YDI</given-names></name><name><surname>Reaven</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Comparison of the effects of atenolol and nifedipine on glucose, insulin, and lipid metabolism in patients with hypertension</article-title><source>American Journal of Hypertension</source><volume>4</volume><fpage>199</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1093/ajh/4.3.199</pub-id><pub-id pub-id-type="pmid">2043298</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skurski</surname><given-names>J</given-names></name><name><surname>Penniman</surname><given-names>CM</given-names></name><name><surname>Geesala</surname><given-names>R</given-names></name><name><surname>Dixit</surname><given-names>G</given-names></name><name><surname>Pulipati</surname><given-names>P</given-names></name><name><surname>Bhardwaj</surname><given-names>G</given-names></name><name><surname>Meyerholz</surname><given-names>DK</given-names></name><name><surname>Issuree</surname><given-names>PD</given-names></name><name><surname>O’Neill</surname><given-names>BT</given-names></name><name><surname>Maretzky</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Loss of iRhom2 accelerates fat gain and insulin resistance in diet-induced obesity despite reduced adipose tissue inflammation</article-title><source>Metabolism</source><volume>106</volume><elocation-id>154194</elocation-id><pub-id pub-id-type="doi">10.1016/j.metabol.2020.154194</pub-id><pub-id pub-id-type="pmid">32135161</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slentz</surname><given-names>CA</given-names></name><name><surname>Bateman</surname><given-names>LA</given-names></name><name><surname>Willis</surname><given-names>LH</given-names></name><name><surname>Shields</surname><given-names>AT</given-names></name><name><surname>Tanner</surname><given-names>CJ</given-names></name><name><surname>Piner</surname><given-names>LW</given-names></name><name><surname>Hawk</surname><given-names>VH</given-names></name><name><surname>Muehlbauer</surname><given-names>MJ</given-names></name><name><surname>Samsa</surname><given-names>GP</given-names></name><name><surname>Nelson</surname><given-names>RC</given-names></name><name><surname>Huffman</surname><given-names>KM</given-names></name><name><surname>Bales</surname><given-names>CW</given-names></name><name><surname>Houmard</surname><given-names>JA</given-names></name><name><surname>Kraus</surname><given-names>WE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Effects of aerobic vs. resistance training on visceral and liver fat stores, liver enzymes, and insulin resistance by HOMA in overweight adults from STRRIDE AT/RT</article-title><source>American Journal of Physiology. Endocrinology and Metabolism</source><volume>301</volume><fpage>E1033</fpage><lpage>E1039</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00291.2011</pub-id><pub-id pub-id-type="pmid">21846904</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slentz</surname><given-names>CA</given-names></name><name><surname>Bateman</surname><given-names>LA</given-names></name><name><surname>Willis</surname><given-names>LH</given-names></name><name><surname>Granville</surname><given-names>EO</given-names></name><name><surname>Piner</surname><given-names>LW</given-names></name><name><surname>Samsa</surname><given-names>GP</given-names></name><name><surname>Setji</surname><given-names>TL</given-names></name><name><surname>Muehlbauer</surname><given-names>MJ</given-names></name><name><surname>Huffman</surname><given-names>KM</given-names></name><name><surname>Bales</surname><given-names>CW</given-names></name><name><surname>Kraus</surname><given-names>WE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Effects of exercise training alone vs a combined exercise and nutritional lifestyle intervention on glucose homeostasis in prediabetic individuals: a randomised controlled trial</article-title><source>Diabetologia</source><volume>59</volume><fpage>2088</fpage><lpage>2098</lpage><pub-id pub-id-type="doi">10.1007/s00125-016-4051-z</pub-id><pub-id pub-id-type="pmid">27421729</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>WM</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Multiscale Embedded Gene Co-expression Network Analysis</article-title><source>PLOS Computational Biology</source><volume>11</volume><elocation-id>e1004574</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1004574</pub-id><pub-id pub-id-type="pmid">26618778</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sood</surname><given-names>S</given-names></name><name><surname>Szkop</surname><given-names>KJ</given-names></name><name><surname>Nakhuda</surname><given-names>A</given-names></name><name><surname>Gallagher</surname><given-names>IJ</given-names></name><name><surname>Murie</surname><given-names>C</given-names></name><name><surname>Brogan</surname><given-names>RJ</given-names></name><name><surname>Kaprio</surname><given-names>J</given-names></name><name><surname>Kainulainen</surname><given-names>H</given-names></name><name><surname>Atherton</surname><given-names>PJ</given-names></name><name><surname>Kujala</surname><given-names>UM</given-names></name><name><surname>Gustafsson</surname><given-names>T</given-names></name><name><surname>Larsson</surname><given-names>O</given-names></name><name><surname>Timmons</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>iGEMS: an integrated model for identification of alternative exon usage events</article-title><source>Nucleic Acids Research</source><volume>44</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw263</pub-id><pub-id pub-id-type="pmid">27095197</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stathias</surname><given-names>V</given-names></name><name><surname>Turner</surname><given-names>J</given-names></name><name><surname>Koleti</surname><given-names>A</given-names></name><name><surname>Vidovic</surname><given-names>D</given-names></name><name><surname>Cooper</surname><given-names>D</given-names></name><name><surname>Fazel-Najafabadi</surname><given-names>M</given-names></name><name><surname>Pilarczyk</surname><given-names>M</given-names></name><name><surname>Terryn</surname><given-names>R</given-names></name><name><surname>Chung</surname><given-names>C</given-names></name><name><surname>Umeano</surname><given-names>A</given-names></name><name><surname>Clarke</surname><given-names>DJB</given-names></name><name><surname>Lachmann</surname><given-names>A</given-names></name><name><surname>Evangelista</surname><given-names>JE</given-names></name><name><surname>Ma’ayan</surname><given-names>A</given-names></name><name><surname>Medvedovic</surname><given-names>M</given-names></name><name><surname>Schürer</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>LINCS Data Portal 2.0: next generation access point for perturbation-response signatures</article-title><source>Nucleic Acids Research</source><volume>48</volume><fpage>D431</fpage><lpage>D439</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz1023</pub-id><pub-id pub-id-type="pmid">31701147</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoelzel</surname><given-names>CR</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Cincotta</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Circadian-timed dopamine agonist treatment reverses high-fat diet-induced diabetogenic shift in ventromedial hypothalamic glucose sensing</article-title><source>Endocrinology, Diabetes &amp; Metabolism</source><volume>3</volume><elocation-id>e00139</elocation-id><pub-id pub-id-type="doi">10.1002/edm2.139</pub-id><pub-id pub-id-type="pmid">32704560</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stokes</surname><given-names>T</given-names></name><name><surname>Timmons</surname><given-names>JA</given-names></name><name><surname>Crossland</surname><given-names>H</given-names></name><name><surname>Tripp</surname><given-names>TR</given-names></name><name><surname>Murphy</surname><given-names>K</given-names></name><name><surname>McGlory</surname><given-names>C</given-names></name><name><surname>Mitchell</surname><given-names>CJ</given-names></name><name><surname>Oikawa</surname><given-names>SY</given-names></name><name><surname>Morton</surname><given-names>RW</given-names></name><name><surname>Phillips</surname><given-names>BE</given-names></name><name><surname>Baker</surname><given-names>SK</given-names></name><name><surname>Atherton</surname><given-names>PJ</given-names></name><name><surname>Wahlestedt</surname><given-names>C</given-names></name><name><surname>Phillips</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Molecular Transducers of Human Skeletal Muscle Remodeling under Different Loading States</article-title><source>Cell Reports</source><volume>32</volume><elocation-id>107980</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.107980</pub-id><pub-id pub-id-type="pmid">32755574</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sturm</surname><given-names>N</given-names></name><name><surname>Mayr</surname><given-names>A</given-names></name><name><surname>Le Van</surname><given-names>T</given-names></name><name><surname>Chupakhin</surname><given-names>V</given-names></name><name><surname>Ceulemans</surname><given-names>H</given-names></name><name><surname>Wegner</surname><given-names>J</given-names></name><name><surname>Golib-Dzib</surname><given-names>JF</given-names></name><name><surname>Jeliazkova</surname><given-names>N</given-names></name><name><surname>Vandriessche</surname><given-names>Y</given-names></name><name><surname>Böhm</surname><given-names>S</given-names></name><name><surname>Cima</surname><given-names>V</given-names></name><name><surname>Martinovic</surname><given-names>J</given-names></name><name><surname>Greene</surname><given-names>N</given-names></name><name><surname>Vander Aa</surname><given-names>T</given-names></name><name><surname>Ashby</surname><given-names>TJ</given-names></name><name><surname>Hochreiter</surname><given-names>S</given-names></name><name><surname>Engkvist</surname><given-names>O</given-names></name><name><surname>Klambauer</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Industry-scale application and evaluation of deep learning for drug target prediction</article-title><source>Journal of Cheminformatics</source><volume>12</volume><elocation-id>26</elocation-id><pub-id pub-id-type="doi">10.1186/s13321-020-00428-5</pub-id><pub-id pub-id-type="pmid">33430964</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Narayan</surname><given-names>R</given-names></name><name><surname>Corsello</surname><given-names>SM</given-names></name><name><surname>Peck</surname><given-names>DD</given-names></name><name><surname>Natoli</surname><given-names>TE</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Gould</surname><given-names>J</given-names></name><name><surname>Davis</surname><given-names>JF</given-names></name><name><surname>Tubelli</surname><given-names>AA</given-names></name><name><surname>Asiedu</surname><given-names>JK</given-names></name><name><surname>Lahr</surname><given-names>DL</given-names></name><name><surname>Hirschman</surname><given-names>JE</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Donahue</surname><given-names>M</given-names></name><name><surname>Julian</surname><given-names>B</given-names></name><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Wadden</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>IC</given-names></name><name><surname>Lam</surname><given-names>D</given-names></name><name><surname>Liberzon</surname><given-names>A</given-names></name><name><surname>Toder</surname><given-names>C</given-names></name><name><surname>Bagul</surname><given-names>M</given-names></name><name><surname>Orzechowski</surname><given-names>M</given-names></name><name><surname>Enache</surname><given-names>OM</given-names></name><name><surname>Piccioni</surname><given-names>F</given-names></name><name><surname>Johnson</surname><given-names>SA</given-names></name><name><surname>Lyons</surname><given-names>NJ</given-names></name><name><surname>Berger</surname><given-names>AH</given-names></name><name><surname>Shamji</surname><given-names>AF</given-names></name><name><surname>Brooks</surname><given-names>AN</given-names></name><name><surname>Vrcic</surname><given-names>A</given-names></name><name><surname>Flynn</surname><given-names>C</given-names></name><name><surname>Rosains</surname><given-names>J</given-names></name><name><surname>Takeda</surname><given-names>DY</given-names></name><name><surname>Hu</surname><given-names>R</given-names></name><name><surname>Davison</surname><given-names>D</given-names></name><name><surname>Lamb</surname><given-names>J</given-names></name><name><surname>Ardlie</surname><given-names>K</given-names></name><name><surname>Hogstrom</surname><given-names>L</given-names></name><name><surname>Greenside</surname><given-names>P</given-names></name><name><surname>Gray</surname><given-names>NS</given-names></name><name><surname>Clemons</surname><given-names>PA</given-names></name><name><surname>Silver</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>WN</given-names></name><name><surname>Read-Button</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Haggarty</surname><given-names>SJ</given-names></name><name><surname>Ronco</surname><given-names>LV</given-names></name><name><surname>Boehm</surname><given-names>JS</given-names></name><name><surname>Schreiber</surname><given-names>SL</given-names></name><name><surname>Doench</surname><given-names>JG</given-names></name><name><surname>Bittker</surname><given-names>JA</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name><name><surname>Wong</surname><given-names>B</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles</article-title><source>Cell</source><volume>171</volume><fpage>1437</fpage><lpage>1452</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.10.049</pub-id><pub-id pub-id-type="pmid">29195078</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>YBY</given-names></name><name><surname>Qu</surname><given-names>X</given-names></name><name><surname>Howard</surname><given-names>V</given-names></name><name><surname>Dai</surname><given-names>L</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>P</given-names></name><name><surname>Puelles</surname><given-names>VG</given-names></name><name><surname>Nikolic-Paterson</surname><given-names>DJ</given-names></name><name><surname>Caruana</surname><given-names>G</given-names></name><name><surname>Bertram</surname><given-names>JF</given-names></name><name><surname>Sleeman</surname><given-names>MW</given-names></name><name><surname>Li</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Smad3 deficiency protects mice from obesity-induced podocyte injury that precedes insulin resistance</article-title><source>Kidney International</source><volume>88</volume><fpage>286</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1038/ki.2015.121</pub-id><pub-id pub-id-type="pmid">25945408</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>G</given-names></name><name><surname>Tu</surname><given-names>Y</given-names></name><name><surname>Tao</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways</article-title><source>Oncotarget</source><volume>7</volume><fpage>53558</fpage><lpage>53570</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.10669</pub-id><pub-id pub-id-type="pmid">27448964</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>CK</given-names></name><name><surname>Leuenberger</surname><given-names>N</given-names></name><name><surname>Tan</surname><given-names>MJ</given-names></name><name><surname>Yan</surname><given-names>YW</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Kambadur</surname><given-names>R</given-names></name><name><surname>Wahli</surname><given-names>W</given-names></name><name><surname>Tan</surname><given-names>NS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Smad3 deficiency in mice protects against insulin resistance and obesity induced by a high-fat diet</article-title><source>Diabetes</source><volume>60</volume><fpage>464</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.2337/db10-0801</pub-id><pub-id pub-id-type="pmid">21270259</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>MS</given-names></name><name><surname>Yang</surname><given-names>YX</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>HF</given-names></name><name><surname>Tan</surname><given-names>L</given-names></name><name><surname>Zuo</surname><given-names>CT</given-names></name><name><surname>Dong</surname><given-names>Q</given-names></name><name><surname>Tan</surname><given-names>L</given-names></name><name><surname>Suckling</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>JT</given-names></name><collab>Alzheimer’s Disease Neuroimaging Initiative</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Associations of Alzheimer’s disease risk variants with gene expression, amyloidosis, tauopathy, and neurodegeneration</article-title><source>Alzheimer’s Research &amp; Therapy</source><volume>13</volume><elocation-id>15</elocation-id><pub-id pub-id-type="doi">10.1186/s13195-020-00755-7</pub-id><pub-id pub-id-type="pmid">33419465</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Szwajda</surname><given-names>A</given-names></name><name><surname>Shakyawar</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>T</given-names></name><name><surname>Hintsanen</surname><given-names>P</given-names></name><name><surname>Wennerberg</surname><given-names>K</given-names></name><name><surname>Aittokallio</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Making sense of large-scale kinase inhibitor bioactivity data sets: a comparative and integrative analysis</article-title><source>Journal of Chemical Information and Modeling</source><volume>54</volume><fpage>735</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1021/ci400709d</pub-id><pub-id pub-id-type="pmid">24521231</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarragó</surname><given-names>MG</given-names></name><name><surname>Chini</surname><given-names>CCS</given-names></name><name><surname>Kanamori</surname><given-names>KS</given-names></name><name><surname>Warner</surname><given-names>GM</given-names></name><name><surname>Caride</surname><given-names>A</given-names></name><name><surname>de Oliveira</surname><given-names>GC</given-names></name><name><surname>Rud</surname><given-names>M</given-names></name><name><surname>Samani</surname><given-names>A</given-names></name><name><surname>Hein</surname><given-names>KZ</given-names></name><name><surname>Huang</surname><given-names>R</given-names></name><name><surname>Jurk</surname><given-names>D</given-names></name><name><surname>Cho</surname><given-names>DS</given-names></name><name><surname>Boslett</surname><given-names>JJ</given-names></name><name><surname>Miller</surname><given-names>JD</given-names></name><name><surname>Zweier</surname><given-names>JL</given-names></name><name><surname>Passos</surname><given-names>JF</given-names></name><name><surname>Doles</surname><given-names>JD</given-names></name><name><surname>Becherer</surname><given-names>DJ</given-names></name><name><surname>Chini</surname><given-names>EN</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A Potent and Specific CD38 Inhibitor Ameliorates Age-Related Metabolic Dysfunction by Reversing Tissue NAD+ Decline</article-title><source>Cell Metabolism</source><volume>27</volume><fpage>1081</fpage><lpage>1095</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2018.03.016</pub-id><pub-id pub-id-type="pmid">29719225</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Timmons</surname><given-names>JA</given-names></name><name><surname>Larsson</surname><given-names>O</given-names></name><name><surname>Jansson</surname><given-names>E</given-names></name><name><surname>Fischer</surname><given-names>H</given-names></name><name><surname>Gustafsson</surname><given-names>T</given-names></name><name><surname>Greenhaff</surname><given-names>PL</given-names></name><name><surname>Ridden</surname><given-names>J</given-names></name><name><surname>Rachman</surname><given-names>J</given-names></name><name><surname>Peyrard-Janvid</surname><given-names>M</given-names></name><name><surname>Wahlestedt</surname><given-names>C</given-names></name><name><surname>Sundberg</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Human muscle gene expression responses to endurance training provide a novel perspective on Duchenne muscular dystrophy</article-title><source>FASEB Journal</source><volume>19</volume><fpage>750</fpage><lpage>760</lpage><pub-id pub-id-type="doi">10.1096/fj.04-1980com</pub-id><pub-id pub-id-type="pmid">15857889</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Timmons</surname><given-names>JA</given-names></name><name><surname>Szkop</surname><given-names>KJ</given-names></name><name><surname>Gallagher</surname><given-names>IJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Multiple sources of bias confound functional enrichment analysis of global -omics data</article-title><source>Genome Biology</source><volume>16</volume><fpage>15</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1186/s13059-015-0761-7</pub-id><pub-id pub-id-type="pmid">26346307</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Timmons</surname><given-names>JA</given-names></name><name><surname>Atherton</surname><given-names>PJ</given-names></name><name><surname>Larsson</surname><given-names>O</given-names></name><name><surname>Sood</surname><given-names>S</given-names></name><name><surname>Blokhin</surname><given-names>IO</given-names></name><name><surname>Brogan</surname><given-names>RJ</given-names></name><name><surname>Volmar</surname><given-names>CH</given-names></name><name><surname>Josse</surname><given-names>AR</given-names></name><name><surname>Slentz</surname><given-names>C</given-names></name><name><surname>Wahlestedt</surname><given-names>C</given-names></name><name><surname>Phillips</surname><given-names>SM</given-names></name><name><surname>Phillips</surname><given-names>BE</given-names></name><name><surname>Gallagher</surname><given-names>IJ</given-names></name><name><surname>Kraus</surname><given-names>WE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A coding and non-coding transcriptomic perspective on the genomics of human metabolic disease</article-title><source>Nucleic Acids Research</source><volume>46</volume><fpage>7772</fpage><lpage>7792</lpage><pub-id pub-id-type="doi">10.1093/nar/gky570</pub-id><pub-id pub-id-type="pmid">29986096</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Timmons</surname><given-names>JA</given-names></name><name><surname>Volmar</surname><given-names>CH</given-names></name><name><surname>Crossland</surname><given-names>H</given-names></name><name><surname>Phillips</surname><given-names>BE</given-names></name><name><surname>Sood</surname><given-names>S</given-names></name><name><surname>Janczura</surname><given-names>KJ</given-names></name><name><surname>Törmäkangas</surname><given-names>T</given-names></name><name><surname>Kujala</surname><given-names>UM</given-names></name><name><surname>Kraus</surname><given-names>WE</given-names></name><name><surname>Atherton</surname><given-names>PJ</given-names></name><name><surname>Wahlestedt</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Longevity-related molecular pathways are subject to midlife “switch” in humans</article-title><source>Aging Cell</source><volume>18</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1111/acel.12970</pub-id><pub-id pub-id-type="pmid">31168962</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Travelli</surname><given-names>C</given-names></name><name><surname>Aprile</surname><given-names>S</given-names></name><name><surname>Rahimian</surname><given-names>R</given-names></name><name><surname>Grolla</surname><given-names>AA</given-names></name><name><surname>Rogati</surname><given-names>F</given-names></name><name><surname>Bertolotti</surname><given-names>M</given-names></name><name><surname>Malagnino</surname><given-names>F</given-names></name><name><surname>di Paola</surname><given-names>R</given-names></name><name><surname>Impellizzeri</surname><given-names>D</given-names></name><name><surname>Fusco</surname><given-names>R</given-names></name><name><surname>Mercalli</surname><given-names>V</given-names></name><name><surname>Massarotti</surname><given-names>A</given-names></name><name><surname>Stortini</surname><given-names>G</given-names></name><name><surname>Terrazzino</surname><given-names>S</given-names></name><name><surname>Del Grosso</surname><given-names>E</given-names></name><name><surname>Fakhfouri</surname><given-names>G</given-names></name><name><surname>Troiani</surname><given-names>MP</given-names></name><name><surname>Alisi</surname><given-names>MA</given-names></name><name><surname>Grosa</surname><given-names>G</given-names></name><name><surname>Sorba</surname><given-names>G</given-names></name><name><surname>Canonico</surname><given-names>PL</given-names></name><name><surname>Orsomando</surname><given-names>G</given-names></name><name><surname>Cuzzocrea</surname><given-names>S</given-names></name><name><surname>Genazzani</surname><given-names>AA</given-names></name><name><surname>Galli</surname><given-names>U</given-names></name><name><surname>Tron</surname><given-names>GC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity</article-title><source>Journal of Medicinal Chemistry</source><volume>60</volume><fpage>1768</fpage><lpage>1792</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b01392</pub-id><pub-id pub-id-type="pmid">28165742</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Triana-Martínez</surname><given-names>F</given-names></name><name><surname>Picallos-Rabina</surname><given-names>P</given-names></name><name><surname>Da Silva-Álvarez</surname><given-names>S</given-names></name><name><surname>Pietrocola</surname><given-names>F</given-names></name><name><surname>Llanos</surname><given-names>S</given-names></name><name><surname>Rodilla</surname><given-names>V</given-names></name><name><surname>Soprano</surname><given-names>E</given-names></name><name><surname>Pedrosa</surname><given-names>P</given-names></name><name><surname>Ferreirós</surname><given-names>A</given-names></name><name><surname>Barradas</surname><given-names>M</given-names></name><name><surname>Hernández-González</surname><given-names>F</given-names></name><name><surname>Lalinde</surname><given-names>M</given-names></name><name><surname>Prats</surname><given-names>N</given-names></name><name><surname>Bernadó</surname><given-names>C</given-names></name><name><surname>González</surname><given-names>P</given-names></name><name><surname>Gómez</surname><given-names>M</given-names></name><name><surname>Ikonomopoulou</surname><given-names>MP</given-names></name><name><surname>Fernández-Marcos</surname><given-names>PJ</given-names></name><name><surname>García-Caballero</surname><given-names>T</given-names></name><name><surname>Del Pino</surname><given-names>P</given-names></name><name><surname>Arribas</surname><given-names>J</given-names></name><name><surname>Vidal</surname><given-names>A</given-names></name><name><surname>González-Barcia</surname><given-names>M</given-names></name><name><surname>Serrano</surname><given-names>M</given-names></name><name><surname>Loza</surname><given-names>MI</given-names></name><name><surname>Domínguez</surname><given-names>E</given-names></name><name><surname>Collado</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Identification and characterization of Cardiac Glycosides as senolytic compounds</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>4731</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-12888-x</pub-id><pub-id pub-id-type="pmid">31636264</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Um</surname><given-names>SH</given-names></name><name><surname>Frigerio</surname><given-names>F</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Picard</surname><given-names>F</given-names></name><name><surname>Joaquin</surname><given-names>M</given-names></name><name><surname>Sticker</surname><given-names>M</given-names></name><name><surname>Fumagalli</surname><given-names>S</given-names></name><name><surname>Allegrini</surname><given-names>PR</given-names></name><name><surname>Kozma</surname><given-names>SC</given-names></name><name><surname>Auwerx</surname><given-names>J</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity</article-title><source>Nature</source><volume>431</volume><fpage>200</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1038/nature02866</pub-id><pub-id pub-id-type="pmid">15306821</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vella</surname><given-names>V</given-names></name><name><surname>Malaguarnera</surname><given-names>R</given-names></name><name><surname>Nicolosi</surname><given-names>ML</given-names></name><name><surname>Morrione</surname><given-names>A</given-names></name><name><surname>Belfiore</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Insulin/IGF signaling and discoidin domain receptors: An emerging functional connection</article-title><source>Biochimica et Biophysica Acta. Molecular Cell Research</source><volume>1866</volume><elocation-id>118522</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbamcr.2019.118522</pub-id><pub-id pub-id-type="pmid">31394114</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volmar</surname><given-names>CH</given-names></name><name><surname>Salah-Uddin</surname><given-names>H</given-names></name><name><surname>Janczura</surname><given-names>KJ</given-names></name><name><surname>Halley</surname><given-names>P</given-names></name><name><surname>Lambert</surname><given-names>G</given-names></name><name><surname>Wodrich</surname><given-names>A</given-names></name><name><surname>Manoah</surname><given-names>S</given-names></name><name><surname>Patel</surname><given-names>NH</given-names></name><name><surname>Sartor</surname><given-names>GC</given-names></name><name><surname>Mehta</surname><given-names>N</given-names></name><name><surname>Miles</surname><given-names>NTH</given-names></name><name><surname>Desse</surname><given-names>S</given-names></name><name><surname>Dorcius</surname><given-names>D</given-names></name><name><surname>Cameron</surname><given-names>MD</given-names></name><name><surname>Brothers</surname><given-names>SP</given-names></name><name><surname>Wahlestedt</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>M344 promotes nonamyloidogenic amyloid precursor protein processing while normalizing Alzheimer’s disease genes and improving memory</article-title><source>PNAS</source><volume>114</volume><fpage>E9135</fpage><lpage>E9144</lpage><pub-id pub-id-type="doi">10.1073/pnas.1707544114</pub-id><pub-id pub-id-type="pmid">29073110</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vujkovic</surname><given-names>M</given-names></name><name><surname>Keaton</surname><given-names>JM</given-names></name><name><surname>Lynch</surname><given-names>JA</given-names></name><name><surname>Miller</surname><given-names>DR</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Tcheandjieu</surname><given-names>C</given-names></name><name><surname>Huffman</surname><given-names>JE</given-names></name><name><surname>Assimes</surname><given-names>TL</given-names></name><name><surname>Lorenz</surname><given-names>K</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Hilliard</surname><given-names>AT</given-names></name><name><surname>Judy</surname><given-names>RL</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>KM</given-names></name><name><surname>Klarin</surname><given-names>D</given-names></name><name><surname>Pyarajan</surname><given-names>S</given-names></name><name><surname>Danesh</surname><given-names>J</given-names></name><name><surname>Melander</surname><given-names>O</given-names></name><name><surname>Rasheed</surname><given-names>A</given-names></name><name><surname>Mallick</surname><given-names>NH</given-names></name><name><surname>Hameed</surname><given-names>S</given-names></name><name><surname>Qureshi</surname><given-names>IH</given-names></name><name><surname>Afzal</surname><given-names>MN</given-names></name><name><surname>Malik</surname><given-names>U</given-names></name><name><surname>Jalal</surname><given-names>A</given-names></name><name><surname>Abbas</surname><given-names>S</given-names></name><name><surname>Sheng</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Kaestner</surname><given-names>KH</given-names></name><name><surname>Susztak</surname><given-names>K</given-names></name><name><surname>Sun</surname><given-names>YV</given-names></name><name><surname>DuVall</surname><given-names>SL</given-names></name><name><surname>Cho</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Gaziano</surname><given-names>JM</given-names></name><name><surname>Phillips</surname><given-names>LS</given-names></name><name><surname>Meigs</surname><given-names>JB</given-names></name><name><surname>Reaven</surname><given-names>PD</given-names></name><name><surname>Wilson</surname><given-names>PW</given-names></name><name><surname>Edwards</surname><given-names>TL</given-names></name><name><surname>Rader</surname><given-names>DJ</given-names></name><name><surname>Damrauer</surname><given-names>SM</given-names></name><name><surname>O’Donnell</surname><given-names>CJ</given-names></name><name><surname>Tsao</surname><given-names>PS</given-names></name><collab>HPAP Consortium</collab><collab>Regeneron Genetics Center</collab><collab>VA Million Veteran Program</collab><name><surname>Chang</surname><given-names>KM</given-names></name><name><surname>Voight</surname><given-names>BF</given-names></name><name><surname>Saleheen</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis</article-title><source>Nature Genetics</source><volume>52</volume><fpage>680</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1038/s41588-020-0637-y</pub-id><pub-id pub-id-type="pmid">32541925</pub-id></element-citation></ref><ref id="bib130"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>A</given-names></name><name><surname>Cohen</surname><given-names>N</given-names></name><name><surname>Kelder</surname><given-names>T</given-names></name><name><surname>Amit</surname><given-names>U</given-names></name><name><surname>Liebman</surname><given-names>E</given-names></name><name><surname>Steinberg</surname><given-names>DM</given-names></name><name><surname>Radonjic</surname><given-names>M</given-names></name><name><surname>Ruppin</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Drugs that reverse disease transcriptomic signatures are more effective in a mouse model of dyslipidemia</article-title><source>Molecular Systems Biology</source><volume>11</volume><elocation-id>791</elocation-id><pub-id pub-id-type="doi">10.15252/msb.20145486</pub-id><pub-id pub-id-type="pmid">26148350</pub-id></element-citation></ref><ref id="bib131"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>TM</given-names></name><name><surname>Levy</surname><given-names>JC</given-names></name><name><surname>Matthews</surname><given-names>DR</given-names></name><name><surname>Homa</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Use and abuse of HOMA modeling</article-title><source>Diabetes Care</source><volume>27</volume><fpage>1487</fpage><lpage>1495</lpage><pub-id pub-id-type="doi">10.2337/diacare.27.6.1487</pub-id><pub-id pub-id-type="pmid">15161807</pub-id></element-citation></ref><ref id="bib132"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wamil</surname><given-names>M</given-names></name><name><surname>Coleman</surname><given-names>RL</given-names></name><name><surname>Adler</surname><given-names>AI</given-names></name><name><surname>McMurray</surname><given-names>JJV</given-names></name><name><surname>Holman</surname><given-names>RR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Increased Risk of Incident Heart Failure and Death Is Associated With Insulin Resistance in People With Newly Diagnosed Type 2 Diabetes: UKPDS 89</article-title><source>Diabetes Care</source><volume>44</volume><fpage>1877</fpage><lpage>1884</lpage><pub-id pub-id-type="doi">10.2337/dc21-0429</pub-id><pub-id pub-id-type="pmid">34162666</pub-id></element-citation></ref><ref id="bib133"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Chiang</surname><given-names>HC</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Liang</surname><given-names>B</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Du</surname><given-names>S</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Epidermal growth factor receptor is a preferred target for treating amyloid-β-induced memory loss</article-title><source>PNAS</source><volume>109</volume><fpage>16743</fpage><lpage>16748</lpage><pub-id pub-id-type="doi">10.1073/pnas.1208011109</pub-id><pub-id pub-id-type="pmid">23019586</pub-id></element-citation></ref><ref id="bib134"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Monteiro</surname><given-names>CD</given-names></name><name><surname>Jagodnik</surname><given-names>KM</given-names></name><name><surname>Fernandez</surname><given-names>NF</given-names></name><name><surname>Gundersen</surname><given-names>GW</given-names></name><name><surname>Rouillard</surname><given-names>AD</given-names></name><name><surname>Jenkins</surname><given-names>SL</given-names></name><name><surname>Feldmann</surname><given-names>AS</given-names></name><name><surname>Hu</surname><given-names>KS</given-names></name><name><surname>McDermott</surname><given-names>MG</given-names></name><name><surname>Duan</surname><given-names>Q</given-names></name><name><surname>Clark</surname><given-names>NR</given-names></name><name><surname>Jones</surname><given-names>MR</given-names></name><name><surname>Kou</surname><given-names>Y</given-names></name><name><surname>Goff</surname><given-names>T</given-names></name><name><surname>Woodland</surname><given-names>H</given-names></name><name><surname>Amaral</surname><given-names>FMR</given-names></name><name><surname>Szeto</surname><given-names>GL</given-names></name><name><surname>Fuchs</surname><given-names>O</given-names></name><name><surname>Schüssler-Fiorenza Rose</surname><given-names>SM</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Schwartz</surname><given-names>U</given-names></name><name><surname>Bausela</surname><given-names>XB</given-names></name><name><surname>Szymkiewicz</surname><given-names>M</given-names></name><name><surname>Maroulis</surname><given-names>V</given-names></name><name><surname>Salykin</surname><given-names>A</given-names></name><name><surname>Barra</surname><given-names>CM</given-names></name><name><surname>Kruth</surname><given-names>CD</given-names></name><name><surname>Bongio</surname><given-names>NJ</given-names></name><name><surname>Mathur</surname><given-names>V</given-names></name><name><surname>Todoric</surname><given-names>RD</given-names></name><name><surname>Rubin</surname><given-names>UE</given-names></name><name><surname>Malatras</surname><given-names>A</given-names></name><name><surname>Fulp</surname><given-names>CT</given-names></name><name><surname>Galindo</surname><given-names>JA</given-names></name><name><surname>Motiejunaite</surname><given-names>R</given-names></name><name><surname>Jüschke</surname><given-names>C</given-names></name><name><surname>Dishuck</surname><given-names>PC</given-names></name><name><surname>Lahl</surname><given-names>K</given-names></name><name><surname>Jafari</surname><given-names>M</given-names></name><name><surname>Aibar</surname><given-names>S</given-names></name><name><surname>Zaravinos</surname><given-names>A</given-names></name><name><surname>Steenhuizen</surname><given-names>LH</given-names></name><name><surname>Allison</surname><given-names>LR</given-names></name><name><surname>Gamallo</surname><given-names>P</given-names></name><name><surname>de Andres Segura</surname><given-names>F</given-names></name><name><surname>Dae Devlin</surname><given-names>T</given-names></name><name><surname>Pérez-García</surname><given-names>V</given-names></name><name><surname>Ma’ayan</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Extraction and analysis of signatures from the Gene Expression Omnibus by the crowd</article-title><source>Nature Communications</source><volume>7</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1038/ncomms12846</pub-id><pub-id pub-id-type="pmid">27667448</pub-id></element-citation></ref><ref id="bib135"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>DhHP-6 ameliorates hepatic oxidative stress and insulin resistance in type 2 diabetes mellitus through the PI3K/AKT and AMPK pathway</article-title><source>The Biochemical Journal</source><volume>477</volume><fpage>2363</fpage><lpage>2381</lpage><pub-id pub-id-type="doi">10.1042/BCJ20200402</pub-id><pub-id pub-id-type="pmid">32510127</pub-id></element-citation></ref><ref id="bib136"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wauson</surname><given-names>EM</given-names></name><name><surname>Guerra</surname><given-names>ML</given-names></name><name><surname>Barylko</surname><given-names>B</given-names></name><name><surname>Albanesi</surname><given-names>JP</given-names></name><name><surname>Cobb</surname><given-names>MH</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Off-target effects of MEK inhibitors</article-title><source>Biochemistry</source><volume>52</volume><fpage>5164</fpage><lpage>5166</lpage><pub-id pub-id-type="doi">10.1021/bi4007644</pub-id><pub-id pub-id-type="pmid">23848362</pub-id></element-citation></ref><ref id="bib137"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welsh</surname><given-names>EA</given-names></name><name><surname>Eschrich</surname><given-names>SA</given-names></name><name><surname>Berglund</surname><given-names>AE</given-names></name><name><surname>Fenstermacher</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Iterative rank-order normalization of gene expression microarray data</article-title><source>BMC Bioinformatics</source><volume>14</volume><elocation-id>153</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-14-153</pub-id><pub-id pub-id-type="pmid">23647742</pub-id></element-citation></ref><ref id="bib138"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>G</given-names></name><name><surname>Gatt</surname><given-names>A</given-names></name><name><surname>Clarke</surname><given-names>E</given-names></name><name><surname>Corcoran</surname><given-names>J</given-names></name><name><surname>Doherty</surname><given-names>P</given-names></name><name><surname>Chambers</surname><given-names>D</given-names></name><name><surname>Ballard</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Drug repurposing for Alzheimer’s disease based on transcriptional profiling of human iPSC-derived cortical neurons</article-title><source>Translational Psychiatry</source><volume>9</volume><elocation-id>220</elocation-id><pub-id pub-id-type="doi">10.1038/s41398-019-0555-x</pub-id><pub-id pub-id-type="pmid">31492831</pub-id></element-citation></ref><ref id="bib139"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>RS</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Yu</surname><given-names>HN</given-names></name><name><surname>Song</surname><given-names>DY</given-names></name><name><surname>Baik</surname><given-names>TK</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Expression of ErbB4 in the neurons of Alzheimer’s disease brain and APP/PS1 mice, a model of Alzheimer’s disease</article-title><source>Anatomy &amp; Cell Biology</source><volume>44</volume><fpage>116</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.5115/acb.2011.44.2.116</pub-id><pub-id pub-id-type="pmid">21829755</pub-id></element-citation></ref><ref id="bib140"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>JH</given-names></name><name><surname>Shimoni</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>WS</given-names></name><name><surname>Subramaniam</surname><given-names>P</given-names></name><name><surname>Iyer</surname><given-names>A</given-names></name><name><surname>Nicoletti</surname><given-names>P</given-names></name><name><surname>Rodríguez Martínez</surname><given-names>M</given-names></name><name><surname>López</surname><given-names>G</given-names></name><name><surname>Mattioli</surname><given-names>M</given-names></name><name><surname>Realubit</surname><given-names>R</given-names></name><name><surname>Karan</surname><given-names>C</given-names></name><name><surname>Stockwell</surname><given-names>BR</given-names></name><name><surname>Bansal</surname><given-names>M</given-names></name><name><surname>Califano</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Elucidating Compound Mechanism of Action by Network Perturbation Analysis</article-title><source>Cell</source><volume>162</volume><fpage>441</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.05.056</pub-id><pub-id pub-id-type="pmid">26186195</pub-id></element-citation></ref><ref id="bib141"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>JG</given-names></name><name><surname>Wang</surname><given-names>JQ</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Ning</surname><given-names>G</given-names></name><name><surname>Jin</surname><given-names>W</given-names></name><name><surname>Yuan</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>c-Abl inhibition mitigates diet-induced obesity through improving insulin sensitivity of subcutaneous fat in mice</article-title><source>Diabetologia</source><volume>60</volume><fpage>900</fpage><lpage>910</lpage><pub-id pub-id-type="doi">10.1007/s00125-016-4202-2</pub-id><pub-id pub-id-type="pmid">28074253</pub-id></element-citation></ref><ref id="bib142"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Ai</surname><given-names>D</given-names></name><name><surname>Suo</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>McDermott</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>JDJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Accurate Drug Repositioning through Non-tissue-Specific Core Signatures from Cancer Transcriptomes</article-title><source>Cell Reports</source><volume>25</volume><fpage>523</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.09.031</pub-id></element-citation></ref><ref id="bib143"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Roe</surname><given-names>SM</given-names></name><name><surname>Cliff</surname><given-names>MJ</given-names></name><name><surname>Williams</surname><given-names>MA</given-names></name><name><surname>Ladbury</surname><given-names>JE</given-names></name><name><surname>Cohen</surname><given-names>PTW</given-names></name><name><surname>Barford</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Molecular basis for TPR domain-mediated regulation of protein phosphatase 5</article-title><source>The EMBO Journal</source><volume>24</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7600496</pub-id><pub-id pub-id-type="pmid">15577939</pub-id></element-citation></ref><ref id="bib144"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>JK</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>SS</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Qiu</surname><given-names>HY</given-names></name><name><surname>Shi</surname><given-names>TT</given-names></name><name><surname>Yang</surname><given-names>FY</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>CP</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>YH</given-names></name><name><surname>Huang</surname><given-names>HX</given-names></name><name><surname>Kayoumu</surname><given-names>A</given-names></name><name><surname>Feng</surname><given-names>JP</given-names></name><name><surname>Xie</surname><given-names>RR</given-names></name><name><surname>Zhu</surname><given-names>XR</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>GR</given-names></name><name><surname>Zhang</surname><given-names>MR</given-names></name><name><surname>Xie</surname><given-names>CL</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>XQ</given-names></name><name><surname>Xu</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>From Hyper- to Hypoinsulinemia and Diabetes: Effect of KCNH6 on Insulin Secretion</article-title><source>Cell Reports</source><volume>25</volume><fpage>3800</fpage><lpage>3810</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.12.005</pub-id><pub-id pub-id-type="pmid">30590050</pub-id></element-citation></ref><ref id="bib145"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>P</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yin</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Overexpression of βCaMKII impairs behavioral flexibility and NMDAR-dependent long-term depression in the dentate gyrus</article-title><source>Neuropharmacology</source><volume>116</volume><fpage>270</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2016.12.013</pub-id><pub-id pub-id-type="pmid">27993520</pub-id></element-citation></ref><ref id="bib146"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Ross</surname><given-names>SA</given-names></name><name><surname>Halseth</surname><given-names>AE</given-names></name><name><surname>Hollenbach</surname><given-names>PW</given-names></name><name><surname>Hill</surname><given-names>RJ</given-names></name><name><surname>Gulve</surname><given-names>EA</given-names></name><name><surname>Bond</surname><given-names>BR</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Role of PYK2 in the development of obesity and insulin resistance</article-title><source>Biochemical and Biophysical Research Communications</source><volume>334</volume><fpage>1085</fpage><lpage>1091</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2005.06.198</pub-id><pub-id pub-id-type="pmid">16039993</pub-id></element-citation></ref><ref id="bib147"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Trapp</surname><given-names>BD</given-names></name><name><surname>Nussinov</surname><given-names>R</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name><name><surname>Loscalzo</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Target identification among known drugs by deep learning from heterogeneous networks</article-title><source>Chemical Science</source><volume>11</volume><fpage>1775</fpage><lpage>1797</lpage><pub-id pub-id-type="doi">10.1039/c9sc04336e</pub-id><pub-id pub-id-type="pmid">34123272</pub-id></element-citation></ref><ref id="bib148"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhan</surname><given-names>J</given-names></name><name><surname>Chitta</surname><given-names>RK</given-names></name><name><surname>Harwood</surname><given-names>FC</given-names></name><name><surname>Grosveld</surname><given-names>GC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Phosphorylation of TSC2 by PKC-δ reveals a novel signaling pathway that couples protein synthesis to mTORC1 activity</article-title><source>Molecular and Cellular Biochemistry</source><volume>456</volume><fpage>123</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1007/s11010-019-03498-8</pub-id><pub-id pub-id-type="pmid">30684133</pub-id></element-citation></ref><ref id="bib149"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Pache</surname><given-names>L</given-names></name><name><surname>Chang</surname><given-names>M</given-names></name><name><surname>Khodabakhshi</surname><given-names>AH</given-names></name><name><surname>Tanaseichuk</surname><given-names>O</given-names></name><name><surname>Benner</surname><given-names>C</given-names></name><name><surname>Chanda</surname><given-names>SK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Metascape provides a biologist-oriented resource for the analysis of systems-level datasets</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>1523</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-09234-6</pub-id><pub-id pub-id-type="pmid">30944313</pub-id></element-citation></ref><ref id="bib150"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>MH</given-names></name><name><surname>Kirkpatrick</surname><given-names>SS</given-names></name><name><surname>Davis</surname><given-names>BJ</given-names></name><name><surname>Nelson</surname><given-names>JS</given-names></name><name><surname>Wiles</surname><given-names>WG</given-names></name><name><surname>Schlattner</surname><given-names>U</given-names></name><name><surname>Neumann</surname><given-names>D</given-names></name><name><surname>Brownlee</surname><given-names>M</given-names></name><name><surname>Freeman</surname><given-names>MB</given-names></name><name><surname>Goldman</surname><given-names>MH</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species</article-title><source>The Journal of Biological Chemistry</source><volume>279</volume><fpage>43940</fpage><lpage>43951</lpage><pub-id pub-id-type="doi">10.1074/jbc.M404421200</pub-id><pub-id pub-id-type="pmid">15265871</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><p>Appendix figures (<xref ref-type="fig" rid="app1fig1">Appendix 1—figures 1</xref>–<xref ref-type="fig" rid="app1fig11">11</xref>).</p><fig id="app1fig1" position="float"><label>Appendix 1—figure 1.</label><caption><title>Network analysis statistics from MEGENA.</title><p>Analysis of the combined ‘disease’ insulin resistance (IR) and ‘treatment’ response IR genes using tissue gene expression data (<xref ref-type="bibr" rid="bib122">Timmons et al., 2018</xref>; <xref ref-type="bibr" rid="bib123">Timmons et al., 2019</xref>) identified those genes that had the greatest connectivity in tissue. These values were used to re-rank and select the top 60 upregulated (positively correlating) and 60 downregulated (negatively correlating) genes regulated in common in adipose and muscle tissue (see Methods).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68832-app1-fig1-v1.tif"/></fig><fig id="app1fig2" position="float"><label>Appendix 1—figure 2.</label><caption><title>Network-based analysis of the gene lists from Table 1 analysed using protein-protein interaction data.</title><p>A notable characteristic of these gene lists was that prior knowledge using multi-omic interaction databases (<ext-link ext-link-type="uri" xlink:href="http://apps.broadinstitute.org/genets">http://apps.broadinstitute.org/genets</ext-link>) was unable to connect the members of the list, indicating that previously unknown information was contained within each list and our novel analysis. There were &lt;3% overlap of genes across the signatures considered in this study (Table S1) and only two genes common between signatures 3A and 4 (INSR, GRB14), and these were not essential for the performance of the RNA-based insulin resistance-drug repurposing (IR-DR) signature. See Figure S3 and ‘Discussion’ for reference to additional human signatures beyond IR.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68832-app1-fig2-v1.tif"/></fig><fig id="app1fig3" position="float"><label>Appendix 1—figure 3.</label><caption><title>Distribution of scores from clinical input signatures.</title><p>Using the input gene lists from Table 1 and the CLUE dataset of &gt;2500 compound signatures, the degree of match (-100 to +100) was established across nine cell types. (<bold>A</bold>) Distribution of scores was plotted and demonstrates that the majority of compounds are not significantly active. (<bold>B</bold>) For comparison, it can also be observed that a human muscle in vivo pro-growth signature (<xref ref-type="bibr" rid="bib111">Stokes et al., 2020</xref>) yields an excess of negatively acting compounds, confirming as expected that the drug database may be biased for anti-tumour/anti-growth compounds.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68832-app1-fig3-v1.tif"/></fig><fig id="app1fig4" position="float"><label>Appendix 1—figure 4.</label><caption><title>Breakdown of the drug classes of positive scoring insulin resistance-drug repurposing (IR-DR) compounds based on their known primary pharmacological actions.</title><p>From &gt;250 active compounds, 140 were associated with a positive action on the IR-DR signature and thus predicted to treat IR. Using the pre-assigned pharmacological descriptors of each compound, they were groups into general classes of compound and represented by a pie-chart. Over 45% of the compounds were classed as kinase inhibitors, while the remaining positively acting compounds belonged to a broad range of pharmacological classes</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68832-app1-fig4-v1.tif"/></fig><fig id="app1fig5" position="float"><label>Appendix 1—figure 5.</label><caption><title>Breakdown of the drug classes of negatively scoring insulin resistance-drug repurposing (IR-DR) compounds.</title><p>From &gt;250 active compounds, ~100 were associated with a negative action on the IR-DR signature and thus predicted to aggravate IR. Using the pre-assigned pharmacological descriptors of each compound, they were grouped into general classes of compound. 17% of the compounds were classed as tubulin inhibitors, while the remaining compounds belonged to a relatively narrow range of pharmacological classes including compounds associated with activation of pro-inflammatory pathways and disruption of cell cycle.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68832-app1-fig5-v1.tif"/></fig><fig id="app1fig6" position="float"><label>Appendix 1—figure 6.</label><caption><title>Calculated physicochemicals do not distinguish between positive and negative acting drugs.</title><p>Calculated physicochemical descriptors (RDKit) were used to compare positively or negatively acting on the insulin resistance-drug repurposing (IR-DR) signature for systemic properties that might contribute to assay score (MolWt, HeavyAtomCount, NumHeteroatoms, MolLogP, NumRotatableBonds, TPSA, NumAromaticRings, NumSaturatedRings, NumAliphaticRings, RingCount, BalabanJ, NumHAcceptors, NumHDonors). The results were plotted using mean and standard deviation.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68832-app1-fig6-v1.tif"/></fig><fig id="app1fig7" position="float"><label>Appendix 1—figure 7.</label><caption><title>Venn diagram overlap of putative drug targets.</title><p>Comparison of drug signature, estimated protein targets of active drugs and knock-down (KD) and overexpression (OE) resources in CLUE that could be cross-compared with the insulin resistance-drug repurposing (IR-DR) signature.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68832-app1-fig7-v1.tif"/></fig><fig id="app1fig8" position="float"><label>Appendix 1—figure 8.</label><caption><title>Contrast between gene list and pathway-level connections.</title><p>Comparison of insulin resistance-drug repurposing (IR-DR) drug signature genes with 73 knock-down/overexpression (KD/OE) validated proteins from the positively acting IR-DR drug list. This demonstrates that while (<bold>A</bold>) no individual validated protein targets were in the drug repurposing signature, many belonged to pathways that contained the known drug targets (<bold>B</bold>). Blue lines connect common pathways.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68832-app1-fig8-v1.tif"/></fig><fig id="app1fig9" position="float"><label>Appendix 1—figure 9.</label><caption><title>DeepPurpose-based target protein predictions.</title><p>(<bold>A</bold>) Identification of predicted positive mediators of a positive insulin resistance-drug repurposing (IR-DR) score agrees with the pharmacological analysis. (<bold>B</bold>) Identification of predicted negatively acting proteins, diminishing the strength of a positive IR-DR score, or cancelling out any positive activity, agrees with and extends the known pharmacology.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68832-app1-fig9-v1.tif"/></fig><fig id="app1fig10" position="float"><label>Appendix 1—figure 10.</label><caption><title>Exploratory analysis of predicted protein target affinity.</title><p>(A) Drugs that positively or negatively associate with the insulin resistance-drug repurposing (IR-DR) score applied to compounds with limited or no existing pharmacological data (other than for epidermal growth factor receptor [EGFR]). (B) Correlation between fusion rank score and IR-DR assay score for individual protein targets. For example, the more potent the predicted action was against MAP3K19 (smaller value) the poorer the IR-DR score was.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68832-app1-fig10-v1.tif"/></fig><fig id="app1fig11" position="float"><label>Appendix 1—figure 11.</label><caption><title>Transcripts related to HOMA2-IR, independent of donor chronological age, in muscle and adipose tissue.</title><p>Primary analysis relied on identifying RNA that tracked with HOMA2-IR in muscle as this tissue represented the largest number of independent data sets – for both fasting tissue status and response to lifestyle intervention. Thereafter the candidates identified in muscle were examined in adipose tissue. The statistical ‘significance’ of the relationship (e.g. FDR &lt; 5%), the magnitude and direction of the linear relationship (correlation coefficient) all informed the final selection of marker genes. As can be observed, in this analysis, the fasting HOMA2-IR genes and the treatment response HOMA2-IR genes represent a largely independent pool of genes (only VCL, GSTO1, SEC31B, FERMT2, OGFOD3, CENPV and NDUFAF5 were common to both states).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68832-app1-fig11-v1.tif"/></fig></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.68832.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Icahn School of Medicine at Mount Sinai</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>This study reports the discovery of EGFR related tyrosine kinase inhibitors as agents that could potentially be repurposed to counteract metabolic disturbances arising from insulin resistance. The authors have used a computational approach to define a gene signature, which was then inputted to identify 130 compounds that interacted with pathways involved in insulin resistance. Important clinical implications may eventually follow from these studies.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.68832.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Reviewing Editor</role><aff><institution>Icahn School of Medicine at Mount Sinai</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;A human multi-tissue and dynamic transcript signature enables drug repurposing for metabolic disease&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Nancy Carrasco as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p><italic>Reviewer #1:</italic></p><p>Pure drug repurposing (e.g. moving a treatment for cancer into clinical evaluation in diabetes) is a controversial yet attractive path toward increasing our treatment options for diseases in need of effective therapies. Critics point out that this type of 'true repurposing' is rarely successful. The concept remains popular given the cost, time and risk associated with de novo drug development. Methods continue to evolve and the study by Timmons et al. advances a computational approach that aligns the transcriptional signatures associated with insulin resistance (a common pathogenesis of multiple diseases) to the reported transcriptional responses to drug exposures.</p><p>Reviewer #2 (Public Review):This article provides insights into drug repurposing for metabolic disease.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.68832.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) The paper is relatively hard to follow with the sequential description of figures, supplemental figures, tables and supplemental tables occupying multiple sections of the manuscript. Most of these figures and tables are not highly informative and required significant effort to relate back to key points being made in the manuscript. The authors would be well served to attempt to make their figures more descriptive.</p></disp-quote><p>The article is formatted in the “results-discussion” format due to the complexity of the topic, the broad range of pharmacological properties to discuss and the multiple disciplines used in generating the data for each subtopic. We would like to emphasis the section headers as important information that help walk the reader through the article. We have made significant efforts to edit and simplify the manuscript.</p><p>The figures are data-driven and not illustrations and as such the format is often determined by the underlying raw data and clustering methodologies. We assume Figure 1 is acceptable as it provides an over-view to the methods and flow of data through the analysis steps.</p><p>We have modified Figure 2 to make it more descriptive, and to deal with a misunderstanding regarding our presentation of compound physico-chemical data (which is now placed in the supplement, as those data are ‘negative’ control data). [THIS IS NOW FIG S6]</p><p>Figure 3 [THIS IS NOW FIG 2] is complex, but then it is a summary of the entire biological pathways targeted by all positive acting drug targets and it traverses many biological processes. It is however a very convention data plot for these types of data. It demonstrates that the in vivo IR genes do not always reside with pathways targeted by the drugs (based on known protein targets and pathway membership). Critically, the 73 protein targets were individually validated as being active in the IR screen using the RNAi data. Figure 4 and 5 [NOW FIG 3] are parallel and relatively simple drug vs target plots and we provide clearer titles. One set derived from laboratory pharmacology data (blue) and the other replicating the general wet-lab findings using a deep learning model of drug target predictions (purple).</p><p>Apologies, we do not understand what is confusing about either Table 1 or Table 2.</p><disp-quote content-type="editor-comment"><p>2) A major issue is the free-flowing nature of the manuscript's description of the data signatures, drug signatures, experimental outcomes and speculation around relevance of each of these elements. The section describing the potential role of PKC is a good illustration where the authors implicate the role of the various PKC isoforms as possibly playing a role as either promotors or suppressors of IR. They highlight the scores of two PKC activators (both based on the naturally occurring phorbal esters scaffolds) and two PKC inhibitors (both based on the bisindolylmaleimide family of kinase inhibitors). The latter (the inhibitors) show divergent outcomes in the IR-DR scoring system yet somehow seem to reinforce the authors interpretation that PKC is a highly interconnected target within the broader world of insulin resistance. There is a lot to unpack in all this including the broad polypharmacology of the bisindolylmaleimides and a vast literature involving PKC as metabolic diseases. However, the authors move past the potential relevance without any real examination and notably dismiss the highly divergent outcome of the two PKC inhibitors. This is an odd choice as it immediately causes the reader to question the value of the authors up-front assumptions and all of the outcomes that follow.</p></disp-quote><p>We do not agree that there is a great deal of speculation – we focus on explaining the known pharmacology of the positive acting compounds, illustrating a novel work-flow to explore their selectivity.</p><p>The representation of our PKC data inaccurate however we recognise we contributed to this confusion with some of our descriptions. We also feel that the placement of the section of the PKC text was suboptimal – as PKC topic was not meant to represent a benchmark for our work – and have revised that aspect of the article.</p><p>To address their specific concerns about PKC.</p><p>Firstly, we demonstrate that RNAi directed against specific isoforms produce some expected positive and negative IR assay scores, while there are no isoform selective PKC drugs to model specificity. We show that “knockdown of PKC-β (+74) and PKC-theta (+97) yielded positive IR-DR scores; while loss of PKC-α (-75) and -Eta (-75) produced poor IR-DR scores and overexpression of PKC-α was positive (+85).”.</p><p>This data is very striking and an important contribution to the PKC field. These isoform specific assay scores are consistent with the field of work on PKC in Diabetes (See citations within Roden and Shulman, 2019). So, for example inhibition of PKC-β and -theta appears beneficial while loss of -α is detrimental. We complete the comment on the known roles of PKC isoforms by referring to PKC-δ’s detrimental role. These data are novel and clearly supportive of the importance of our IR-DR model. These data also explain why predicting the net activity of non-specific PKC inhibitors is challenging.</p><p>Regarding the pharmacology – in total from &gt;2500 drugs, only 27 are listed as targeting PKC, 4 of which are listed as activators. Unfortunately, most of the so-called PKC inhibitors demonstrate poly-pharmacology, targeting proteins beyond kinases and most are inactive in our assay so there is no ‘pharmacology vs selectivity’ pattern to model (or contradict our other PKC data). Still, the pharmacology of the active compounds related to PKC were not contradictory (the available compounds do not have good isoform specific properties). The four compounds credited with global “PKC activator” properties, all score negatively in our assay, including the two we mentioned (Prostratin, Ingenol, phorbol-12-myristate-13-acetate and thapsigargin (non-significantly negative, -57)). There is no good isoform specific data but it is quite plausible that excess α or eta activation is sufficient to yield a negative score.</p><p>For the well described PKC inhibitors, one inhibitor was active, another was inactive (not negative-acting as the reviewer implies). Bisindolylmaleimide has ~0.2uM activity against -α, -δ, -theta, -eta and -epsilon and yields a net positive score (+87). One rational for its net positive score is simple; it inhibits more of the negatively acting PKC isoforms, on balance, in the cells studied. The related high molecular mass Bisindolylmaleimide IX was inactive. It also targets -α, -eta, -iota, -δ, -theta and -γ in vitro but with far greater (&lt;10nM) potency but is also a &lt;10nM inhibitor of other kinases. A simple explanation why Bisindolylmaleimide IX was inactive in the IR-DR assay is that it targets a wider range of ATP binding sites in a variety of kinases. Either way there is no contradiction in the scores, as there were no score reversals for PKC inhibitors.</p><p>There is no doubt that studies have revealed that “PKC is a highly interconnected target within the broader world of insulin resistance” and we would direct you to the work of Shulman et al., and other laboratories as the basis for that statement. It would be churlish of us to not cite this body of work as our isoform specific RNAi analysis significantly adds to the IR literature as we link the isoform knock-down to a robust novel human assay for IR. Our quote of literature reports that “Bisindolylmaleimide is a potent PKC-δ inhibitor” is however a mistake (as it is equally active against other isoforms) and have amended that statement along with moving the PKC section to page 7.</p><disp-quote content-type="editor-comment"><p>3) Papers that provide new hypothesis-generating data (and methods) are great. But this work also purports to identify immediate options for patients. The sections on PKC and TOR do not advance the goal of highlighting translationally promising outcomes from this study.</p></disp-quote><p>We agree, and they both belong to the category of chemicals previously associated with insulin signalling and insulin resistance rather than key examples we pick to illustrate a pathway of translation to the clinic.</p><p>As the reviewer recognises in their following comment (4) we focus on the class “EGFR inhibitors” – but this is because we had sufficient data (range of active and inactive compounds) to form some position on potential mechanisms of actions; while independent laboratories have chronically doses some of this class, to demonstrate efficacy in models of metabolic disease. It would seem that lower-dose members of this class have obvious potential utility at reversing IR especially in shorter term clinical conditions (e.g. viral/inflammation induced severe IR) and this hypothesis could be tested immediately, as trial-ready pharmacological tools exist.</p><disp-quote content-type="editor-comment"><p>4) The authors ultimately land on EGFR inhibitors (mostly) and spend much of the paper trying to deconvolute the role of each agents polypharmacology and potency as a contributing factor in the overall score in the IR-DR scale. Ultimately highlighting that 'multiple protein targets of EGFR inhibitors explain the IR-DR assay performance'. Mostly this section names the proteins and refers to a published association with some form of relevant biology. Again, this type of result is categorized as 'hypothesis generating' not an explanation.</p></disp-quote><p>We do not agree with this representation of our approach or the implications made.</p><p>Our manuscript cannot be an in-depth analysis of <italic>every</italic> class of chemical identified as we have &gt;200 active drugs. We focus on the potential of large-scale OMIC driven pharmacology to produce detailed quantitative relationships within a large class of chemical inhibitor and their protein targets which is why we ‘land’ on EGFR. It is only possible to contrast the OMIC driven scores when there is matching large scale primary in vitro pharmacological potency and plentiful selectivity data (i.e. off target data). This was plausible for EGFR inhibitors and the sort of quantitative relationship we present is highly novel.</p><p>In parallel to our project (running from 2017 to date) independent laboratories have demonstrated efficacy of selected EGFR inhibitors in a number of animal models of metabolic disease (See manuscript citations). Their recently published work was discovered during the literature analysis of our unbiased modelling and does not represent “hypothesis generation” but rather represents independent confirmation that illustrates a degree of potential efficacy. Critically, our entirely independent and human data-driven evidence provides novel connection to this class of drug, which indicates it merits clinical evaluation in metabolic disease.</p><p>The most efficient way to progress the use of this new human-data driven knowledge is to publish it. If we were a pharmaceutical company, and had &gt;$10M to spend, we would re-screen and progress multiple analogues in vivo; and target of every combination of the protein kinases we rank within the EGFR analysis, to clarify specificity. It is also worth noting that our use of transcriptomics proved more impactful/actionable than the comparable high profile GWAS studies – which also claim to provide targets for treatment in metabolic disease.</p><disp-quote content-type="editor-comment"><p>5) Overall, the field of drug repurposing would benefit from new methods. Pharmacological transcriptional signature manipulation has real potential. But in its current form the manuscript doesn't organize its methods, data or outcomes in a manner that provides the reader confidence in the method or outcomes. Further, the high degree of speculation and the frequent use of literature association to derive conclusion is ultimately a distraction from the potential findings.</p></disp-quote><p>We agree that ‘pharmacological transcriptional signature manipulation has real potential’.</p><p>We present the data in a “results and discussion” format because we have &gt;10 nominal classes of drugs and their numerous targets. To scatter the multiple levels of new data and supportive evidence across the manuscript would seem to us to make the article more difficult to assimilate, not less. Sadly, multi-disciplinary projects do not necessarily benefit from traditional publishing formats.</p><p>We do not agree with the critic of our methods – we provide all relevant methods in a substantial methods section and provide the computational code used to implement the analysis, as well as a list of the primary data files used and a full table of the results. The placement of the methods section is dictated by the journal format.</p><p>We do not recognise the claim that we include a ‘high degree of speculation’. It is not speculation to demonstrate a direct quantitative relationship between drug potency (Ki) and OMIC assay score. It is not speculation that most OMIC drug repurposing articles present a detailed examination of just 1 drug and fail to establish if the input transcriptional signature provides a substantial number of true positives – while we provide a set of results that contains a substantial number of true positives. It is not speculation to rely on entirely independent in vivo and clinical data to indicate that a compound from our analysis already demonstrates in vivo efficacy. It also seems unreasonable to criticise use of pre-existing in vivo efficacy from the literature as if this is a weakness. We have made numerous stylistic modifications to simplify the text and improve the flow of each section.</p><disp-quote content-type="editor-comment"><p>6) There were several instances where the authors implicated the possibility that alignment in 'physiochemical' properties drive the in vitro activity that they note. First, the authors are certainly referring to 'physicochemical' properties which are descriptors of a small molecule which govern how small molecules interact with biological constructs like membranes and proteins (TPSA, MW, LogP, etc). Next, they pass by their analysis entirely – simply saying its not the issue (they present a tSNE plot in Figure 2A but don't explain it). It is highly unlikely that these agents are working through a non-specific pharmacology that is driven by physicochemical properties. But if the authors are going to introduce the concept they have to explain it.</p></disp-quote><p>We apologise for the confusion created; we do NOT propose that ‘physicochemical' profiles explain our cell-based activity scores. Quite the opposite.</p><p>It is well accepted that simple caveats (such as drug solubility or cell penetrance) contribute to variation in high through put screens and impact on compound potency. We considered the ‘physicochemical' profiles of the ‘active’ vs ‘inactive’ compounds (or positive or negative scoring) to examine if any simple unfortunate bias related to the observed pharmacology. Not because we believed that this was a factor (other attempts to look at this have also considered it a to have limited influence on the OMIC driven results) but rather just as part of a standard quality control process of looking at this type of large scale pharmacology data. We have modified the text to clarify this point.</p><disp-quote content-type="editor-comment"><p>7) The authors place great importance on using data from multiple tissues, more specifically – adipose and muscle. However, it is not clear how significantly the pool of the reported compounds was reduced, relative to the union of the compounds that could be detected if either one tissue was used. And more importantly, would these compounds display similar properties and statistics as the reported list of compounds?</p></disp-quote><p>The project aimed to compare the utility of a ‘fasting disease’ or ‘treatment response’ signature versus the combination (Table 1 in the manuscript) and used much larger (and far more costly) GWAS data as one comparator.</p><p>The reviewer raises a very interesting additional line of investigation, that would require additional adipose biopsy treatment responses studies (to match the number of muscle treatment response studies). This would allow comparable muscle and adipose signatures for comparison. Instead, by combining all our available tissue treatment responses data we focus on the true-positive within the OMIC data while this ignores tissue-specific processes. The fact that there are many common features is also a very novel observation.</p><disp-quote content-type="editor-comment"><p>8) At the very least, the &quot;disease signature&quot; of 337 genes should be put in the perspective of the total number of genes differentially expressed in adipose or muscle tissues. A figure similar to Figure S6 or a funnel diagram would greatly help in following the flow of the experiment.</p></disp-quote><p>We agree and we have produced the Venn diagram as request and placed it within the method description (Figure S13).</p><disp-quote content-type="editor-comment"><p>9) Compounds that negatively regulate the IR-DR signature (Figure S4) include HDAC inhibitors; however, beneficial effects of HDAC inhibitors in terms of IR have been demonstrated in multiple settings, including in vivo models and clinical trials (Lee et al. 2020) (Sharma and Taliyan 2016) (Dewanjee et al. 2021). Therefore, it's not clear why HDAC inhibitors may aggravate IR, according to negative scores. It would be interesting to investigate, if this result may be explained by the off-target effects of compounds in this list.</p></disp-quote><p>We agree with the reviewer that HDAC inhibition is an interesting area for metabolic disease.</p><p>We and others have recently reported that low-dose HDAC inhibition, including HDAC3i, has a beneficial profile in neurodegenerative disease models(Janczura et al., 2018; Sartor et al., 2019). We have come to the general conclusion, based on those studies, that lower intermittent exposure (due to limited t/2) of HDACi was potentially the key. This and the high concentration of HDACi in the cell studies has implications for the present IR study.</p><p>As you mention (Lee et al., 2020) it was reported that MS-275 (Entinostat, Class I) positively treated IR in the high-fat fed model yet we find that high dose Entinostat yields a negative assay score (consistently with several other HDACi, e.g. SAHA (Vorinostat) a Class I, II and IV inhibitor).</p><p>We believe this could relate to the high dose of HDACi used in the large-scale drug-screen – potentially reflecting an inappropriate impact on tubulin biology (majority of TUBB inhibitors also scored negatively) and their general lack of selectivity. However, it may also be more complex. Recent studies by the Schenk Lab, using scriptaid – which was inactive in our assay –illustrated that Scriptaid’s use to supporting the potential for HDAC5 inhibition in muscle insulin resistance, may reflect coincidental non-HDAC activities (Martins et al., 2019). A broader role for the known actions of HDACs in β-cell function add to the complexity. – see updated general discussion.</p><p>When carrying out large scale screening, ensuring a high true positive rate is key as it would be intractable to sort through a high false positive rate and completely limit the approach for novel diseases with few bench markers. In that sense our priority is to demonstrate that a high true positive rate is possible, and one that yields some relationship to potency across a family of compounds (e.g. EGFR family). We have updated the manuscript to more clearly emphasise this point (Page 6).</p><disp-quote content-type="editor-comment"><p>10) The explanation for Alisertib-mediated inhibition of AURKB, which drives a detrimental IR-DR score is controversial since Alisertib treatment has anti-inflammatory properties and significantly reduced HOMA-IR index in the STZ+HFD diabetic mice model (Meng et al. 2020). This result suggests that the positive effects mediated by Alisertib targets, AURKA and EGFR, outweigh the detrimental ones from AURKB inhibition, which is not reflected in terms of IR-DR score. Notably, Imatinib, which lacks a significant IR- DR score, was also capable to improve IR in HFD murine model (Pichavaram et al. 2021). The following observations indicate, that more precise balance is required in terms of compound targets, as in its current setting, the application of scores may lead to the potential loss of candidates for drug repurposing.</p></disp-quote><p>While we expect any high throughput assay to generate some false negative results, the aim is to have a high true positive rate as this is the only manageable way to progress ‘hits’ to the clinic.</p><p>However, for the two examples provided we do not think these are false-negative results – as both examples include serious contradictions, and neither provide evidence for a direct reversal of IR. Indeed, Imatinib made IR worse in chow fed animals, Table 2, Page 6.</p><p>Regarding Alisertib: Meng et al. 2020(Meng et al., 2020) used Alisertib in a model where insulin production was removed with Streptozotocin (STZ) and a HFD fed. STZ ablates insulin production and is not a model of insulin resistance. The reported benefits from Alisertib were also unclear – for example fasting glucose and weight-gain remained unchanged. Alisertib did <italic>reduce</italic> serum insulin during an insulin tolerance test, but this implies enhanced clearance of injected insulin. HOMA values were also calculated from ITT data (injected exogenous insulin), but this is not a valid use of the HOMA model. An indirect impact on IR by targeting macrophage inflammation was proposed but it is not an insulin resistance model and the efficacy data are contradictory.</p><p>Regarding Imatinib: As Imatinib is not an EGFR inhibitor we did not consider from the perspective of targeting EGFR – but rather it targets a kinase that some EGFR inhibitors also targeted. Indeed, Imatinib was reported to improve vascular responses to insulin (CVJ et al., 2021) and this is ascribed to PDGF signalling.</p><p>In the study highlighted by the reviewer, Pichavaram et al. 2021, vascular hyperplasia was studied in a high fat fed mode of insulin resistance. Imatinib (25mg/kg daily IP) was dosed 3 weeks into the 6-week high fat diet (HFD) and insulin was studied at the end of the intervention. Imatinib prevented HFD weight gain (a phenotype driven by greater calorie intake over controls), yet Imatinib was reported to neither change food nor calorie intake but yet ‘abolished’ the HFD feed efficiency calculation indicating an inconsistent data set.</p><p>Nevertheless, Imatinib reversed the HFD weight gain first, and this led to lower fasting insulin (after the prevention of weight-gain). This is not direct reversal of insulin resistance, but a ‘removal’ of the experimental intervention that helped cause insulin resistance. Interestingly, Imatinib ~ doubled fasting HOMA-IR from 1.5 to 2.89 in the control chow fed animals, indicating that it does not directly improve insulin sensitivity.</p><disp-quote content-type="editor-comment"><p>129 – &quot;because most drugs act systemically&quot; – Although that is true, a drug's action in different tissues is not always uniform. See PMID:26626077 for reference. The authors are advised to discuss the issue of off-target tissue-specific interactions of the method used in their project.</p></disp-quote><p>The present project is not designed to examine tissue specific negative interactions. As mentioned above, to build additional tissue-specific models additional human clinical intervention data is needed to make robust statistical models for those conditions.</p><disp-quote content-type="editor-comment"><p>158 – &quot;We checked whether the 254 active compounds had any simple physicochemical properties driving in vitro activity&quot; – This sentence is followed by the biological annotations of the compounds, although their common chemical properties are just as important. Although the reader is advised to inspect Figure S5, this is a matter that deserves more coverage in the main text. Do these 254 compounds share any common chemical properties? Can they be separated into clearly defined structural clusters? How many of them comply with Lipinski's rule? Are any of these compounds protected by a patent? Although Figure 2A displays clusters of compounds grouped by chemical properties, it is unclear if any of these clusters can be characterized by certain chemical properties.</p></disp-quote><p>The analysis presented in original Figure S5 [NOW FIG S6] indicates that positive or negative activity is NOT associated with any of the chemical features (some of which relate to Lipinski’s rule of 5 (which also inferences oral bioavailability, something not captured by a cell based in vitro screen). We are unsure why the reviewer would like the relationship between patent status and drug action discussed.</p><p>Further, the original Figure 2A [NO LONGER INCLUDED] shows no pattern that segregates active drugs from those that were inactive. While interesting, a more in-depth analysis of the relationship between active drugs in cells and physicochemical properties should really be based on multiple bio-assays and represents a focus and project out-with the aims of the present study. The present physicochemical analysis was simply there to ensure that no obvious simple confounding properties distinguish active drugs from inactive (Figure 2A), nor positive from negatively scoring active drugs (Figure S5). The data presented indicate there were no obvious confounding physicochemical properties – to limit confusion we have moved both data plots to the supplement. We have revised the text to make this analysis clear and fit better within the flow of the manuscript.</p><disp-quote content-type="editor-comment"><p>188 – &quot;PKC-δ also increases with age and is associated with age-related IR&quot; – It is interesting to see if the authors tried finding the links between the identified compounds and their potential as geroprotectors? Are any of the compounds listed in a database such as geroprotectors.org? A lot of attention is paid to the metabolic pathways IR-DR molecules may be involved in. Perhaps, the authors should make a small subsection about aging-related pathways, such as for example, NAD-salvage.</p></disp-quote><p>This is an interesting suggestion. We examined this idea by contrasting a robust multi-tissue human age gene expression signature (of the same size as our IR signature) using the same methods as employed in the present study. This age signature represents one that responds in primary cells to drugs, shown to induce an increase in life-span in model systems (Timmons Age Cell, 2019). We then examined the response of each of our significant IR active drugs and found 64 of the IR drugs were also able to regulate the Age signature. Somewhat predictably, the vast majority belonged to the IGF1/AKT/mTOR axis. All but 1 EGFR compound was inactive in the ‘age’ assay. We have referred to the idea of using multiple bio-assays to triangulate or prioritise compounds in the final discussion.</p><disp-quote content-type="editor-comment"><p>433 – &quot;gold-standard lifestyle intervention&quot; – The authors are advised to briefly describe the lifestyle IR treatment. Is the identified &quot;treatment signature&quot; of 148 signatures characteristic of IR people only? Do healthy controls under this kind of intervention experience similar expression shifts?</p></disp-quote><p>Revised as requested (description of lifestyle treatments). Please not that IR is a continuum rather than a classification, and treatment responses are also on a continuum. We integrated data from a wide range of life-style intervention protocols applied to sedentary and/or over-weight individuals. Our work on this topic, so far, indicates that molecular markers for the variable outcome response can be agnostic to precise life-style protocol. Indeed, our focus was to identify genes that contribute to treatment responses irrespective of the precise life-style protocol as these are more likely to be general regulators of metabolism.</p><disp-quote content-type="editor-comment"><p>456 – &quot;We averaged signature matching across the 9 cell lines&quot; – It is implied that all cell lines are equal, although some of them are probably more similar to the adipose/muscle domain of the study.</p></disp-quote><p>Similarity between cell lines and primary tissues can only be true to a point, however our interpretation of the present analysis is that the cell lines – rather distinct from mature muscle or adipocytes – do reflect the major biochemical processes sufficiently to capture/represent relevant insulin signalling pathway responses. Critically, averaging across all cell types helps remove cell specific noise/responses and increases the sample size – providing the most statistically robust and cell agnostic profile possible. We think it is, from a statistical perspective, an error to look at single cell type data with the existing assay format.</p><disp-quote content-type="editor-comment"><p>Thank you for resubmitting the paper entitled &quot;A human multi-tissue and dynamic transcript signature enables drug repurposing for metabolic disease&quot; for further consideration by <italic>eLife</italic>. Your revised article has been evaluated by a Senior Editor and a Reviewing Editor. We are sorry to say that we have decided that this submission will not be considered further for publication by <italic>eLife</italic>.</p><p>[Editors’ note: The authors appealed the second decision. What follows is the authors’ response to the second round of review]</p></disp-quote><disp-quote content-type="editor-comment"><p>– The whole manuscript is dependent on the assumption that the IR drug response signature derived from the Connectivity Map can be generated by averaging data across 9 cell lines (listed on page 15 of the resubmitted manuscript: PC3 and VCAP are prostate cancer cells. A375 are melanoma cells. A549 is an epithelial lung cancer line. HA1E is an epithelial kidney line. HCC515 is a lung adenocarcinoma. HT29 is a colon adenocarcinoma. MCF-7 is a breast carcinoma line. HEPG2 is a hepatocellular carcinoma.).</p></disp-quote><p>This is an unfortunate misrepresentation of the project. We do not assume what the reviewer is stating. In fact, the reviewer is stating part of our research hypothesis. We were evaluating if a novel multi-gene DR model, developed from our extensive clinical studies, can match relevant drugs signatures with a high true positive rate compared with alternative signatures generated using alternative OMIC strategies (as one set of controls).</p><disp-quote content-type="editor-comment"><p>The assumption is that the transcriptional responses to a class of drugs (say EGFR inhibitors) can be collected from each of these divergent cell types and worked into a set of common transcriptional responses and subsequently we assume that all cells respond similarly when exposed to that drug class. Doesn't this require that the 9 cell lines express EGFR (the correct isoforms) and/or the correct off-target kinases that are contributing to the signature? Even a cursory review of the literature will tell us that A549 and HepG2 are known to overexpress and have a growth dependence on EGFR. Inhibiting a target that a cell line is dependent on will have broad transcriptional consequences relative to inhibiting the same target in a cell that has no dependency.</p></disp-quote><p>We used the term “averaging” to convey a simple idea and have now reworded it to “aggregate” across cell lines as this might help clarify any misunderstanding on the influence of ranking across cells.</p><p>Firstly, the cell normalised scores considers the tendency for a cell type to respond more or less frequently to all drugs. Scores are summarised using a method that would not be influenced by a few cells with negative responses as the aggregation method uses the maximum quantile statistic from the within cell line normalised scores. Thus a few inactive cells don’t influence the outcome.</p><p>Secondly, rather than being an assumption, our research strategy stated up front that we were seeking cell agnostic drug responses. We also reflected on the fact that moving from n=3 to n=27 replicates per drug adds robustness (based on the published analyses of the database).</p><p>From first principals each drug targets multiple proteins, that contribute to its net activity, one cannot reject or include individual cell lines in the manner described by the reviewer; nor does it require the exact same conditions for each protein per cell type for several reasons. We narrow the potential targets using three distinct methods – kinase panels with clustering, deep learning predicted target ranking and the RNAi data from proteins known to be bound by active drugs and this modelling and the discussion illustrate that these choices were valid.</p><p>For example, we show that EGFR inhibitors are not “just” EGFR inhibitors, and thus the net response per cell can’t be predicted just based only on EGFR status (we find up to 40% shared variance but as we illustrate this can be due to shared potency relationships across related kinases not just EGFR, as primary potency vs EGFR co-varies with some other related kinases).</p><disp-quote content-type="editor-comment"><p>– Insulin responses in the key tissues/cells which are susceptible to disease causing resistance mechanisms we hope to abrogate are dependent on multiple, diverse and complex autocrine, paracrine and endocrine factors which are almost certainly not present in cell cultures. How do the authors account and correct for the lack of these critical elements of the insulin response? Ultimately, the IR-DR scoring system relies solely on cell intrinsic factors. Possibly this is enough, but the authors would need to demonstrate that fact.</p></disp-quote><p>The reviewer appears to be overlooking our results, while reflecting on some valid but ultimately incorrect assumptions. Of course, we agree that in vivo metabolic signalling is complex. However, it’s not possible to screen millions of compounds in vivo in animals (nor desirable). Steppingstones are needed and we demonstrate that the present novel IR assay, and our approach, selects a substantial number of diversely acting true positive compounds. The broader context is that there is no other valid cell-based insulin resistance screen published at this time.</p><p>Thus, our results demonstrate that the approach is in fact useful, and the preconceptions mentioned, while very understandable, are wrong. We find that up to 50% of our drugs and drug families (Table 1) are functionally linked to modulating insulin signalling and treating metabolic disease, many in vivo. Critically, we also demonstrate a quantitative relationship between binding affinity and multi-gene score illustrating the potential utility to facilitate drug design – such as those used by companies employing AI multi-target drug design.</p><disp-quote content-type="editor-comment"><p>– The authors do highlight studies that suggest EGFR inhibitors have a positive effect on various IR related disease states. When reviewing these studies, the mechanistic aspects are not fully explained so we can't directly compare with the IR-DR signatures posited in this study. Again, it's an interesting hypothesis that IR phenotypes in diverse cells/tissues in organs ranging from the kidney to the pancreases to the liver could all be responding to EGFR inhibitors through a reversion of a transcriptional program uncovered by averaging the transcriptional response nine immortalized cancer cell lines to EGFR inhibition. But that's honestly a big theoretical jump that must be backed up with some data.</p></disp-quote><p>We feel that it is odd to refer to a “theoretical jump” when we have clearly done the “jump” and shown that in practice a robust clinical RNA signature identifies a set of diverse classes of compound, many of which directly modulate IR and metabolic disease in vivo.</p><p>The fact that a medicinal chemist at one time in their life called some of these drugs “EGFR” inhibitors is unfortunate. We would call them “multi-gene inhibitors targeting the EGFR tyrosine kinase like proteins”.</p><p>Evaluation of a drugs mechanism of action (MOA) is secondary connecting a novel clinical IR signature directly with drugs that have efficacy. Selecting an active drug from thousands of options is the key aim of DR, not establishing a specific MOA. That is a secondary aim and we do go on to illustrate that our analysis helps to provide greater detail on how some drugs, which are active in vivo, may be working.</p><p>– Essential Revisions 7 Author's Reply: The project aimed to compare the utility of a 'fasting disease' or 'treatment response' signature versus the combination (Table 1 in the manuscript) and used much larger (and far more costly) GWAS data as one comparator. The reviewer raises a very interesting additional line of investigation, that would require additional adipose biopsy treatment responses studies (to match the number of muscle treatment response studies).</p><disp-quote content-type="editor-comment"><p>New Comment:</p><p>Why is it impossible to perform the same kind of analysis without more biopsies? Although the statistical power of the findings will not be the same, there should be significant hits. It is beneficial to demonstrate how much the double tissue approach has allowed shrinking the search space.</p></disp-quote><p>The actual unknown here is whether the search space would be increased with a larger adipose data-set (more detectable in common with muscle) and not as the reviewer is implying. This is not a topic we can explore without additional clinical data. We do show how the double tissue approach shrinks the search space by showing the gene list size is reduced by including adipose constraints on muscle (shared genes). Adipose responses to treatment are less well-defined in our clinical studies. But a gene passes the filter only if in both. If we take the adipose list and ‘shrink’ it by the muscle list’ we get the exact same answer- the subset of adipose in muscle.</p><p>– Additional Reviewer Comments – 158 Author's Reply: The analysis presented in original Figure S5 indicates that positive or negative activity is NOT associated with any of the chemical features</p><disp-quote content-type="editor-comment"><p>New Comment:</p><p>i) tSNE is highly sensitive to minor changes in initial settings, so there is no association between activity and the position of a compound in this particular tSNE implementation hardly proves the point. There might be a tSNE implementation in which the compounds are neatly separated by activity.</p><p>ii) The illustration of Figure S5 is not self-evident. Some might say that there are actually clusters enriched in active/inactive compounds. To demonstrate that there is no association between tSNE position and activity, the observations should be separated into clusters followed by a comparison of odds ratios (for example, using the chi2 test).</p><p>These tSNE results should have been placed in the Supplementary section.</p></disp-quote><p>We have removed the tSNE plot, as the options are too numerous to systematically explore what the reviewer is referring to. There is no information, within in the current tSNE plot that supports the view that there is physical-chemical bias between active and inactive drugs and thus nothing to direct the exploration of many thousands of permutations.</p><p>The purpose of the tSNE plot was to illustrate the properties of the clue.io database and not specifically address our data and so we have removed this plot from the manuscript. Notably, the mean physical chemical properties for the active vs inactive compounds speaks more directly to our data and that plot is retained.</p><disp-quote content-type="editor-comment"><p>– Additional Reviewer Comments – 188 Author's Reply: This age signature represents one that responds in primary cells to drugs, shown to induce an increase in lifespan in model systems (Timmons Age Cell, 2019). We then examined the response of each of our significant IR active drugs and found 64 of the IR drugs were also able to regulate the Age signature. Somewhat predictably, the vast majority belonged to the IGF1/AKT/mTOR axis. All but 1 EGFR compound was inactive in the 'age' assay. We have referred to the idea of using multiple bio-assays to triangulate or prioritize compounds in the final discussion.</p><p>New Comment: This information should be discussed in the main text. Perhaps, other works on data-driven search for geroprotectors and assembling the gene expression signatures of tissue-specific aging should be mentioned in the discussion.</p></disp-quote><p>We have cited a key geroprotection drug repurposing article in the discussion however we are over the length limits for the present manuscript format.</p><disp-quote content-type="editor-comment"><p>– Additional Reviewer Comments – 456 Author's Reply: We think it is, from a statistical perspective, an error to look at single-cell type data with the existing assay format.</p><p>New Comment: Adipose and muscle tissues were chosen for being directly involved in energy storage affected by IR. But the cell lines chosen for verification contain epithelium and cancer cell lines. The authors should clearly state the limitations of this methodology. Some truly effective compounds might not be able to generate the desired signature in these cell lines due to their intrinsic differences. While it is presented to decrease the number of &quot;false positive&quot; compounds, this procedure may increase the number of &quot;false negative&quot; compounds. In addition, we would suggest reviewing the popular methods in computational workflows of drug repurposing.</p></disp-quote><p>The reviewer rather misrepresents our project with this new comment. We do not “verify” in cancer cell lines, as active scores in these cells per se does not validate the novel input signatures. Validation reflects that compounds we identified include numerous true positives or that they target pathways known to control insulin sensitivity, and thus illustrating that our novel IR clinical input signature is valid. It is important to note our RNA models were successful while other OMIC models were not.</p><p>We agree that all assays will yield false negatives and false positives – and we discuss the reasons for this throughout the article and in the limitations of our study. A key property of a good DR assay is one that produces a low rate of false positives while delivering a substantial number of chemically diverse potential leads, as only a finite number of small molecules can be further screened in animal models or taken into clinical development. Unfortunately, space limits us to producing a more comprehensive review of the DR literature but it is something we agree is needed in the literature as not all available approaches are genuinely showing promise.</p><p>Authors: The actual unknown here is whether the search space would be <bold><underline>increased</underline></bold> with a larger adipose data-set (more detectable in common with muscle) and not as the reviewer is implying. This is not a topic we can explore without additional clinical data. We do show how the double tissue approach shrinks the search space by showing the gene list size is reduced by including adipose constraints on muscle (shared genes). Adipose responses to treatment are less well-defined in our clinical studies. But a gene passes the filter only if in both. If we take the adipose list and ‘shrink’ it by the muscle list’ we get the exact same answer- the subset of adipose in muscle.</p><disp-quote content-type="editor-comment"><p>[Editors’ note: the authors submitted for reconsideration following the decision after peer review. What follows is the decision letter after the second round of review.]</p><p>– Insulin responses in the key tissues/cells which are susceptible to disease causing resistance mechanisms we hope to abrogate are dependent on multiple, diverse and complex autocrine, paracrine and endocrine factors which are almost certainly not present in cell cultures. How do the authors account and correct for the lack of these critical elements of the insulin response? Ultimately, the IR-DR scoring system relies solely on cell intrinsic factors. Possibly this is enough, but the authors would need to demonstrate that fact.</p><p>– The authors do highlight studies that suggest EGFR inhibitors have a positive effect on various IR related disease states. When reviewing these studies, the mechanistic aspects are not fully explained so we can't directly compare with the IR-DR signatures posited in this study. Again, it's an interesting hypothesis that IR phenotypes in diverse cells/tissues in organs ranging from the kidney to the pancreases to the liver could all be responding to EGFR inhibitors through a reversion of a transcriptional program uncovered by averaging the transcriptional response nine immortalized cancer cell lines to EGFR inhibition. But that's honestly a big theoretical jump that must be backed up with some data.</p></disp-quote></body></sub-article></article>